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Abstract 
 
Background  
Stroke is the foremost medical condition responsible for acquired disability and 
dependency.  The initial psychological and physical deficits should arguably be 
identified early to allow interventions to be put in place if potential long-term 
sequelae are to be minimised.   
Physical impairments within stroke cohorts have been extensively researched and 
reported.  We have access to numerous scales that describe general physical 
functioning during daily activities and its effects on independence and quality of 
life.  Deficits in movement are easily identified and attributes of physical 
movements can be associated with such obvious measurement terms as strength, 
speed, co-ordination and task completion.  As these attributes can be graded, it is 
simple to compare patients over time, within stroke cohorts and against the general 
population:  controlled studies are straightforward, even if natural biological 
variation demands large samples. 
However, though physical impacts on a patient may be easily observed and 
measured, corresponding deficits in cognition and mood are less easily detected 
and quantified.  Psychological problems are common within stroke populations, and 
exert both short and long term effects throughout all stages of rehabilitation.  
Despite our awareness of the potentially critical effects of psychological factors on 
patient outcome, there is a dearth of high quality research in this area.  Although 
many cognitive and mood assessments are available, including some that were 
developed specifically for use in stroke, these are neither regularly administered 
nor have been convincingly shown to be accurate and reliable in identifying specific 
deficits.  Thus, it is understandable that research available to us that describes 
prevalence and effects of cognitive and mood problems post-stroke is sparse in 
comparison to our knowledge of physical deficits.   
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Methodology 
In order to begin to understand the effects that cognition and mood have on patient 
outcome post-stroke, a way of identifying prominent issues is required.  Knowing 
that their effects can have both short and long term impact, reliable screening 
beginning early after stroke onset could offer opportunities to improve patient 
outcome through early implementation of interventions.   
Before an appropriate screening tool can be selected, evidence is required to 
support its feasibility and accuracy within acute stroke cohorts.  In this thesis, I 
investigate cognitive and mood-screening assessments in stroke, across a series of 
linked projects.   
I carried out a review of the current research and I surveyed stroke units to identify 
which cognitive and mood assessments are commonly implemented. I collated and 
offer synthesis of the published data on accuracy of cognitive assessment 
instruments.  I used these results to inform a diagnostic test accuracy study, 
examining selected measures that are commonly used in UK practice to screen for 
cognitive and mood problems.  Based on these results, I designed (and was awarded 
grant funding for) a clinical study to assess test properties of cognitive and mood 
screening instruments in a rehabilitation setting and to describe potential obstacles 
affecting patient assessment.  
  
Findings 
There is heterogeneity in the choice of cognitive and mood tests employed across 
research and clinical practice.  There was some overlap in assessment choice within 
these domains but no clear consensus on a preferred assessment tool.  This is in 
part explained by the substantial number of tests available, it is telling that the 
most popular assessments accounted for only a fraction of the tool assessments 
employed.  My literature based work also points to a relative lack of published 
science employing a cognitive or mood assessment tool.  
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My review of diagnostic test accuracy found that properties of cognitive tools 
commonly used in practice and research (Folstein’s Mini Mental State Examination: 
MMSE, the Montreal Cognitive Assessment: MoCA, the Addenbrookes’ Cognitive 
Examination Revised: ACE-R and the Cambridge Cognitive Examination revised: R-
CAMCOG) were susceptible to changing populations and purpose of assessment, with 
test properties differing when screening tools are used in acute and chronic stage of 
stroke. Depending on the cut-offs that are used to define “screen positive” cases, 
these tools would have varying ability to identify multi=domain cognitive 
impairment or dementia.  Generally when applying standard (i.e. the traditional 
cut-off described for test use in an unselected population) cut-offs, sensitivity was 
good but specificity was low.  Specificity could be improved when the cut-offs were 
altered while maintaining reasonable sensitivity and this suggests that screen 
positive thresholds may need to be altered to suit a stroke population	  	  	  The need for 
lowering our standard cut-offs suggests that there may be factors present in typical 
acute stroke patients which affect assessment accuracy compared to the 
populations and purpose for which these scales have been developed.   
Using the MOCA in the acute setting of my clinical study, confirmed that stroke 
cohorts require altered cut-offs to improve accuracy in cognitive impairment 
detection.  A stroke cognitive assessment that can be derived from a standard 
neurological examination *the Cog4) has been described.  Cross sectional 
comparison of MoCA and Cog 4 suggest that Cog4 has questionable validity and 
stroke specific cognitive measures are required since scores derived from other 
types of measures are not necessarily testing the most appropriate domains for 
stroke deficits.   
A lack of published data on cognitive and mood screening in the first days post-
stroke suggested that describing the feasibility of assessing stroke patients in an 
acute setting would be a useful topic for research.  My subsequent clinical study 
incorporated verbal and non-verbal assessments for mood and the MOCA.  As well as 
usual test accuracy outcomes I considered feasibility issues such as proportion of 
patients suitable for initial approach, acceptance of assessment, prevalence of 
common stroke related impairments that mandate assistance or cause difficulty in 
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completing assessments, or that preclude assessment altogether.  A moderate 
proportion of patients who were approached declined to take part and several 
others required external assistance to complete the assessments.  Shorter, less 
cognitively demanding assessments required less assistance and appeared to offer 
higher accuracy for predicting mood problems at follow-up.  These results suggest 
that delaying cognitive and mood assessments until later during the post-stroke 
period may reduce the interference from acute stroke deficits.   
The final piece of work generated from my PhD studies, and that is ongoing, 
continues the theme of feasibility of cognitive and mood assessments.  Cognitive 
and mood assessments are performed in stroke rehabilitation centres.  The 
rehabilitation setting was chosen, as it will include varying patterns of physical and 
cognitive impairment.  By comparing brief assessments and more lengthy measures 
of cognition, I hope to identify the most appropriate testing scheme that minimises 
patient burden.  As part of this work I will describe the impact of stroke deficits on 
assessment and quantification of the patient’s psychological capabilities. 
 
Conclusions 
In conclusion, these studies have demonstrated a lack of guidance and of protocols 
for cognitive and mood assessment post-stroke.  The evident heterogeneity in 
choices of assessment in research and usual practice indicated a need for evidence 
based accuracy studies.  In conducting these I found that usual measures are 
susceptible to the population, timing, and cut-off used to define test positive cases, 
together indicating undesirable sources of variation.  Transient stroke-related 
problems may lead to overestimation of persistent impairments.  Although acute 
screening of cognition and mood would be possible, such screening may not be 
widely acceptable to patients and would require a high level of assistance from 
health professionals.  Acute screening should only be performed if there are 
potential benefits that could impact on the patient from identification of cognitive 
or mood problems at this early stage.  With the transient changes in cognition and 
mood that the majority of stroke survivors experience, screening is best left until 
later in the patient journey.  However, there may still be potential feasibility issues 
v	  
	  
of administration and assessment completion during later stages.  Therefore, I 
suggest that studies that investigate what assessments are feasibly administered to 
stroke patients in later stages are required.  This will inform future trial 
recruitment for complete data requirements as well as provide clearer picture of 
stroke survivors’ affected cognitive domains and or mood problems.     
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Chapter 1 Introduction 
1.1. Epidemiology of stroke and stroke related disability 
Stroke is the second highest cause of death in the developed world (10% of 
deaths)(1), and the main cause of adult disabilities in Europe and the USA(2).  Each 
year, 15 million people worldwide have a stroke.  Of these 5 million die and 5 
million suffer lasting impairment.(1) Frequency of ischaemic stroke ranges between 
85-90% of all strokes versus 10-15% for haemorrhagic stroke (hospitalised and 
community settings).(3-5)  
In a community sample, 88% of stroke survivors had some form of motor deficit.(6) 
It is estimated that six million Europeans are living with a stroke related 
impairment(7).  The greatest rate of functional recovery takes place by 3 to 6 
months post-stroke.(6, 8) At least half of survivors experience significant functional 
disability a year after their stroke(9).  More motor deficits are present in stroke 
survivors greater than 75 years old, but recovery is associated with stroke severity 
and not age (6).  
Common impairments are weakness in limbs (especially in the upper limb 
77.4%)(10) with long term arm movement difficulties affecting 40%, sensation 
changes about 80%, and visual disturbances around 66% (11).  Other physical 
problems include: incontinence (48.2%)(10)- 15% continuing to suffer with 
incontinence at 1 year post-stroke.(11)   
Haemorrhagic stroke patients have a higher incidence of severe headaches, 
convulsions(4) as well as an (up to four times) increase in mortality in the first 3 
months post-stroke(5), but lower incidence of paresis and sensory deficits than 
ischaemic stroke survivors.(4) 
Physical impairments are well described within the epidemiology of stroke but this 
is not true for cognitive and mood impairments.  
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1.1.1. Post-stroke cognitive impairments  
Cognitive and mood impairments are common after stroke affecting around one 
third of survivors.(11-13) Cognitive domains commonly affected are: attention, 
orientation, language and memory (14, 15) with a general cognitive impairment 
profile of more pronounced deficits in executive function and attention processing 
assessment.(16)  
Stroke is a major risk factor for developing dementia, the risk increasing with age 
from 15% at 60-69 years to 36% in those over 80 years; and it increases over time 
with an incidence of 9-17% at 1 year to 33% by 5 years.  However, 7-16% of survivors 
had pre-stroke dementia that only becomes apparent post-stroke. (13, 17)  
 
1.1.2. Mood impairments post-stroke  
Prevalent mood problems are depression and anxiety.(18) Mood disorders post-
stroke, especially depression, are associated with previous strokes, social activity 
decline and living alone.  There are four main stroke related features that render 
survivors susceptible to developing depression.  These are: physical impairments 
and fatigue which reduce involvement in activities; other medical problems which 
can add to the stress independent of the stroke; experience of a stroke can lead to 
a more negative way of thinking; cognitive impairments affecting the way in which 
information is processed.(19) Post-stroke cognitive problems, however, are a main 
risk factor, accounting for 42% of mood changes.(20, 21) 
 
1.2. Nosology of post-stroke cognitive problems 
Cognitive impairments post-stroke are integrated in nature and have overlapping 
features; this poses difficulty for clinical assessment and to distinguish criteria for 
classification.(22, 23)   This had led to broad terminology being used to cover all 
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types of dysfunction.  In an attempt to clarify the various cognitive problems that 
can be seen post-stroke, I have provided definitions of the most common problems. 
Figure 1-1 attempts to illustrate the various cognitive impairments found post 
stroke and how they overlap.   
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Figure 1-1 Venn diagram of post-stroke cognitive complications 
 
MCI= Mild Cognitive Impairment, VCI=Vascular Cognitive Impairment 
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1.2.1. Delirium 
Delirium is a cause of cognitive impairment. It is defined as a “multifactorial 
neuropsychiatric syndrome with numerous predisposing and precipitating 
factors”.(24) In acute stroke patients this occurs within 13-48% compared to 10-25% 
patients in general medical wards.(25)  
The main difference between post-stroke delirium - when delirium is occurring 
alone and not leading to further cognitive decline- and cognitive decline is that 
delirium is temporary; however the strong links between vascular conditions and 
the exacerbation these have on any pre-existing dysfunction makes this difficult to 
distinguish from other common post-stroke cognitive impairments.(25, 26)  
Furthermore, disruption from stroke leading to delirium has been associated with 
long-term cognitive impairment.  It is thought that delirium may increase the 
neurodegenerative processes and thus have more than a temporary impact on 
cognition.(27) 
Delirium has three forms: hypoactive/hypoalert, hyperactive/hyperalert and a mix 
of these syndromes.(28) Different symptoms are associated with each.  Hypoactive 
(most common post-stroke)(28) corresponds with: facial inexpression, motor 
retardation, speech retardation, decreased reactions, perplexity and mental 
slowness.  In patients with hyperactive type delirium: increased and incoherent 
talking (logorrhoea), aggression, motor hyperactivity, increased reactivity and 
delusions are common.(29) Mixed delirium presents with a combination of 
hypo/hyperactive symptoms or signs with no clear pattern described.(30, 31) 
Delirium is not only associated with increased negative outcomes (including: poor 
functional outcome, time in inpatient care, increased risk of mortality and medical 
complications)(25, 32, 33) but can also be the beginning of developing/underlying 
dementia(26) and cognitive decline(34, 35) in some patients. 
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1.2.2. Vascular cognitive impairment 
Vascular Cognitive Impairment (VCI) is a term used to group the variety of cognitive 
impairments that occur due to vascular abnormalities.(22) Common types of VCI 
post-stroke include: Post-stroke cognitive impairment (any deficit in any cognitive 
domain following a stroke)(36); post-stroke dementia (the development of any type 
of dementia after having a stroke) including Alzheimer’s, multi-infarct and mixed 
dementias (36); and vascular cognitive impairment with or without dementia 
(cognitive decline in the context of any cranial vascular abnormalities).(37) The 
level of cognitive impairment post-stroke varies between individuals, stroke type 
and domains.(14, 17, 38)  With severe impairments the risk for developing dementia 
increases.   
 
1.2.3. Mild cognitive impairment  
Mild cognitive impairment (MCI) is a syndrome where “cognitive decline is greater 
than expected for an individual’s age and education level but does not interfere 
notably with activities of daily life”.(39) MCI can impair a variety of domains.(16, 
40, 41)  There are two subtypes that have been described: amnesic and non 
amnesic(42).  These are cognitive impairments that either affect or spare the 
memory domain.  Each of these subtypes can also affect a single or multiple 
cognitive domains.(42) The criteria for diagnosis include: individual and others 
noticing memory loss (in the presence of amnesic MCI), no other area of cognitive 
function with apparent impairment, able to be independent in daily activities, no 
other medical condition that could be underlying memory loss, do not meet the 
criteria for dementia.(43-45)   
People who develop MCI are more likely to have cerebrovascular problems.(46) 
Those with MCI are at risk of progressing in cognitive decline and developing 
dementia.  Annually, 9.6% progressed to dementia(47), between 8.1 and 8.3% to 
Alzheimer’s Dementia (47, 48), 1.9% to vascular dementia(47) within clinical 
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settings (e.g. memory clinics).  This decreased to 4.9%, 6.8% and 1.6% respectively 
within community settings.(47)    
 
1.2.4. Dementia  
Dementia differs from MCI by dysfunction affecting several cognitive domains more 
severely and impairs daily functioning reducing the individuals’ independence.(39)   
Dementia prevalence within the population is high, which could be due to an aging 
population, but the majority affected are in under-developed countries.(49) In 
2005, 24.3 million were diagnosed with a form of dementia and this is expected to 
double every 20 years.(50) Recent global estimates suggest an overall increase in 
incidence.(49) However, there is some evidence suggesting that annual prevalence 
may have begun to decrease within England and Wales.(51) This discrepancy could 
be due to the improvement of early life education and health explanatory factors as 
well as an aging population living longer.(49, 51) 
Dementia contributes to 11.2% of disabilities in the over 60s.(52) The prevalence of 
post-stroke dementia varies across different settings: around 30% in the community 
and 6-32% in hospitals.(17) In patients who are experiencing their first stroke, 
around 10% develop dementia with this increasing to one in three patients who 
suffer from recurrent strokes.(53)    
     
1.2.4.1. Pathology of dementia  
There are many types of dementia, each with different characteristics and causes: 
Alzheimer’s disease, vascular dementia, other degenerative cause dementia, mixed 
dementia.  The most common subtypes are Alzheimer’s disease (54% of all causes of 
dementia) and vascular dementia (16%).(54)    
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Alzheimer’s disease dementia (AD) is characterised by the presence of plaques in 
the brain.(55, 56)  Research suggests that the presence of these causes irreversible 
neurodegeneration.(57-60)     
Vascular dementia brings about cognitive decline through the lack of blood flow 
from the cerebral arteries.(61) Unlike AD, vascular dementia does not follow 
specific neuroanatomical patterns(62).  However, it is thought that cerebrovascular 
ischemia may provoke the production of precursors (proteins that bring on 
formation of plaques) of AD in the ischemic areas.(63) 
 
1.2.4.2. Risk factors for dementia 
The main independent risk factors for Alzheimer’s dementia are; apolipoprotein E 
(ApoE), increasing age, sex (higher risk in females), smoking, diabetes mellitus, 
vascular disease, hypertension, head trauma, low educational level and (in certain 
parts of the world) exposure to chemicals such as fertilizers and pesticides.(61)   
Risk factors for vascular dementia are; history of cerebrovascular disorders, stroke, 
hypertension, diabetes, high levels of low-density lipoproteins, smoking, cerebral 
white matter lesions, exposure to chemicals, alcohol and genetic diseases.(61, 63) 
Although there are some differences in risk factors between Alzheimer’s and 
vascular dementia, there is also a large level of overlap of risk factors that is 
reflected in the similar pathology.(60,62) 
There is also some evidence for a relationship between depression and development 
of dementia but the underlying process is unclear.(64, 65) 
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1.3. Impact of cognition on stroke recovery 
1.3.1. Cognitive impact on physical ability  
Patients with attention or global cognitive deficits have more severe functional 
disabilities than those with isolated memory impairments(66) and have a 
significantly reduced ability to recover even when cognition itself does not feature 
in the activity performance.(67) Furthermore, cognitive abilities on entering 
rehabilitation services have a significant positive correlation to end of 
rehabilitation functional outcome and are negatively correlated both with the 
length of stay in services(68) and independent living.(14) Specifically, it is the 
‘higher order’ cognitive abilities (comprehension, judgement, short term verbal 
memory and abstract thinking) that generally seem to have a larger influence when 
determining the length of stay in services, referral to outpatient therapies and use 
of therapies at home post discharge.(69) There is also evidence that comprehension 
levels impact on walking ability.(70) Attention deficits have also been found 
negatively to affect performance of daily activities and social interactions.(71) 
Problems with attention are also related to higher levels of accidents and falls.(72)   
 
1.3.2. Domain differences and changes 
1.3.2.1. Timing  
Research has shown that various cognitive domains are affected depending on the 
area of the cortex damaged and the time after the stroke.(15, 73, 74)  At the acute 
stage (<1 month) common areas affected are: executive function (particularly 
speed and attention, 72%)(15); visuo-perception/construction and numerical ability, 
affecting approximately 34-39%; 30-38% and 30%, respectively.(15, 74)  Recognition 
memory is the least affected area overall.(75) 
Attention and speed of information processing are the most prominent 
impairments.  They affect performance in all other domains, which may give false 
representations of the patient’s true capabilities.  Under assessment time 
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constraints, 70% of patients have difficulties and this is reduced to 50% when timing 
is no longer a factor.(75)    
Post-stroke impairments, however, are not stable in severity or expression.  
Patients between acute stage and 3 months post-stroke show significant 
improvement across executive functions especially within: speed and attention 
(number of patients with impairment halved); numerical ability and perception.(15) 
Transient impairments are most prevalent in the first week post-stroke (39%) 
compared with after this week (19%).(76) The dynamic nature of post stroke 
impairments can be illustrated by visual and verbal memory impairments compared 
to speed and attention. Generally visual and verbal memory are at a lower level of 
severity than other impairments at the acute stage but unlike other deficits, they 
do not improve over the first 3 months.(15) For speed and attention impairments 
improve rapidly over the first few months post stroke are the most persistent; more 
patients have impairment in this area after 3 months despite rapidly improving over 
the first few months.(15)   
There is some evidence of cognitive impairment stabilising from 3 months to at 
least 2 years post-stroke: those that have no/some/vast impairment generally 
maintain this level with few improving or declining.(73) This suggests that if we can 
predict a patient’s stabilised outcome from screening or acute assessments, then a 
patient’s long-term cognitive outcome could be identified and management 
adapted during the acute stage.  However, there is a lack of research into domain 
impairment stabilisation thus our understanding of post-stroke impairments must 
improve before this goal can be achieved.  
 
1.3.2.2. Classification of impairment 
As mentioned before, there is a lot of overlap between the subtypes of cognitive 
impairment.  Vascular cognitive impairment (VCI) and Vascular Dementia (VaD) both 
affect the majority of cognitive domains (less impact on verbal retention).(77, 78)  
Frequencies of impairment across domains (in descending order) include: 
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information processing speed, praxis-gnosis, visual memory, mental flexibility, 
abstraction, attention and visuo-construction.  They are distinguished by severity 
and level of impairment present within each population, measured using 
neuropsychological batteries and other cognitive domain specific assessments.  Key 
distinguishing areas are attention and concentration.  In order to classify patients 
into impaired (VaD or VCI) and no cognitive impairment (NCI), domains including 
abstraction, mental flexibility, processing speed and working memory are 
compared.  Using these domains 84% of patients can be correctly classified into 
impaired (VaD and VCI) or NCI groups.(78) The important component that can 
correctly distinguish 76.6% (of the VCI sub domain) of VaD patients is the severity of 
concentration impairment.(78)  
 
1.4. Impact of stroke on mood 
1.4.1. Mood changes associated with stroke  
Mood responses associated with stroke include anxiety(18), depression(79, 80), 
emotionalism (unprovoked, unfitting and uncontrollable emotional response), 
catastrophic reaction (inability to complete tasks or feeling inappropriately 
pressured during a task) and indifference (characterised by apathy and a lack of 
motivation).(81, 82)  At the acute stage, post-stroke major depression is estimated 
to occur in 25% of patients.(83) Studies show the prevalence of depression and 
anxiety symptoms post-stroke is high(79) and negatively impacts on mortality and 
recovery.(84-86) However, it is important to draw a distinction between depressive 
or anxiety symptoms (found for example on a psychometric mood scale such as 
HADS) and a clinical diagnosis of anxiety or depression.  These are not the same and 
arguably, some prevalence studies may over estimate the prevalence of depression 
(the clinical syndrome) by conflating it with the presence of depressive symptoms. 
In a recent systematic review of the incidence and prevalence of post-stroke mood 
problems, pooled analysis suggested that at anytime post-stroke prevalence was 
about 29% and was stable overall within ten years post-stroke.  There was no 
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significant difference found in prevalence across the various stages post-stroke: up 
to one month 28%; one to six months 31%; six months to a year 33%; and over one 
year 25%.  Prevalence also was not significantly different depending on the setting.  
Hospital and rehabilitation settings post-stroke each had a prevalence of 30% and 
community settings only 22%.  From pooled analysis, depression incidence post-
stroke within the first 5 years varied from 39% to 52%.  There was significant 
heterogeneity across study findings but this demonstrated the instability of 
development and recovery from depression.(87)   
Although poorly researched in comparison, anxiety is thought to occur between 4-
28%(88) and 3% for adjustment disorder.(89)  
Pooled prevalence of any type of anxiety disorder after stroke is 20%.  At the acute 
stage anxiety prevalence is 20% versus 23% up to five months and 24% from six 
months and after stroke.  Like depression, there is a slight variation in prevalence 
across different settings: 25% in hospitals, 21% in rehabilitation and 22% within the 
community.(90) Compared to general hospital inpatients, mood disorders are higher 
in stroke cohorts.(91, 92)  
The most common types of anxiety disorders post-stroke are phobias and 
generalised anxiety disorders. There is however, no significant difference in anxiety 
prevalence between patients suffering from first ever stroke and recurrent 
stroke.(90)   
Another common symptom is fatigue.  This is defined as “a sense of exhaustion, 
lack of perceived energy or tiredness that is distinct from sadness or 
weakness”.(93) This occurs in around 24% of stroke survivors at the acute stage 
(within the first few weeks) post-stroke.(93) There is a lot of overlap between these 
emotional responses, which increases the difficulty of distinguishing each affect in 
terms of epidemiology and impact on recovery, in both the long and short term.(81, 
94)   
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1.4.1.1. Depression 
There are predisposing factors that make stroke patients more susceptible to 
developing depression and for it to be maintained at one year post-stroke.  These 
include a previous history of depression, prior strokes, impairment in 
communication, low level of functional independence, perceived stress, low levels 
of reasoning capability and a low level of internal locus of control (the belief that 
the individual has control over what happens in life events).(20, 95-98)  
Other factors that can predict post-stroke depression at any stage include: post-
stroke disability, pre-stroke history of depression, cognitive impairment, stroke 
severity, anxiety and a lack of support from family or social circle.(87)   
There is also some evidence that suggests that ischemic strokes in the left 
hemisphere increase the possibility of depression with cognitive impairment, which 
increases the persistence of the depression compared to depression alone.(99, 100)   
Early neuroimaging studies suggested a relationship between stroke lesion location 
and mood disorder. Subsequent reviews have found significant heterogeneity among 
lesion study findings.   Overall, there was no significant association between lesion 
location and development of PSD in all type depression, major depression or various 
depression types within the first month post stroke.(87, 101)  
 
1.4.1.2. Emotionalism 
Post-stroke Emotionalism (PSE) is characterised by an “increase in the frequency of 
crying or laughing episodes” compared to the pre-stroke state of the patient.  It is 
characterised by having a sudden onset, with the emotions feeling like they are 
beyond the patient’s control.(82) PSE has now been described as being on a 
continuum with two main levels of severity.  The first is pathological laughter and 
crying (PLC).  Brought about through emotionally nonspecific stimuli, it has no 
effect on patients’ mood after the episode of laughter or crying.  The patient does 
however lose control of their facial expressions during an episode. The less severe 
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end of the continuum is emotional lability (EL).  Unlike PLC, this is triggered 
through stimuli that have an emotional context.  Feelings and expression are also 
experienced as unexpected and uncontrollable.  EL however, can affect the 
patient’s mood after an episode.(102)  
The prevalence of PSE in stroke survivors is between 10 and 20%. PSE has a large 
overlap with post-stroke depression (PSD) with between 30-50% of PSE patients also 
suffering from PSD.(103) The difference is that PSE is a ‘dysfunctional expression of 
emotion’ and depression an ‘abnormal formulation of emotion’.(103) In addition 
PSD has been shown to decrease over the first 3 months post-stroke and PSE 
increases in prevalence.(104) Nevertheless, unlike PSD, PSE has some evidence that 
significantly relates occurrence to lesion location.  The evidence suggests that 
microbleeds in the anterior and paramedian regions of the thalamus lead to a poor 
thalamofrontal connection which is the route of the out of control feelings and 
emotional symptoms.(105) As it is well known that executive functions (such as 
emotional control) are mainly within the frontal regions of the cortex, PSE has been 
found to correlate with microbleeds in the frontal cortex alongside executive 
function impairment.(106, 107)  This again supports the idea that emotional 
problems likely have a strong association with cognitive impairments.  
 
1.4.1.3. Anxiety 
Post-stroke anxiety, like depression, is common in community dwelling stroke 
survivors, especially in younger patients with a lower level of education.(108) 
Around 30% of patients are in the borderline category (above normal range but 
below cut-off for a problem) and 16% reported as having anxiety problems.(108) 
There is a high level of co-morbidity between PSD and post-stroke anxiety 
(PSA).(88) It is therefore difficult to distinguish the factors that put patients at risk 
of anxiety alone.  PSA is less well researched than PSD, but it is also known to 
impact on quality of life(109) and engagement with rehabilitation.(110) Patients 
debilitated by uncontrollable worry may avoid physical therapy sessions for fear of 
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failure (due to setting themselves unrealistic goals)(111) and/or falling.(112) Fear 
of stroke recurrence can be a further problem.(113) 
However, some evidence has been found comparing characteristics of stroke 
patients with various levels of worry and anxiety with and without depression.  The 
results suggest that unlike depression, anxiety is not as vulnerable to the patients’ 
background or stroke severity but the structures damaged by the stroke.  These 
tend to be more posterior than depression related lesion areas.(114) A common 
anxiety disorder in stroke (Generalised Anxiety Disorder) has been found to be 
associated with lesions in the right hemisphere and the left when co-morbid 
hemisphere with depression.(115-117) However, as previously mentioned for PSD, 
there are mixed findings in relation to mood disorders and lesion location.    There 
may be a significant relationship between anxiety and depression and the location 
of the lesion.  However, the heterogeneity within mood assessment methods, 
research design and patient demographics suggests this relationship requires further 
work to be established.(118)   
 
1.4.1.4. Adjustment disorder 
Stroke not only leads to disruptions in mood, it can also be difficult for stroke 
survivors to accept and come to terms with the disabilities they have been left with 
and how this now impacts on their way of living.(119) Adjustment is: “the process 
of adaptation that occurs over time as the individual manages, learns from and 
accommodates the multiple changes which have been precipitated by changed 
circumstances in their lives”.(120) Adjustment disorder is defined by the DSM-IV as 
“marked distress that is in excess of what would be expected given the nature of 
the stressor or by significant impairment in social or occupational functioning”(121) 
It can be acute (symptoms resolving within 6 months of the stressful trigger) or 
chronic (symptoms persisting past 6 months).(122) In an adult (non-stroke) 
psychiatric population, occurrence is between 5 and 21%.(123) Depending on the 
difficulties the patient encounters, the adjustment process has to be flexible, 
especially in stroke survivors where there is a wide variety of severity and type of 
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challenges to cope with.(119, 124)  Stroke survivors with aphasia have described 
obstacles such as: the impairment itself, how they feel, isolated from others, 
inaccessibility to help and poor knowledge of their condition.  The strategies in 
which these are challenged include: new ways of communication, interacting and 
sharing experiences with others in similar situations, help provided to make 
interacting easier as well as information on their disability and how to feel more in 
control.(125)    
For stroke patients in general, there are four main themes that contribute to 
adjustment.  These are: personal attributes (determination, perseverance, positive 
attitude, hopefulness and inner strength); adjustment strategies which are either 
practical (adapting activities, relearning old skills, goal setting) or mental 
(considering alternatives i.e. “what could have happened”); social support 
combining practical, emotional or moral help; and environmental changes such as 
structural modifications of home to accommodate for disability, provision of health 
care either locally or directly to home.(124)  
Before a patient adjusts to their new situation, coping strategies can either be 
unhelpful or beneficial.  Unhelpful or negatively orientated techniques include: 
avoiding situations, worrying, fantasising that things will be different, thinking that 
it is their fault and inappropriate use of harmful substances such as drugs or 
alcohol.  These cause the patient to experience higher levels of anxiety, 
depression, dysfunctional thinking as well as impacting negatively on their self-
esteem.(126) Beneficial methods are the individual being proactive in finding 
solutions to the problem(s), ability to successfully manage stress through finding 
the funny side of situations and getting involved in activities.  This approach tends 
to be implemented by those with a higher level of self-esteem and pre-stroke 
intelligence.(126) Coping strategies are linked to adjustment, which suggests that 
adjustment is improved with fewer maladaptive coping strategies.(126, 127)  A 
cohort of acquired brain injury patients demonstrated this.  Through a significant 
increase of adaptive coping strategies (seeking support and cognitive processes to 
adapt), patients showed a significant decline in depressive symptoms and an 
increase in reaching goals of therapy.(128)  
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1.4.1.5. Fatigue         
As described previously, post-stroke fatigue (PSF) is a subjective feeling of tiredness 
and exhaustion.  It can be brought about in relation to maintaining effort for a task, 
poor motivation or lack of effectiveness in performance.(129) Like cognitive 
impairment, fatigue prevalence varies with post-stroke timing.  Overall prevalence 
across all times is between 30-72% of stroke survivors.(129-133) It has been shown 
to be a persistent and relatively stable problem after stroke, with around 30% 
having PSF at 6 months and 34% one year after stroke.(134) There is a strong 
association between PSF, PSD and PSA at one year post-stroke.(134, 135) This 
association suggests it might be possible that PSD, PSA and PSF could contribute to 
maintaining each other, however association of such variables does not imply any 
causality.(131, 134) The converse relationship has also been described, with 
depression influencing the effect that fatigue had on physical ability.(132) 
However, this may only be true for some stroke survivors.  The relationship 
between fatigue and mood may be even more complex, one review found that 
although severe fatigue is regularly interpreted as a sign of depression, only a small 
proportion of these patients have higher depression assessment scores.  In addition, 
depressive symptom variance in patient groups was explained by lack of physical 
activity.(133)    
 
Fatigue also negatively affects post-stroke recovery in the long and short term.  PSF 
is linked to; cognitive impairment especially in attention and executive function 
domains(134), feeling of loss of control(135), speech impairments, feeling of poor 
health, attendance or living in a rehabilitation centre, low level of independence in 
activities of daily living and an increased mortality rate after 3 years.(131) These 
effects are likely to have a reciprocal relationship with a low mood(129, 136) and 
overall poor outcome i.e. feeling unwell will prevent or reduce attempts at 
activities of daily living independently.(131, 135)   
Characteristics that have been shown to predispose stroke survivors to PSF include: 
older adults, low levels of self motivation, pre-stroke rehabilitation care, pre-
stroke dependency on activities of daily living as well as prior stroke history.(131)        
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1.4.2. Effect of mood on stroke outcomes 
PSD and PSA lead to an increase in mortality.  Patients with PSD have been found to 
be three times higher chance of mortality within ten years post stroke than non 
depressed survivors independent of other risk factors.(137) There is a high risk of 
suicide with stroke cohorts making up 7.2% of annual incidence of all suicides in one 
area of a community sample(138) and a significant association between higher 
ratings of depressed mood and mortality at 12 and 24 months post-stroke.(139) 
Although suicide is an important aspect as it is potentially preventable, in absolute 
numbers, suicide as a cause of death in stroke has modest effects. 
Quality of life(109, 140) and engagement with rehabilitation are also affected.(110) 
Anxiety is also associated the level of pain a patient is in, their emotional reaction, 
ability to sleep as well as how socially isolated they become.  Co-morbid anxiety 
and depression are related to a decline in energy levels thus making it harder for 
patients to benefit from interventions (140) and have the motivation to participate 
in physical activities and engage with others.(141) PSE has also been found to be 
associated with features of distress, negative psychological states and relationships 
which affect quality of life post-stroke.(142)   
Furthermore PSD present while the patient is within hospital settings negatively 
impairs activities of daily living.  Although functional abilities improve after 
depression is treated (143), patients who suffered from depression have a slower 
rate of recovery even after PSD has depleted.  These effects have been found up to 
two years post stroke.(144) Low levels of functional outcome at 15 months post 
stroke are independently related to depression at 3 months post-stroke but this 
relationship is not present when using physical ability at 3 months to relate to 
depression status at 15 months.(145)   
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1.5. Assessing cognition and mood impairment in stroke survivors  
Stroke survivors with cognitive or mood deficits may have better outcomes if 
diagnosis is made at an early stage and appropriate management is started 
promptly (67, 146).  A recent national priority setting exercise identified 
“psychological problems” (particularly cognitive impairment and depression) as the 
most important but under-researched issues for stroke survivors and carers.(147) As 
they have potential effects on all aspects of function, some have argued that 
cognitive measures themselves may be a useful “global outcome” measure for 
stroke trials.(148) The gold standard for diagnosis of clinically significant cognitive 
impairment is measured through a detailed neuropsychological battery and a 
structured psychological interview for mood disorders. The gold standard for 
dementia is a clinical diagnosis using the DSM-IV criteria.  These vary depending on 
the subtype but the two most common are vascular and Alzheimer’s dementia.  
Vascular dementia is diagnosed if the following are met:(121) 
A. The development of multiple cognitive deficits manifested by both: 
1. Memory impairment (impaired ability to learn new information or to recall 
previously learned information) 
2. One or more of the following cognitive disturbances: 
(a) Aphasia (language disturbance) 
(b) Apraxia (impaired ability to carry out motor activities despite intact motor 
function) 
(c) Agnosia (failure to recognize or identify objects despite intact sensory 
function) 
(d) Disturbance in executive functioning (i.e., planning, organizing, 
sequencing, abstracting) 
B. The cognitive deficits in criteria A1 and A2 each cause significant impairment in 
social or occupational functioning and represent a significant decline from a 
previous level of functioning. 
C. Focal neurological signs and symptoms (e.g., exaggeration of deep tendon 
reflexes, extensor plantar response, psuedobulbar palsy, gait abnormalities, 
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weakness of an extremity) or laboratory evidence indicative of cerebrovascular 
disease (e.g., multiple infarctions involving cortex and underlying white matter) 
that are judged to be etiologically related to the disturbance. 
D. The deficits do not occur exclusively during the course of a delirium. 
 
The patient is diagnosed with Alzheimer’s disease dementia the following criteria 
are met: 
A. The development of multiple cognitive deficits manifested by both  
(1) Memory impairment (impaired ability to learn new information or to recall 
previously learned information)  
(2) One (or more) of the following cognitive disturbances:  
(a) Aphasia (language disturbance)  
(b) Apraxia (impaired ability to carry out motor activities despite intact 
motor function)  
(c) Agnosia (failure to recognize or identify objects despite intact 
sensory function)  
(d) Disturbance in executive functioning (i.e., planning, organizing, 
sequencing, abstracting) 
B. The cognitive deficits in Criteria A1 and A2 each cause significant impairment in 
social or occupational functioning and represent a significant decline from a 
previous level of functioning.  
C. The course is characterized by gradual onset and continuing cognitive decline.  
D. The cognitive deficits in Criteria A1 and A2 are not due to any of the following:  
(1) Other central nervous system conditions that cause progressive deficits in 
memory and cognition (e.g., cerebrovascular disease, Parkinson's 
disease, Huntington's disease, subdural hematoma, normal-pressure 
hydrocephalus, brain tumour)  
(2) systemic conditions that are known to cause dementia (e.g., 
hypothyroidism, vitamin B or folic acid deficiency, niacin deficiency, 
hypercalcemia, neurosyphilis, HIV infection)  
(3) substance-induced conditions  
E. The deficits do not occur exclusively during the course of a delirium.  
F. The disturbance is not better accounted for by another Axis I disorder 
(e.g., Major Depressive Episode, Schizophrenia).  
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These are time consuming and stretch the already limited resources of 
psychological services.  Therefore, the use of accurate screening tests is the best 
strategy to be employed in an attempt to reduce such a burden and implement 
early intervention.  UK national dementia strategy emphasises the need for good 
quality, early diagnosis to facilitate evidence based intervention and discussions 
around management and prognosis. However, many people with dementia remain 
undiagnosed or are diagnosed late in their disease journey. The importance of 
cognition and mood is recognised in International guidelines, where routine 
assessment is recommended for all stroke survivors but no direction is offered as to 
the preferred strategy.(149, 150)  Despite the importance of measurement of these 
areas post-stroke, there are arguments that screening may be causing more harm 
than good. Without evidence for effective interventions screening may overwhelm 
psychological and other services as well as cause distress to patients and 
family.(151, 152)  This is discussed in more detail later.  
In clinical stroke trials, outcomes are usually based around domains of: physical 
function; quality of life and mortality.(153) There is however potential benefit in 
including cognitive/mood assessments in trials.  For intervention trials, stroke 
survivors with substantial cognitive or mood deficits are often excluded.  However, 
lesser problems with mood and cognition may still impact on activity and 
participation outcomes.   
 
1.5.1. Assessments 
Health professionals have developed many tools to measure both cognition (with 
its’ various domains) and mood.  Despite having tools developed specifically for use 
in stroke, these are not regularly administered.(154) Instead, measurement choice 
is based on the popular clinical assessments used in unselected older adults and on 
opinion and preference of the health professional. There is a large overlap in 
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assessments chosen for the older adults, those with suspected dementia and those 
suggested for stroke patients.(22, 49, 51)  
Assessments can be directly administered to the patient or indirectly to a proxy 
(usually a family member or caregiver).  Depending on the assessment, timing and 
the intended impairment to be measured the choice of available tool differs.  In 
patients with frontal temporal dementia (FTD) and AD, indirect assessments appear 
to be better at quantifying the capability of patients’ day-to-day 
independence.(155) However, in general, proxy assessments of patients’ are not 
always valid.  For example, proxy measured patient quality of life had poor 
correlation with other measures (proxy estimates of health related quality of life 
scales, the Health Utilities Index) when assessed early post-stroke.(156) This finding 
was similar in a study of pain reporting in cognitively impaired children.  Parents 
tended to overestimate pain levels of their child early on.(157) The variations in 
proxy assessment validity could be because of the potential temporary impairments 
of stroke patients, or stress, anxiety and getting used to changes caused by the 
stroke that the proxy might experience affecting judgement of patient ability.  In 
light of this, we would assume that direct assessment would be more accurate in 
the early stages, using indirect assessments for severe cognitive impairments that 
have developed or changed over a reasonable amount of time.      
Below I describe some of the direct and indirect tools administered in both hospital 
and community settings for testing cognition and mood.   
 
1.5.1.1. Cognitive assessments  
Selection of cognitive assessment tends to be based around time required for 
completion, patient burden and requirement for specialist training.  Popular 
assessments include: 
1. Folstein’s Mini Mental State Examination (MMSE) 
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The MMSE is a short 30 point questionnaire to screen and grade cognitive 
impairment.  It was developed to replace lengthy batteries with a shorter more 
efficient assessment.(158) It has 6 sections that include; orientation, registration, 
attention and calculation, recall, language and commands.  It is scored out of 30 
with ≥25 being normal, mild between 21-24, moderate 10-20 or ≤9 indicating severe 
impairment.  It takes between 5-10 minutes to administer.(158) MMSE has been 
used in several seminal research papers.(22) Copyright is now being enforced and 
continued used of the MMSE has financial implications.  The MMSE demonstrates 
good sensitivity to correctly identify people with suspected dementia in specialised 
settings.  However it does not show the same capabilities for diagnosing MCI and 
AD, or distinguishing one from the other.  Furthermore, the components of the 
MMSE are unable to provide a measure of executive function.(159) For these 
reasons many centres are exploring, and are recommended to seek, alternative 
screening tools.(160) 
 
2. Montreal Cognitive Assessment (MoCA) 
The MoCA was originally developed as a brief screening tool to identify older adults 
with MCI that score in ‘normal range’ on other commonly used assessments.(161) 
MoCA has many properties that make it attractive for use with stroke survivors, 
however normative data are derived from community dwelling older adults and 
traditional MoCA score cut-offs were designed to distinguish mild cognitive 
impairment.(162) It is a 30-point test (≥26 is normal), taking about 10 minutes to 
complete.  It assesses several domains; short-term memory-recall; visuospatial 
ability; executive functions; language and orientation.  It is recommended for use 
in stroke by specialist societies.(22)   
There are mixed reports regarding validity of the MMSE and MoCA in identifying 
post-stroke cognitive impairments depending on the setting.(138, 163)  Despite the 
MoCA having a higher sensitivity than the MMSE overall, they both appear to be 
equally as efficient at identifying impairment at the acute stage post-stroke.(164, 
165)  However, there is an argument that with a change of cut-off, the MoCA is the 
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better choice of test as the MMSE is highly focussed towards orientation rather than 
executive function which, as previously discussed, are the telling areas of 
functionally debilitating cognitive impairment.(154, 166) 
 
3. Adenbrookes’ Cognitive Examination –Revised (ACE-R) 
The ACE-R was developed to fulfil the need for a bedside assessment that would 
diagnose and differentiate AD and other dementias, especially FTD.  It encompasses 
items that assess the key cognitive domains involved in AD and FTD not included in 
other measures without the use of expensive clinical equipment.  As the MMSE is 
widely used and validated as a brief mental status assessment, it was included 
within the ACE-R.(167) The ACE-R was validated as a good screening tool for 
cognitive impairment in rehabilitation settings of brain injury patients(155) and the 
language component appropriate to assess for aphasia in non-acute post-stroke 
patients(168) and some cognitive domains (i.e. visuospatial, attention and 
executive function) in acute stroke patients.(169) In post-acute stroke, the ACE-R is 
an effective tool to identify mild cognitive impairment.(166) Nevertheless, it has 
been found to be inappropriate for acute screening for overall cognitive impairment 
post-stroke due to confounding factors of acute stroke affecting performance on a 
lengthy and complex assessment.(169) There is however, a lack of research into the 
use and validity of the ACE-R post stroke. 
Due to the changes in copyright with MMSE a revised ACE the ACE-III has been 
developed.  ACE-III includes items similar to the MMSE but does not allow for a full 
MMSE score to be calculated.  Like the ACE-R, ACE-III is still scored out of 100 and 
assesses five domains: orientation/attention (out of 18), verbal fluency (14), 
memory (26), language (26) and visuospatial function (16).(168, 170)  Research has 
shown that the ACE-R can differentiate between AD and FTD and organic brain 
disease vs. psychiatric states.(171) Therefore, it is suggestive that the ACE-III will 
be able to do the same.  The ACE-R cut-off values vary in accuracy and validity; <88 
gives 94% sensitivity and 89% specificity and <82 gives 84% sensitivity and 100% 
specificity for dementia within community samples.(167) The same cut-off points 
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will be applied to the ACE-III.  Despite the ACE-III showing high sensitivity and 
specificity,(172) it takes around 30 minutes to complete in the general population 
and likely longer in stroke cohorts due to other impairments.  Stroke patients, as 
mentioned previously, have poor attention and concentration as well as reduced 
cognitive processing speed.  These alongside any other physical or speech 
impairments are likely to result in the patient struggling to complete the 
assessment.    
   
4. Hodkinson’s Mental Test and Abbreviated Mental Test (AMT) 
The AMT is a 26 item direct patient assessment.  It was developed to measure 
cognitive impairment in the elderly population.(173) Shortened versions, the AMT-
10(173) and AMT-4(174, 175), have been developed to further reduce clinician and 
patient burden.  Questions are a combination of orientation, recognition, memory 
and attention domains.  Dementia screening tests are preferred that do not require 
reading, writing, drawing and do not rely on a certain education level(176) which is 
something that the AMT provides.  It has been validated for detecting cognitive 
impairment across community and hospital populations.(177-179) However, 
although the AMT is validated across patient cohorts and is quick to complete, it is 
very heavily focussed on orientation and relies on verbal responses.  Thus it is 
unlikely to be suitable for many patients with aphasia.(180)  
 
5. Confusion Assessment Method (CAM) 
The Confusion Assessment Method (CAM) is the most commonly used delirium 
assessment system and has been validated for use in hospital inpatients.(181) The 
CAM is a two part clinical questionnaire to screen for delirium. A main advantage of 
this assessment is that it requires little formal training in comparison to other 
delirium assessments.(44) The first section contains 11 items that assesses overall 
cognitive impairment: acute onset; inattention – presence and abnormality; 
disorganised thinking; altered level of consciousness; disorientation; memory 
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impairment; perceptual disturbances; psychomotor agitation and retardation; 
altered sleep-wake cycle.  The second section comprises of four main features 
found to distinguish delirium from other cognitive impairments: acute onset and 
fluctuation course; inattention; disorganised thinking; altered level of 
consciousness.  Diagnosis of delirium is the presence of the first two features plus 
one of the others.(182) It takes around 5 minutes to administer.  
Although the CAM has not been specifically validated in acute stroke cohorts, it has 
been validated to identify delirium within ‘critically ill’ hospitalised patients.  
Moreover, the CAM-ICU format has been validated in post-stroke patients within 
intensive care units.(157, 183)  It is therefore limited in identifying global cognitive 
impairment. 
 
6. Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE) 
The Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE) is a 
questionnaire filled out by a caregiver/relative to determine the cognitive status of 
the person in question.  It assesses change in ability as a screen for cognitive 
decline or dementia.  It has 26 or 16 items relating to everyday tasks.  The 
informant has to rate the person in question in each task from 1 (much improved) 
to 5 (much worse).(184) It takes about 5 minutes to complete. 
The IQCODE has had mixed reviews in detecting post-stroke dementia(185, 186), 
but has been suggested to be used as supplementary information to complement 
patient based clinical assessments.(156, 187)  It has, however, been recommended 
and used as a good measure of pre-morbid stroke cognitive status(188, 189) and 
correlated with other cognitive assessment that can be administered post-
stroke.(190) However, an indirect assessment does not give a true measure of a 
patient’s performance and may over or under exaggerate a person’s cognitive 
capabilities. 
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1.5.1.2. Mood assessments 
Mood assessments are generally self-reporting questionnaires that rate feelings over 
a recent period of time.  Again these require usually little training in 
administration.  The favoured mood assessments include: 
1. The Centre for Epidemiologic Studies Depression Scale (CES-D) 
The CES-D assesses depressive symptoms over the previous week using negatively 
and positively phrased statements about behaviour and feelings.(191) It is a self-
report questionnaire that was designed for use in the community.  There are 20 
phrases scored on a likert scale of how often they have experienced this statement 
(rarely or none of the time - less than 1 day to most or all of the time – 5 to 7 days), 
each is rated 0-3.  There are 4 positively phrased statements, which are scored 
backwards in their regularity of occurrence.  Higher scores are representative of a 
lower mood.  There are 9 areas of symptoms covered by the questionnaire.  These 
include: sadness, loss of interest, appetite, sleep, thinking or concentration, guilt, 
tiredness, movement and suicidal ideation.  The categories for depression are based 
on the cut-offs: less than 16 for low depression, 16-25 for mild depression and 26 
and over for major depression.(48) It has been validated in community (60, 70, 192) 
and stroke populations.(193-196)  
2. Hospital Anxiety and Depression Scale (HADS) 
HADS(197) is a validated screen for depression and anxiety in acute hospital settings 
and stroke (198, 199), reports of accuracy are mixed.(200-202) HADS comprises 14 
multiple-choice items (7 for depression and 7 for anxiety) each scored 0-3 giving a 
total score of 42 (21 per subscale).  HADS is designed to not be influenced by 
somatic problems.  This is achieved through items relating more to feelings of 
enjoyment towards activities rather than physical ability, and avoidance of items 
relating to somatic symptoms of medical illnesses e.g. insomnia or fatigue. This 
design means HADS is not influenced by somatic problems, making it more suitable 
as a mood symptom screen for all types of physically impaired or ill patients.(198) 
HADS can be administered verbally.  Conventional scoring defines “definite 
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abnormal mood” as HADS≥11/21 for each subscale; scores of 8-10 are “possible 
abnormal mood”.  However, it has been suggested that in stroke cohorts cut points 
should be lowered to improve accuracy especially in cases where there are 
communication problems.(51, 201, 203)  Cut-offs as low as >4 or >5 have been 
found to be reasonable in detecting mood problems.(202, 204)  Although, when a 
higher cut off for depression subscale (≥7 or ≥8) and lower for anxiety (≥5 or ≥7) is 
implemented, accuracy increases.(49, 199)  
 
3. Geriatric Depression Scale (GDS) 
The GDS was developed specifically for screening an older adult population for 
depression.  There are 3 versions of GDS: 30, 15 and 4 point scales.(71) The 30-
point version of the scale has been validated in stroke cohorts but research suggests 
it is likely to require a complementary, more specific instrument used in tandem 
(i.e. Becks Depression Inventory).(193, 205, 206)  It is a self-rating questionnaire 
comprising of 30 statements about feelings over the past week with a binary answer 
(yes or no) for each.  The statements are phrased in a positive or negative way with 
the corresponding ‘depressive’ answer representing 1 point.  Scored out of 30, 
normal range is considered between 0 to 9 (inclusive), mildly depressed between 10 
to 19 (inclusive) and very depressed 20 to 30.(71) This has been validated in 
hospital populations(207) and as a shorter version.(72)   
The CES-D, HADS and GDS all require a certain degree of concentration in order to 
process and choose a response to a multiple choice answer. Stroke patients with 
poor attention may struggle even when supported and the scales are verbally 
administered. Furthermore, each scale likely requires a degree of intact executive 
function.  As there is a high proportion of cognitive impairment within stroke 
patients, especially with executive function, responses to such scales could be 
affected and thus may provide a less than accurate assessment of mood symptom 
presence. Simplified measures such as DISCS and Yale Single Question may be more 
appropriate.(208, 209)  
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1.5.2. Identification of post-stroke cognitive and mood impairment 
Before an abnormality can be treated we require a clear way of identifying it.(210) 
By gathering information on abnormalities across patients, disorders can be 
described and defined.  In order for disorders to be identified, an accurate form of 
assessment is needed.  Health professionals require tools that can distinguish 
presence or absence of a disease before an intervention can be attempted.(211, 
212) 
Assessment in the first few days after stroke may be complicated by impairments of 
communication, physical function and medical illness.  Aphasia, common in 
stroke(213),  can lead to depression post-stroke(96) but also can limit measures 
used and provide inaccurate diagnosis.(214, 215)    Stroke severity and resulting 
physical impairment may complicate assessments that require motor skills.  Stroke 
severity (motor impairment) is related to depression(216, 217) and likely to be 
related to anxiety(218).    
In order to decide what is and is not a good identifier, statistical measures are used 
to describe the capability of the measurement tool and compare it against others.  
Assessments are generally compared to the best way of identifying the disease, also 
known as the ‘reference standard’, to determine test accuracy.(219)      
 
1.5.3. Precision 
Commonly used clinical accuracy descriptors are: sensitivity, specificity, likelihood 
ratios and predictive values.  These relate to the probability and performance of 
the assessment being analysed (index test) giving a correct disease positive or 
disease negative classification base on the reference standard outcome and disease 
prevalence.(211) 
Sensitivity is a measure of the assessment ability to identify subjects with a 
specified disease.  In other words it is the probability of the subject getting a 
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positive index test result when they have the disease in question.  Specificity 
complements sensitivity in that it describes the proportion of subjects that get a 
negative index test result that do not have the disease in all of those without the 
disease in the cohort being assessed.  It is the probability that a negative test result 
will be found in a non-diseased subject.(220) There is generally a trade off between 
sensitivity and specificity.  If the test involves a graded score then the probabilities 
associated with sensitivity and specificity can be made to vary depending on the 
diagnostic threshold.  By increasing the threshold, sensitivity decreases and 
specificity increases and vice versa when threshold is lowered.(221) This is 
illustrated in Figure 1-2.(211) 
TN FN FP TP
specificity=99% sensitivity=69%
diseasednon-diseased
0 40 80 120 160
test measurement
diagnostic threshold
	  
Figure 1-2 Effect of varying diagnostic threshold on test accuracy 
Taken from the Cochrane handbook for systematic reviews of diagnostic test accuracy (chapter 10 
p12)(211) 
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Likelihood ratios are the ratio of an expected index test result in those with a 
disease to those without disease.  It links the probability of the subject’s pre and 
post test disease presence i.e. how likely is it that a certain test result will occur in 
those with or without the disease.  There are two different ratios calculated from 
accuracy data.  The first, positive likelihood ratio (LR +), is how likely it is that a 
positive index test result will occur in a subject with the disease than a subject 
without.  This is usually >1. Second is the negative likelihood ratio (LR -), which is 
the ratio of probability that an index negative test result will occur in a diseased 
subject to the probability that it will occur in a non-diseased subject. Therefore it 
is how much less likely that a diseased subject will be classified as negative than 
someone without the disease.  This is usually <1.  Each of these ratios are 
calculated from sensitivity and specificity of the index test: LR+ = sensitivity/(1-
specificity) and LR- = (1-sensitivity)/specificity.(220)  
Predictive values, also a measure of accuracy, differ in that they take into account 
sensitivity and specificity along with the prevalence of the disease.  The positive 
predictive value (PPV) is the proportion of patients that have a positive index test 
result in the total number of subjects with the disease i.e. the probability that a 
positive test result will be in a subject with the disease.  Negative predictive value 
(NPV) is the opposite, the probability that subjects without the disease will have a 
negative test result.  These probabilities are dependent on the prevalence of the 
disease within the cohort being tested i.e. in a population with a high prevalence of 
the disease will have a high PPV and low NPV.(220)   
Calculation of these measures are illustrated through a 2x2 table.(127, 183) (Table 
1-1). 
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Table 1-1 2X2 table to calculate sensitivity and specificity 
 REFERENCE STANDARD  
 
INDEX 
TEST 
 Disease Present Disease Not 
Present 
 
Test Positive True Positive  
(TP) 
False Positive    
(FP) 
PPV 
TP/(TP+FP) 
Test Negative False Negative   
(FN) 
True Negative   
(TN) 
NPV 
TN/(FN+TN) 
 Sensitivity 
TP/(TP+FN) 
Specificity 
TN/(FP+TN) 
 
 
 
PPV= Positive Predictive Value, NPV= Negative Predictive Value 
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From the 2x2 table the positive and negative predictive values can also be 
calculated.  These are probability calculations.  They measure the probability that 
a positive or negative disease outcome on the index test is a true positive or 
negative disease presence.  These values are a measure of how well the test can 
identify those with and without the disease in comparison to the gold 
standard.(194) 
Interpretation of what is good sensitivity/specificity is subjective.  In statistics 
arbitrary values of ‘poor’ and ‘good’ sensitivity and specificity have been 
described, but these values are of limited utility in practice as the threshold at 
which we define acceptable test accuracy is fundamentally dependent on the 
clinical meaning of false positive and false negative results.  
For example false positives could lead to invasive and painful follow-up procedures 
if testing for cancer. Unnecessary cancer treatment carries risks.  Alternatively, if 
the patient were given a false negative they would be missing out on potential 
treatments that they could benefit from.  In this work, I am trying to determine if 
the patient is at risk of dementia or other multiple domain cognitive impairments 
that could infringe on their recovery post stroke.  Unlike my example of cancer, 
there is a lack of established beneficial treatments or therapies.  Mood problems 
are similar in that not all stroke patients respond well to antidepressants or anti-
anxiety medications.  Some psychological therapies are available but again vary in 
effectiveness depending on the patient.  However, both cognitive and mood 
problems can lead to a lack of independence, reduce activities of daily living and 
thus quality of life.   
False positives could inflict psychological distress on the patient and family, 
generate unnecessary stigma of a mental health diagnosis, increase costs for future 
planning, incur direct costs and burden from further tests, place strain on 
relationships and force inappropriate lifestyle changes yet with no guaranteed 
beneficial treatment.  False negatives from screening could prevent the patient 
from receiving help when it would have the biggest beneficial impact.  They would 
not gain access to educational or supportive resources, would incur increased 
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financial costs as their condition deteriorates, may become a danger to themselves 
and or others, and loose the opportunity to plan for implementation of their wishes 
when they lose capacity to make their own decisions.  They also suffer from 
adjustment issues from being given the wrong information from screening test.  
For a measure to be valid it must also be reliable along with accurate.  Reliability is 
defined as ‘the ratio of variance of the true values between individuals to the 
variance of the observed values (combination of individual variation and 
measurement error)’.(222) An assessment must be able to perform in the same way 
across a population.  There are three overlapping terms that cover assessment 
reliability.  These are: interrater – ability for the assessment to be administered by 
different people and perform in the same way; intrarater – ability of the assessment 
to be consistent when administered over several occasions by the same person; 
test-retest reliability – for the assessment itself to be consistent with measurement 
when administered to the same patient.(223) Inconsistencies across these can lead 
to assessment validity decreasing.(224, 225)  
Validity describes how well an assessment measures what it claims to test.  There 
are five types of validity: construct validity – does the test assess what it is meant 
to; concurrent validity – does the assessment correlate with other similar tests 
overall and in individual components; face validity – if the test seems to measure 
what it is meant to; localisation validity – does the assessment tap into different 
domains accurately; ecological validity – can the assessment predict actual 
capabilities of the individual assessed.(223) 
 
1.5.4. Prognosis 
An important component of valid identification of deficits is distinguishing between 
transient problems and those that have a long-term impact.  The most important 
problems are those that will persist.  In addition to cross sectional descriptions of 
test accuracy (i.e. comparing and index test and gold standard at a single time 
point) there is an argument for describing ability of a screening test at a certain 
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time point to predict development or persistence of a problem.  This approach is 
often referred to as delayed verification accuracy.(226) Therefore in screening 
tools, sensitivity is generally favoured over specificity so that those with a potential 
issue can be properly assessed after a positive screening result.  This discussion is 
continued in section 1.5.6.  
 
1.5.5. Feasibility and acceptability 
In order for problems to be detected the tests not only have to be accurate but 
able to be administered/completed by the patients.  If the assessment cannot be 
completed by the majority of patients within a certain population then resulting 
data will be biased.(227) Feasibility can be determined by describing proportions of 
patients who are able to complete assessments against the total population that 
would be tested.  It can be useful to describe to what extent extra assistance is 
required to attempt/complete measures.  Acceptability can be estimated from 
those that refused/withdrew compared to those that consented.  Potential 
strategies to improve feasibility and acceptability include explanation of the 
screening tool by the test administrator(195); protocols in place for when a positive 
result is found(196); proper training in the use of assessments to improve 
confidence of the administrator and to reduce assessment time.(200)    
 
1.5.6.   Cognitive and mood screening debate 
Guidelines recommend that all stroke survivors are assessed for cognitive and mood 
dysfunction(150, 228, 229) However, lack of evidence for interventions having a 
positive effect on outcomes questions the benefits of screening measures.(230) It 
has been argued that early diagnosis with no available effective interventions or 
treatment for cognitive problems could cause more harm than good, leading to 
overburdening of medical resources and unnecessary testing.(152) Furthermore 
there is evidence of negative psychological effects on patients diagnosed with 
dementia.  The diagnosis can lead to patient distress, frustration, anger as well as 
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affecting close relationships and even increasing the risk of suicide.(231, 232)  
Research suggests that this issue is more apparent in cognitive screening and not 
mood.(233) 
      
In order to make recommendations regarding neuropsychological assessments, 
especially in screening for cognitive impairment, their needs to be development in 
several areas.  Research is required in diverse patient groups to identify the 
benefits and possible harmful effects of assessment and if this differs between 
patient cohorts.  Investigations into the characteristics and natural development of 
cognitive impairment and mood problems (e.g. depression and anxiety disorders) is 
needed to improve our understanding of potential diagnostic benefits as well as 
development of accurate screening and diagnostic tools across a variety of 
populations.(234) In clinical practice, if we are to offer screening we must have 
robust strategies to deal with any potential problems detected by the assessments, 
this could include training and educated of healthcare staff and improved access to 
support services.(229, 235)     
 
1.6. Main research aim 
This research therefore aims to identify: what, if, when and how cognitive and 
mood screening can be implemented at certain stages in the stroke patient journey.  
A good screening test should: not require specialist training to administer or 
interpret; be as short as possible to reduce patient burden, administration and 
interpretation time; have good sensitivity and specificity; be able to be completed 
by the majority of patients and not vary in performance depending on patient co-
morbidities or administrator.  I will describe certain of these properties for tools 
used in stroke research and practice.   
I will do so by: identifying the assessments used in research and clinical practice 
and how valid they are in stroke cohorts; investigating the accuracy of these 
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commonly used assessments in identifying multi-domain cognitive impairment, 
dementia and clinically persistent mood problems; determine the feasibility and 
accuracy of cognitive and mood assessments in the acute stroke stage.  
 
1.7. Research strategy  
To investigate these research questions I present a series of projects that follow a 
common thread to describe cognitive and mood assessments in stroke.  I first 
established the prevalent cognitive and mood assessments in the literature and in 
usual practice. In establishing common assessments I carried out diagnostic test 
accuracy reviews and original research of preferred assessments (direct strategies) 
and describe their test accuracy (sensitivity, specificity).  In addition I assessed the 
feasibility of preferred assessments at the acute stage post- stroke.  
I hope that this work will inform treating teams on how to effectively detect 
clinically important cognitive and mood impairments, overcoming obstacles within 
the hospital settings and common physical impairments experienced by stroke 
survivors.   
This should allow for the identification of when post-stroke is it possible to screen 
to provide meaningful information.  Through this, I hope to provide the foundation 
for developing guidance of valid assessment of cognition and mood following stroke.   
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Chapter 2 Investigation of cognitive and 
mood assessments used in research and 
usual practice 
2.1. Introduction 
As discussed in chapter one, clinical research tends to focus on physical function, 
quality of life and mortality as main outcomes post-stroke.(153) With cognition and 
mood impairments impacting on recovery it is important that these are considered 
in research endpoints to give a more detailed view of patient recovery.  With 
evidence of cognition and mood impacting on all aspects of function, some have 
argued that cognitive measures themselves may be a useful “global outcome” 
measure for stroke research.  
Many cognitive/mood assessment instruments are available to researchers, but at 
present there is no consensus on optimal measure(s) for use in stroke practice or 
research.  Literature around the properties of stroke trial assessments is emerging, 
although to date there has been limited research on the properties of common 
cognitive/mood assessments in stroke.  Screening and assessment tools that are 
validated and popular in non-stroke settings may not be appropriate in stroke 
survivors, who are more likely to have language, physical and cognitive impairments 
or to be medically unwell in the acute phase (74, 169, 236).  Training and 
educational resources can improve application of assessments for clinical 
studies(153) however we first have to know which tools are commonly employed.  
At present there are no specific hospital protocols in place for cognitive and mood 
assessment post-stroke despite strategies for rehabilitation assessment and the 
route of care stroke patients should go through.(237, 238)  Thus I sought to describe 
the cognitive/mood assessments used in contemporary published stroke trials in 
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study one and usual clinical practice across Scottish stroke care settings in study 
two. 
 
2.2. Study One: Cognitive and mood assessment in stroke research – 
focussed review of contemporary studies 
There are many measures available to assess for various post-stroke deficits.  
Stroke affects a range of functions at various stages.  Therefore choice of test most 
appropriate to a research study is likely to vary.  For recommendations to be made 
it is useful to describe current practice.  I chose to perform a literature review to 
gather information on which assessments in cognition and mood are used in 
research to guide my later work. 
 
2.2.1. Methods 
I used a sensitive, focussed bespoke literature search strategy.  Following informal 
review of similar research pertaining to functional assessments(153), a cognitive 
screening diagnostic test accuracy review(239) and stroke neuropsychological 
recommendations(22), along with knowledge of journal publication themes, I chose 
to restrict analysis to 16 journals selected based on relevance to stroke; impact 
factor and proportion of clinical studies. The journals selected were: the British 
Medical Journal (BMJ Publishing Group), The Journal of the American Medical 
Association (American Medical Association), The Lancet (Elsevier), The New England 
Journal of Medicine (Massachusetts Medical Society), Age and Aging (Oxford 
Journals), Journal of the American Geriatrics Society (The American Geriatrics 
Society), Lancet Neurology (Elsevier), Neurology (American Academy of Neurology), 
Journal of Neurology, Neurosurgery and Psychiatry (BMJ Publishing Group), 
American Journal of Psychiatry (American Psychiatric Publishing), Archives of 
Clinical Neuropsychology (Oxford Journals), Journal of the International 
Neuropsychological Society (Cambridge Journals), International Journal of  Geriatric 
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Psychiatry (International College of Geriatric Psychoneuropharmacology), Stroke 
(American Heart Association), Cerebrovascular Diseases (Karger) and the 
International Journal of Stroke (World Stroke Organisation). 
Following external peer review advice, a further 6 journals were added to broaden 
the scope of the search.  These were: Neurorehabilitation and Neural Repair (Sage 
Journals), American Journal of Geriatric Psychiatry (Elsevier), Brain (Oxford 
Journals), International Psychogeriatrics (Cambridge Journals), European Journal of 
Neurology (Blackwell Publishing), Neuropsychologia (Elsevier).  Journals 
representing general medicine; geriatric medicine/rehabilitation; neurology; 
psychology; psychiatry and stroke were included. (Figure 2-1) 
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General Medical: British Medical Journal, Journal of the American Medical Association, Lancet,                           
New England Journal of Medicine
Gerontology/Rehabilitation: Age and Ageing, Journal of the American Geriatric Society, 
Neurorehabilitation and Neural Repair 
Neurology: European Journal of Neurology; Lancet Neurology, Neurology,                                                        
Journal of Neurology, Neurosurgery and Psychiatry
Psychiatry: American Journal of Psychiatry, American Journal of Geriatric Psychiatry;                                
International Psychogeriatrics; International Journal of Geriatric Psychiatry, 
Psychology: Archives of Clinical Neuropsychology, Brain; Journal of International Neuropsychology, 
Neuropsychologica
Stroke: Stroke, Cerebrovascular Diseases, International Journal of Stroke 
Total papers screened n=80988
Total papers describing stroke survivors n=8826
Stroke papers with cognitive/mood measures n=485
Total stroke papers Total with cognitive/mood measures
General Medicine 316 9
Gerontology/Rehabilitation 475 25
Neurology 838 111
Psychiatry 75 41
Psychology 129 62
Stroke 6993 237
Stroke survivor studies with cognitive assessment n=330                              
(82% of all papers with cognitive/mood assessments)
Number differing tests used n=300 
Stroke survivor studies with mood assessment n=246                                   
(64% of all papers with cognitive/mood assessments)
Number differing tests used n=67
 
Figure 2-1 Search Strategy for assessing cognitive/mood measures in 
contemporary stroke trials 
*Total papers with a cognitive or mood assessment had overlap and were counted 
in the number of papers with a cognitive assessment as well as those with a mood 
measure. 
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Journals were hand searched for relevant articles January 2000 to October 2011 
inclusive, reviewing all content, including letters and short reports.  Inclusion 
criteria were: original research in adult, human stroke survivors.  From these 
studies, I extracted details on any cognitive or mood assessments employed 
(including inclusion/exclusion criteria; primary outcome and secondary 
outcome(s)).  Selection was deliberately inclusive.  Where additional methodology 
was described in on-line or paper supplement this was accessed.  I did not contact 
authors of manuscripts.  Where a dataset was used more than once, with the same 
outcomes, the primary paper only was considered. 
I used inclusive definitions of cognitive measures (any aspect of cognitive function 
including language and visuospatial/constructional skills) and mood. Where a 
neuropsychological battery was employed I listed the individual test components.  
Quality of life or global measures were included if they included a specific cognitive 
or mood component.  Carer assessments and proxy assessments were included if 
they related to mood/cognition.  Fatigue scales were not included. 
Two researchers (a clinician, Dr Jennifer Harrison and myself) independently hand 
searched journals and compared results.  Resulting lists of cognitive and mood 
measures were checked for relevance by an independent clinician (Dr Terrence 
Quinn) and a clinical psychologist (Dr Niall Broomfield).  Final decision on inclusion 
was by group discussion and consensus.  As a further validity check, an 
independent, blinded researcher (Dr Patricia Fearon) hand searched a random 
selection of four journals and four years.  This search did not reveal any new 
studies, suggesting validity of the original searches.  I described outcomes as 
absolute numbers of assessments and proportions. 
 
2.2.2. Results  
Across 22 journals, the total number of papers was 80988, with 8,826 (11%) papers 
detailing stroke survivor original research.  Of these 485 (5%) had employed 
cognitive or mood assessment scales: 246 papers employing cognition measurement 
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only, 51 mood assessment only and 188 using both.  Where cognitive/mood 
assessments were used, the median number of tests was 2 (IQR 1-3, range 1-21).  A 
cognitive/mood measure was used as primary outcome in 353 (72% of papers with 
cognitive/mood measure); secondary outcome in 56 (11%) and as 
inclusion/exclusion criteria in 59 (12%).  Psychiatry journals were most likely to 
detail cognitive/mood outcomes in stroke survivors (n=41 studies), although 
absolute number of stroke studies was modest (n=75 studies). 
Total number of different cognitive/mood assessments was 367.  Of 67 mood 
assessment scales used in 246 papers, the most prevalent were the Hamilton Rating 
Scale for Depression (n=43 [9% of all papers with cognitive/mood assessment]) and 
short form-36 health survey (n=40 papers [8%]). Where authors used their own 
cognitive assessments or did not specify what measure was used, these were 
excluded from total scale calculations. (Table 2-1)    
Of 300 cognitive assessment scales used in 330 papers, 15 (5%) were clinical 
diagnostic criteria tests (i.e. the DSM-IV); 86 (29%) were neuropsychological test 
batteries or assed multiple cognitive domains the remainder assessed single 
domains.  The most prevalent assessments were Folstein’s mini-mental state 
examination (n=180 [37%]) and Wechsler Adult Intelligence Scale (n=84 [16%]). 
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Table 2-1 prevalent cognitive/mood assessment modalities in 
contemporary published stroke research 
Test Number of papers 
% of total papers with 
cognitive/mood assessment 
(n=485) 
Cognitive Measures † 
Mini Mental State Examination 180 (37%) 
Wechsler Adult Intelligence Scale* 84 (17%) 
Wechsler Memory Scale*  44 (9%) 
Informant Questionnaire on Cognitive Decline in the Elderly 32 (7%) 
Trail Making Tests A and B 28 (6%) 
Mood Measures 
Hamilton Rating Scale for Depression 43 (9%) 
Short Form-36 Health Survey 40 (8%) 
Hospital Anxiety & Depression Scale 29 (6%) 
Beck Depression Inventory 27 (6%) 
Geriatric Depression Scale 25 (5%) 
 
† “Authors own”; unspecified scales excluded 
*subscales of battery 
Included: vocabulary, similarities, information, comprehension, arithmetic, digit span, 
letter-number sequencing, picture completion, block design, matrix reasoning, digit 
symbol-coding and symbol search in various combinations or individually.  
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2.3. Study Two: Questionnaire assessment of usual practice in mood 
and cognitive assessment in Scottish stroke units.  
This study was designed to determine if cognitive and mood assessments are being 
used in usual practice and if they are, do the assessments implemented correspond 
to the lack of consensus we found in study one.  
 
2.3.1. Methods  
2.3.1.1. Piloting  
Questionnaire design and piloting was based on published guidance: The Canadian 
Medical Association Journals guide for self administered surveys; The Journal of 
Internet Medical Research web survey checklist (CHERRIES) and The International 
Journal for Quality; The International Journal for Quality in Health Care Good 
practice in conduct and reporting of survey based research (240-242) and the first 
part of this study demonstrating which cognitive/mood assessments are used in 
stroke research.  I developed the questionnaire to assess key themes: Do 
practitioners assess mood/cognition? When and how are these assessments 
performed?  How do these assessments inform management? A particularly 
challenging scenario is assessment of patients with communication impairments and 
I added a specific question on this.   
I performed pilot work in two sites (Glasgow Western Infirmary and Glasgow Royal 
Infirmary) using a two-stage method.  A draft template was circulated to 
representatives from stroke medicine; nursing and clinical psychology and discussed 
with individuals (in a focus group setting and through written comments collated by 
the authors).  Content was revised using an informal discussion process, combining 
opinions of various members of the stroke multidisciplinary team (professors, 
consultants, registrars, nurses, occupational therapists and physiotherapists).  The 
revised questionnaire was distributed to a wider group and allowed free-text 
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comments on phrasing and formatting.  Comments were collated and decisions on 
final content were made based on authors’ consensus.  
 
2.3.1.2. Distribution 
My final questionnaire was a one-page (A4) paper document with categorical and 
qualitative responses (Appendix B).  I hosted the questionnaire on an open-access 
website.  Responses were anonymous but I requested respondents’ discipline and 
principal work place. 
Mixed methodologies of distribution were used to ensure comprehensive coverage.  
The target group was all staff involved in direct stroke patient management across 
acute, rehabilitation and outpatient care.  I contacted all Scottish, Stroke Managed 
Clinical Network (MCN) co-coordinators (n=12) to distribute the questionnaire across 
their network.  I emailed specialist groups (Scottish Stroke Nurses Forum, Scottish 
Stroke Neuropsychologists, British Geriatric Society (Scotland), British Association 
Stroke Physicians, Stroke Allied Health Professionals and Association of Chartered 
Physiotherapists Interested in Neurology) and distributed paper copies through the 
U.K Stroke Forum delegate pack.  Reminder emails and letters were sent round MCN 
co-coordinators who did not respond after 1 month.  I checked responses against a 
list of hospitals providing stroke care using Scottish stroke care audit data.(243) 
 
2.3.2. Analysis 
For the data, I described absolute and percentage values, comparing responses 
across groups using Chi-square analysis (SPSS statistics 19, IBM).  Qualitative data 
were grouped into shared themes by hand coding the free text responses. 
This study was assessed by the manager and scientific officer for the West of 
Scotland Research Ethics Committee; formal Research Ethics approvals were not 
required (Appendix A).   
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2.3.3. Results 
I received 174 responses, this comprised 10/14 (71%) Scottish Health Boards.  
Respondents represented most mainland Scottish health boards (Figure 2-2); 
Absolute number of returns was highest from Greater Glasgow and Clyde Health 
Board (n=55, 32% of all respondents).  Respondents comprised medical staff (61, 
35%), occupational therapists (27, 16%), other health professionals (including those 
that did not specify a profession) (27, 16%), nurses (23, 13%), psychologists (13, 7%), 
physiotherapists (12, 7%) and speech therapists (11, 6%).  Respondents more 
routinely assessed cognition (n=148, 85%) than mood (n=119, 72%, p<0.001). 
Proportions of respondents performing cognitive/mood assessment were collated 
(Tables 2-2 and 2-3).  Respondents reporting routine assessment of cognition varied 
by health board, there was no geographical difference in number of respondents 
reporting cognitive assessment (p=0.879) but there was for mood assessment 
(p<0.001).  Glasgow and Greater Clyde Health Board had the highest number of 
respondents assessing mood (n=36, 21%).    
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Figure 2-2 Survey response rates across Scottish NHS regions 
*No responses were obtained from Dumfries and Galloway, Forth Valley, Orkney or Shetland NHS 
boards.  
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A variety of tools were used for stroke survivor assessments (cognitive n=45 tools; 
mood n=17).  The MMSE (158) (n=190, 32% of reported assessment use) and the 
HADS (197) (n=121, 53%) were the most commonly used.  There was no difference in 
use of these measures across health boards (MMSE p=0.078, HADS p=0.762) or 
professions (MMSE p=0.535, HADS p=0.953) (Tables 2-2 to 2-6).  Informal and 
bespoke methods were also prevalent, “observation” (n=22, 13%) and “informal 
questioning” (n=25, 14%).  
I defined the ‘acute stroke’ setting as within the first 2 weeks of stroke; 
‘rehabilitation’ was when patients had left the acute stroke ward and were 
receiving further care in a hospital or care facility (usually more than 2 weeks after 
stroke).  Finally, outpatients were those that had been discharged from hospital 
facilities but could still be receiving treatment and support in the community or 
through clinic.  We used percentages to describe frequency of responses due to the 
volume of responses given for each assessment across the settings: for example the 
MMSE may have been reported to be used across both the acute and rehabilitation 
setting by the same responder so all reports of usage were added up for each 
setting and then a % of the overall number of reports (in individual and all settings) 
was calculated. 
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Table	  2-­‐2	  NHS	  board	  reports	  on	  using	  the	  MMSE	  and	  HADS	  across	  all	  settings	  
NHS Board MMSE (n 
of reports 
all 
settings) 
HADS (n 
of reports 
all 
settings) 
Ayrshire and Arran  2 6 
Boarders  1 1 
Fife  5 6 
Forth Valley 0 0 
GG&C 40 23 
Grampian  2 3 
Highland  2 0 
Lanarkshire  4 4 
Lothian 13 11 
Tayside 11 10 
Western Isles 1 0 
 
*Only	   one	   report	   required	   per	   member	   of	   that	   health	   board	   i.e.	   if	   MMSE	   was	   reported	   use	   in	   acute	   and	  
rehabilitation	  setting	  by	  the	  reporter	  then	  it	  was	  only	  counted	  as	  1	  not	  2.	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Table	  2-­‐3	  Cognitive	  assessments	  performed	  by	  staff	  group	  
 
	  
 
 
  
 
N	  (%)	  of	  each	  staff	  group	  performing	  cognitive	  assessment	  
STAFF	  GROUP	   TOTAL	   MoCA	   R-­‐CAMCOG	   AMT	   ACE-­‐R	   MMSE	  
Nurses	   22	   4	  (18%)	   0	   3	  (14%)	   2	  (9%)	   10	  (45%)	  
Speech	  therapy	   11	   0	   0	   1	  (9%)	   1	  (9%)	   1	  ((%)	  
Physiotherapy	  	   12	   0	   0	   2	  (17%)	   1	  (8%)	   0	  
OT	   27	   14	  (52%)	   0	   4	  (15%)	   17/63%)	   8	  (30%)	  
Medical	   61	   10	  (16%)	   2	  (3%)	   42	  (69%)	   10	  (16%)	   38	  (62%)	  
Psychology	   13	   3	  (23%)	   0	   0	   7	  (54%)	   3	  (23%)	  
Other	  AHP	   27	   2	  (7%)	   0	   5	  (19%)	   55	  (19%)	   6	  (22%)	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Table	  2-­‐4	  Mood	  assessments	  performed	  by	  staff	  group	  
N (%) of each staff group performing mood assessment 
STAFF 
GROUP 
TOTAL HADS PHQ-9 GHQ DISCS GDS HRDS 
Nurses 22 6 (27%) 4 (18%) 4 (18%) 2 (9%) 4 (18%) 0 
SALT 11 0 1 (9%) 0 1 (9%) 0 0 
Physiotherapy 12 0 0 0 0 0 0 
OT 27 14 (52%) 1 (4%) 0 3 (11%) 1 (4%) 0 
Medical 61 12 (20%) 0 0 2 (3%) 21 
(34%) 
1 (2%) 
Psychology 13 9 (69%) 0 2 (15%) 3 (23%) 5 (38%) 0 
Other AHP 27 5 (19%) 0 0 0 3 (11%) 1 (4%) 
	  53	  
Table 2-5 Cognitive/mood assessment modalities used across various 
clinical settings 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*percentages were based on the total number of ALL assessment responses made in each setting 
e.g. Cognitive assessments were reported to be used in all settings 589 times making 190 reports of 
MMSE 32% of total reports. 
Test 
Total (n) and %* of respondents reporting use of the 
test within each setting 
All settings Acute 
Stroke 
Rehabilitation Outpatient 
 
Cognitive Assessments 
Folstein’s Mini Mental 
State Examination 190 (32%) 71 (28%) 76 (30%) 43 (17%) 
Hodkinson’s 
Abbreviated Mental 
Test 
125 (21%) 70 (28%) 32 (14%) 23 (22%) 
Addenbrooke’s 
Cognitive Examination 104 (18%) 24 (9%) 63 (27%) 17 (16%) 
Montreal Cognitive 
Assessment 82 (14%) 25 (10%) 42 (18%) 15 (14%) 
Cambridge Cognitive 
Examination 7 (1%) 2 (1%) 4 (2%) 1 (1%) 
Mood Assessments 
Hospital Anxiety and 
Depression Scale 121 (53%) 30 (54%) 63 (53%) 26 (53%) 
Geriatric Depression 
Scale 73 (32%) 21 (38%) 37 (30%) 15 (31%) 
Depression Intensity 
Scale Circles 14 (6%) 2 (4%) 9 (7%) 3 (6%) 
Patient Health 
Questionnaire 9 (4%) 1 (2%) 5 (4%) 3 (6%) 
Hamilton Rating Scale 
for Depression 5 (2%) 0 5 (4%) 0 
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Table 2-6 Respondents reporting cognitive and mood assessment 
described by professional group 
Professional Group 
(n total) 
Routinely assess cognition  
n (%) 
Routinely assess mood  
n (%) 
Medical (61) 59 (96.7%) 49 (80.3%) 
Occupational therapy (27) 26 (96.3%) 20 (74.1%) 
Other health professionals*  
(27) 
23 (85.2%) 17 (63%) 
Nursing (23) 20 (87%) 17 (73.9%) 
Psychology (13) 13 (100%) 12 (92.3%) 
Physiotherapy (12) 5 (41.7%) 4 (33.3%) 
Speech therapy (11) 6 (54.5%) 3 (27.3%) 
*These were all other allied health professionals (dieticians and those who provided no response to 
staff group) 
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From this sample, assessments were more commonly reported to be performed in 
hospital settings; cognitive assessment was mostly reported during first/acute 
admission (n=116, 67% of respondents, p<0.001) while mood was more commonly 
reported in rehabilitation settings (n=100, 58%, p<0.001).  There was heterogeneity 
in reported management strategies for suspected cognitive/mood deficits (n=14 
strategies described).  For patients with possible cognitive/mood problems the most 
common reported management strategy was onward specialist referral (cognition 
n=62, 36%; mood n=71, 41%).  If stroke survivors had a communication problem, the 
commonest reported approach was to seek advice from other specialties and have 
joint assessment and rehabilitation sessions (n=60, 34%).  For mood, adapting the 
test to the patient (n=44, 25%) was the preferred approach in answers. 
 
2.4. Discussion and conclusions 
2.4.1. Study 1  
Study one found that cognitive and mood assessments make up a very small 
percentage of published research.  This could be because of poor reporting or lack 
of guidance surrounding choice of appropriate measure.  Commonly used 
assessments are not universal across research.  It is of course important to note, 
just because the reported percentage of published research dealing with cognition 
and mood assessment in stroke is relatively small, it cannot be concluded that no 
such work has been completed.  Arguably, a further significant problem concerns the 
quality of work already produced. Many of the assessment tools used in existing 
research are heterogeneous, and further, there remains a lack of robust validation 
studies.  Moreover, through not having a consensus of which cognitive and mood 
assessments to use in research, information declines and these problems and their 
effects remain poorly understood.  In addition, as publications are not including 
cognitive and mood assessments as part of analysing stroke outcome, it is 
suggestive that stroke researchers do not put cognition and mood outcomes as a 
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priority in recovery despite knowing the negative effect these can have on 
rehabilitation.   
Despite the clinical importance of cognitive and mood disorders, these aspects of 
stroke are infrequently measured in clinical research.  When employed, 
cognitive/mood measures are most often used as the primary outcome, suggesting 
that researchers only measure these domains in studies focused on neuropsychology 
of stroke.  My data suggest limited overlap between disciplines, 
psychology/psychiatry journals measure cognition and mood but infrequently study 
stroke cohorts, and the converse is true of neurology journals.  Given the potential 
effect of cognitive/mood disorder on global functional outcome (145, 244), 
researchers are failing to measure what could be an important outcome (or indeed 
confounder) in stroke survivors.  In not accounting for these issues, the results of 
the research (whether it is an experimental comparison or correlation) may be 
impacted, biasing the conclusions. 
When cognitive/mood assessments are employed there is heterogeneity.  It is also 
interesting to note that there were almost as many cognitive measures as there 
were studies describing cognitive function.  This in part relates to my inclusive 
definition, comprising cognitive screening/assessment; single and multi-domain 
neuropsychological testing and dementia diagnostic criteria.  Even limiting to single 
domain cognitive tests, the substantial heterogeneity in assessment strategies 
precludes meaningful between-study comparisons and meta-analyses. 
Certain prevalent cognitive/mood assessments may not be appropriate for stroke 
cohorts, for example MMSE is not particularly suited to vascular cognitive 
impairment.(239) Conversely, certain scales prevalent in clinical practice were 
infrequently used in studies,(245) for example the MoCA (n=2 papers) and the 
Repeatable Battery for the Assessment of Neuropsychological Status (n=1 paper).  
Despite the variety of validated tools available, some authors continue to use their 
own bespoke assessment scales.  As well as illustrating heterogeneity in 
assessments, the generated list of outcomes can be used to inform search strategies 
for future systematic reviews of diagnostic accuracy. 
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2.4.2. Study 2 
Study two found that assessments commonly reported in research are not 
representative of those in usual practice.  There is inconsistency as to what 
assessment is used and when (if at all).  There was a general trend towards 
cognition measured earlier than mood.  However, the cognitive and mood 
assessments chosen have not been validated properly in stroke cohorts.  Lack of 
guidance as to how to test patients, stemming from inconsistent research, has 
continued this indecision into usual practice.   
Study 2 demonstrates substantial heterogeneity in assessment and management of 
mood/cognition in stroke survivors.  Use of 62 different assessment tools in a 
geographically small area clearly has implications for audit across services; research 
(shown in study 1) and service planning.  Although the majority of respondents were 
assessing cognition and mood, not all were performing this routinely or across all 
settings.  As with any questionnaire, presumably respondents in study 2 are more 
likely to have had an interest in cognition/mood and may not be representative of 
all healthcare professionals.  I suspect that cognitive/mood assessment across all 
stroke services may be lower than suggested in this survey.  
The use of non-validated, bespoke or informal assessments is a concern.  Certain 
commonly used cognitive measures, although validated in other settings, may not 
be appropriate for stroke survivors.  Folstein’s MMSE does not perform consistently 
well in stroke (239, 246, 247) and ignores executive functioning, a common deficit 
in stroke populations; Hodkinson’s Abbreviated Mental Test (AMT) has not been 
validated in stroke and the properties of ACE in stroke survivors is sensitive to 
timing of assessment (166, 169).  For mood measures, there is a lack of research in 
the acute stroke setting (248) and we have no validated established norms for most 
tests in stroke populations (193, 239). The Hospital Anxiety and Depression Scale 
has been validated in stroke (201, 204, 249) but not the acute setting and the 
Geriatric Depression Scale has not been validated within stroke populations.   
International guidance documents for stroke cognitive and mood assessment are 
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available (22).  The tools recommended in these texts (i.e. MoCA) were not 
commonly used in our sample.  This is the foundation for the next chapters.  I set 
out to describe the feasibility and the validity of these commonly used tools in the 
acute stroke setting.     
As well as heterogeneity in assessment tools used, this work also demonstrates 
heterogeneity in application and intervention.  The many different approaches 
reported for a commonly encountered, specific clinical scenario (the stroke survivor 
with aphasia) perhaps suggests the need for cognitive and mood assessment 
strategies specifically tailored to stroke survivors with language problems (250).  
With this in mind, assessments that have specifically been developed for those with 
language and visual problems (but not specifically for stroke survivors) will be 
included in the following works into feasibility and accuracy.  Based on the 
responses and data we collected we were unable to draw clear conclusions on the 
practice of assessment within individual health boards/units. From the responses 
and data we collected, we would acknowledge as a limitation that we were unable 
to draw clear conclusions on the practice of assessment within individual health 
board/units. Due to the limited responses we collected, the popularity level of 
assessments could thus have been inflated, biasing the results. However, these data 
are still likely despite this limitation to provide some insight into assessments 
chosen by those who are interested in and find cognitive and mood assessments an 
important part of usual practice. 
 
2.4.3. Strengths and limitations 
Study one used a sensitive search strategy, employing hand searching and various 
validity checks.  This approach has previously been successfully employed to 
describe functional outcomes in the stroke literature.(153) The increasing volume 
and multidisciplinary nature of stroke research precluded review across all 
studies.(251) However, my intention was to describe outcome assessments in 
popular medical journals rather than across the complete stroke literature.  My 
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choice of journals was in keeping with other studies that have used similar 
methods.(252)  
The strengths of our second study were the clear research questions and study 
design based on literature recommendations and robust piloting.  The multi-modal 
questionnaire distribution will have ensured that most Scottish stroke staff had the 
opportunity to reply.  The principle limitation was the modest response rate from 
certain regions.  However, I achieved responses from most health boards and so I 
hope to have captured a reasonable snapshot of current practice, which may also 
give insight to usual practice in stroke units across the UK.  I followed best practice 
in achieving maximal response rate (240, 253), but did not have the resource to 
offer financial incentives.      
Despite this modest response, my survey gives the first National descriptions of 
usual practice within Scotland/UK.  
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Chapter 3 Test accuracy of direct 
patient cognitive screening tests for 
diagnosis of post-stroke cognitive 
impairment – systematic review and 
meta-analysis 
Building on evidence presented in previous chapter 
The previous chapter identified heterogeneity of assessment choice in stroke unit 
usual practice.  The low percentage of stroke papers containing cognitive measures 
suggests that one of the reasons behind a lack of consensus is the lack of evidence 
demonstrating the accuracy and validity of certain measures administered to stroke 
cohorts.  This chapter therefore investigates the accuracy of cognitive screening 
assessments to detect common post-stroke cognitive deficits (multi-domain 
cognitive impairment and all type dementia). 
 
3.1. Introduction 
A first step in management of cognitive problems is recognition and diagnosis. 
Informal clinician assessment will miss important cognitive problems (254) and 
formal cognitive assessment of stroke-survivors is recommended.(22, 150, 255) The 
ideal diagnostic strategy would be expert, multidisciplinary assessment, informed 
by comprehensive supplementary investigations. This approach is not feasible at a 
population level.  In practice a two-step system is adopted, with baseline cognitive 
testing used for “screening” or “triage” and detailed specialist assessment available 
depending on the results. 
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Although there is general agreement on the merits of post-stroke cognitive 
assessment, there is no consensus on a preferred testing strategy.(22, 150, 255) 
Various cognitive screening tools are described with substantial variation in test 
strategies as demonstrated in the previous chapter.  
The clinical “meaning” of cognitive problems after stroke will vary according to the 
context of testing. Cognitive impairment diagnosed in the first days post-stroke may 
reflect a mix of delirium, stroke specific impairments and pre-stroke cognitive 
decline.(25, 34, 53)  In the longer term, cognitive assessment may be focussed on 
delineating cognitive strengths and/or weaknesses or on making or refuting a 
diagnosis of dementia. Common to all test situations is a final diagnosis of presence 
or absence of clinically (functionally) important, multi-domain impairments, based 
on expert assessment. A screening assessment should detect this syndrome of all-
cause, post-stroke multi-domain cognitive impairment.  
Collation and synthesis of the evidence describing test accuracy of available 
cognitive screening tools is an important first step to guide policy and practice and 
to highlight where there are knowledge gaps.  I sought to perform systematic 
review and meta-analysis to describe the accuracy of screening tools for assessing 
dementia and multi-domain cognitive impairment in stroke-survivors. 
 
3.2. Methods  
I performed systematic literature review and meta-analysis using techniques 
developed for test accuracy reviews.(256) Where applicable I followed best practice 
in reporting. (257, 258)  Study methods are described in further detail in the 
protocol. (Appendix C) 
 
3.2.1. Aims 
The co-primary aims were to describe: 
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a) Test accuracy of cognitive screening tests for clinical diagnosis of multi-domain, 
cognitive impairment/dementia in stroke-survivors. 
b) Test accuracy of brief, cognitive screening tests against a more detailed 
neuropsychological assessment. 
If data allowed, secondary objectives were to compare differing cut-point scores 
used to define a cut-off of “test positivity” and to compare the effects of 
heterogeneity with specific reference to test context and diagnostic reference 
standard. 
 
3.2.2. Index test  
Index tests of interest were any direct to patient, cognitive screening tests. I 
included any “screening” test where the authors described it as such.  I excluded 
informant based assessments and tests that require testing equipment considered 
non-standard for a stroke service: brain-imaging modalities and various biomarkers 
(CSF, serum) that have been proposed as an aid to diagnosis of dementia.  To date 
no single or combination of biomarkers is sufficiently sensitive or specific to make a 
diagnosis of dementia without corresponding clinical assessment and therefore is 
not standard in a stroke unit. I recognise that language and visuospatial function 
are important components of cognition, but did not include assessments of tools 
designed to exclusively test these domains. I did not include studies that compared 
one screening tool with no reference to a diagnostic gold standard. 
For the second analysis, focus was “brief” screening tests, defined as any test that 
takes less than five minutes to complete. 
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3.2.3. Target condition and reference standard 
The target condition of interest was all-cause multi-domain cognitive impairment 
post-stroke.  This rubric recognises that a diagnosis of important post-stroke 
cognitive problems can be made without necessarily assigning a dementia label. 
As reference standard, I included clinical diagnosis of dementia or dementia 
subtype made using any recognised classification system: the International	  
Classification of Diseases 10th Edition, Mental and Behavioural Disorder (ICD-10, 
World Health Organisation), Diagnostic and Statistical Manual of Mental Disorders 
4th Edition (DSM-IV, American Psychiatric Association) and for diagnostic criteria for 
specific subtypes of dementia described by NINDS-ADRDA for Alzheimer’s type 
dementia and NINDS-AIREN for vascular dementia. I also included multi-domain, 
cognitive problems as detailed on a neuropsychological assessment provided the 
test battery was comprehensive (covering several cognitive domains in depth) and 
results were interpreted to give a diagnostic formulation. Single domain cognitive 
impairment or “cognitive impairment no dementia” were not included due to 
inconsistency in operationalisation of these syndromes.(259) In addition, I included 
both cross-sectional analyses for prevalent dementia and longitudinal follow-up for 
incident dementia, although these two study types will be analysed separately.  I 
performed sub-analysis for studies conducted exclusively in acute stroke-unit; 
rehabilitation and community settings and subgroup analyses was pre-specified 
comparing dementia diagnosis and neuropsychological battery based diagnosis.	  
For assessment of brief tests, I accepted results from a more detailed multi-
domain, screening assessment as reference standard, for example comparison of 
Hodgkinson’s AMT against Folstein’s MMSE.  The acceptable time frame between 
the index tests and the reference standard should either be on the same day or 
within 2 days if a cross sectional study or after 9 months if a delayed cross sectional 
/longitudinal study.	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3.2.4. Participants and setting  
My focus was stroke-survivors. Where study population was mixed, studies were 
included if the proportion of stroke-survivors was greater than 75%. I made no 
distinction between stroke subtypes but excluded studies of traumatic intracerebral 
haemorrhage and subarachnoid haemorrhage. I did not include case-studies 
(defined as having fewer than ten participants). 
I included studies conducted in any clinical setting and at any time post-stroke.  I 
operationalised time since stroke as “hyperacute” (first 7 days); “acute” (8-14 
days); “post acute” (15 days-3 months); “medium term” (3-12 months) and “longer 
term” (post 1 year).  I accepted a time delay of 6 to 9 months between index test 
and reference standard as acceptable due to the chronic nature of dementia and of 
multi domain cognitive impairment.(260, 261)   As we were including papers of 
concurrent and predictive validity we felt this inclusion was reasonable especially 
considering the low numbers of papers in this research area. 
All studies were included, but risk of bias associated with assessment timings was 
reported for individual papers using the “quality assessment” tool.   
 
3.2.5. Search strategy  
All aspects of searching, data extraction and study assessment were performed by 
two reviewers (myself and a neurologist, Dr Johann Selvarajah), based in separate 
centres and blinded to each-others’ results. On review of paired data, disagreement 
was resolved by discussion. 
Dr Terence Quinn and I developed a sensitive search strategy in collaboration with 
an Information Scientist (Candida Fenton) and with assistance from the Cochrane 
Dementia and Cognitive Improvement Group.(Appendix D) 
Search terms were developed using a concepts based approach employing Medical 
Subject Heading terms and other controlled vocabulary. Concepts of interest were 
“stroke”, “dementia” and “cognitive assessment”. Our “cognitive assessment” 
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concept included terms relating to cognitive tests used in stroke, based on previous 
survey data (Chapter 2).  The sensitive search was supplemented with a purposive 
search, focussed on four prevalent cognitive screening tools: AMT, MMSE, MoCA and 
ACE-R. 
I searched multiple, international, cross-disciplinary electronic databases from 
inception to January 2014. ALOIS (Cochrane Dementia and Cognitive Improvement 
Group); ARIF (University of Birmingham); CINAHL (EBSCOhost); Embase (OvidSP); 
LILACS (Bireme); Medline (OvidSP); MEDION (Netherlands); Psychinfo (OvidSP) and 
the DARE, NHS EED, HTA databases (CRD). I applied no language or date 
restrictions. I hand searched recent publications (2010 onwards) in key journals 
including conference proceedings (European Stroke Conference; International 
Stroke Conference; UK Stroke Forum; Age and Ageing; Cerebrovascular Diseases; 
International Journal of Stroke; Lancet Neurology; Stroke). Dr Quinn contacted 
groups with research interest in stroke test accuracy (Dr Ingrid Arevalo Rodrigue, 
author of Cochrane Collaboration review on MMSE; Dr Sarah Cullum, lead author of 
Cochrane Collaboration review on MoCA and Professor Nadina Lincoln, University of 
Nottingham, UK). I utilised “related article” feature in PubMed and examined key 
studies in the citation databases of Science Citation Index and Scopus. I also 
checked reference lists of relevant studies and reviews for further titles, repeating 
the process until no new titles were found. 
 
I screened all titles generated by initial searches for relevance, corresponding 
abstracts were assessed and potentially eligible studies reviewed as full manuscripts 
against inclusion criteria by Dr Selvarajah and myself. As a check of internal 
validity, a random selection of 2,000 titles from the original search was reassessed 
by a third author (Dr Quinn). I tested external validity of our search by sharing lists 
of included papers with independent researchers (acknowledgements). One of my 
supervisors (Dr Quinn) identified exemplar papers relevant to the review question 
(Table 3-2) and he assessed whether these titles were detected by search strategy. 
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Table 3-1 Ten papers used for external validity check of search strategy 
Paper Reference 
Appels BA, Scherder E. The diagnostic accuracy of dementia-screening instruments with an 
administration time of 10 to 45 minutes for use in secondary care: A systematic review. American 
Journal of Alzheimers Disease and other Dementias 2010; 25(4):301-316. 
Blake H, McKinney M, Treece K, Lee E, Lincoln NB. An evaluation of screening measures for cognitive 
impairment after stroke. Age and ageing.2002;31:451-456 
Bour A, Rasquin S, Boreas A, Limburg M, Verhey F. How predictive is the MMSE for cognitive 
performance after stroke. Journal of neurology. 2010;257;630-7. 
Crawford S, Whitnall L, Robertson J, Evans JJ. A systematic review of the accuracy and clinical 
utility of the Addenbrooke's Cognitive Examination and the Addenbrooke's Cognitive Examination-
Revised in the diagnosis of dementia. Int J Geriatr Psychiatry 2011. 
Cullen B, O’Neill B, Evans JJ, Coen RF, Lawlor BA. A review of screening tests for cognitive 
impairment. Journal of Neurology, Neurosurgery and Psychiatry 2007;78:790-9. 
de Koning I, van Kooten F, Dippel DWJ, van Harskamp F, Grobbee DE, Kluft C, Koudstaal PJ. The 
CAMCOG: a useful screening instrument for dementia in stroke patients. Stroke.1998;29:2080-2086.  
Kwa VIH, Limburg M, Voogel Aj, Teunisse S, Derix MMA, Hijdra A. Feasibility of cognitive screening in 
patients with ischaemic stroke using the CAMCOG. A Hospital Based Study. Journal of 
Neurology.1996;243:405-409. 
Nokleby K, Boland E, bergersen H, Schanke AK, Famer L, Wagle J, Wyller TB. Screening for cognitive 
deficits after stroke; a comparison of three screening tools. Clinical rehabilitation.2008; 22:1095-
1104. 
Srikanth V, Thrift AG, Fryer JL, Saling MM, Dewey HM, Sturm JW, Donnan GA. The validity of brief 
screening cognitive instruments in the diagnosis of cognitive impairment and dementia after first-
ever stroke. International Psychogeriatrics.2006;18:295-305. 
Young J, Meagher D, Maclullich A. Cognitive assessment of older people. British Medical Journal. 
2011;343: d5042 doi: 10.1136/bmj.d5042 
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3.2.6. Data extraction and management  
I extracted data to a study-specific, pro-forma, piloted against two papers.(166, 
239) 
For screening tests that give an ordinal summary score, various cut-points can be 
used to define “test positive” cases. Where data were given for a number of cut-
offs, I extracted separate data for each. Where a study may have included useable 
data but these were not presented in the published manuscript I contacted the 
authors directly via email. If the same data set was presented in more than one 
publication, only the primary paper was included. 
 
 
3.2.7. Quality assessment 
Myself and Dr Selvarajah independently assessed quality of study reporting using the 
dementia specific extension to the Standards for Reporting of Diagnostic Accuracy 
(STARDdem) checklist.(Appendix E)  I assessed methodological quality using the 
revised Quality Assessment of Diagnostic Accuracy Studies tool (QUADAS-2).(262) Dr 
Quinn and I had previously developed QUADAS-2 “anchoring statements” specific to 
cognitive assessment.(260)  The process of statement development is illustrated in 
Figure 3-1 and Appendix F.  
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Papers	  gathered	  on	  diagnostic	  accuracy	  studies	  of	  dementia.	  
Selection	  of	  10	  papers	  were	  split	  up	  between	  groups	  of	  two	  and	  
scored	  using	  discussed	  statements.
A	  group	  of	  10	  various	  health	  care	  professionals	  with	  experience	  in	  
cognitive	  impairment	  went	  through	  Quadas-­‐2	  statements	  and	  
discussed	  phrasing	  relevant	  to	  dementia	  using	  two	  pilot	  papers.
Statements	  were	  modified	  and	  rephrased	  to	  fit	  with	  review	  
question	  and	  format	  of	  papers.
Problems	  that	  arose	  with	  statement	  phrasing	  were	  discussed	  
and	  modified	  to	  fit	  the	  general	  review	  question.	  
	  
Figure	  3-­‐1	  Flow	  chart	  of	  developing	  anchoring	  statements	  for	  QUADAS	  2	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3.2.8. Statistical analysis  
I assessed accuracy of screening tests against a dichotomous variable cognitive 
impairment/no cognitive impairment. I created standard “two-by-two” data tables, 
describing binary test results cross-classified with binary reference standard. I did 
not include case-control studies in pooled analyses.  I used accepted cut-offs for 
multi-domain impairment/dementia published in the literature: ACE<88; R-CAMCOG 
<33; MMSE<27 and <25.  For MoCA, a cut-off of <26 was used together with the 
lower cut-off of <22 since the former was developed to detect single rather than 
multi-domain impairment. 
Where data allowed I calculated sensitivity, specificity and corresponding 95% 
confidence intervals (95% CI) and created test accuracy forest plots (RevMan 5.1, 
Cochrane Collaboration). I pooled test accuracy data using the bivariate approach 
(Statistical Analysis Software v9.1, SAS Institute Inc, USA).  This assumes that the 
pooled random effects model takes into account the heterogeneity between studies 
and assessments.  The bivariate approach in meta-analysis pools together (the 
usually negatively correlated) all sensitivity and all specificity from various studies, 
analysing them separately.  From this a Receiver Operating Characteristic (ROC) 
curve can determine a single summary measure of accuracy for each pair of 
sensitivity and specificity.  This summary point is also known as the Diagnostic Odds 
Ratio (DOR): the odds of a positive index assessment result in subjects with the 
disease divided by the odds of a positive result in someone without the disease. 
This accounts for both between study variation and within study variation such as 
the criteria used to define ‘disease positive’ and the heterogeneity of 
symptoms/signs in the examined cohort.(220, 263)     Dr Quinn and I used a bespoke 
macro developed with assistance of a statistical team with an interest in test 
accuracy.(264) Summary metrics of interest were sensitivity/specificity and 
positive/negative likelihood ratios.(265) Dr Quinn created summary curves in ROC 
space with corresponding 95% prediction intervals.  
I assessed potential heterogeneity through visual inspection of forest plots. I pre-
specified two factors that may contribute to heterogeneity, timing of assessment 
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and reference standard. We (myself and Dr Quinn) dichotomized studies into 
“acute” (classified as hyperacute or acute) or “non-acute” and described reference 
standard as “clinical” (clinical diagnosis of dementia) and “neuropsychological 
battery” (multi-domain cognitive impairment). Where sufficient studies were 
available, I assessed effect by plotting summary ROC curves by covariate and 
calculating relative sensitivity and specificity.  Here, relative sensitivity and 
specificity refers to the meta-analysis of sensitivity and specificity across all 
settings.  These values are calculated by taking all studies (handling acute and non 
acute studies separately) and calculating an overall measure for sensitivity and 
specificity in each setting.  The acute values were then divided by their non-acute 
partners (e.g. acute sensitivity/non acute sensitivity).  From general statistical 
principles that apply to likelihood ratios and risk ratios, a 95% confidence interval 
was calculated.  Thus, if the ratio was >1 then sensitivity or specificity was greater 
in the acute setting and whereas if <1 sensitivity or specificity was larger in non-
acute settings.  
 
I did not quantify publication bias, as there is no assessment applicable to test 
accuracy. 
 
Where papers fulfilled inclusion criteria but did not have data suitable for this 
method of analysis I offer a tabulated/narrative description. 
 
3.3. Results 
From 19,182 titles, I reviewed 241 full papers of which 35 papers (34 datasets) 
(164-166, 169, 187, 236, 239, 246, 247, 266-292) were suitable for inclusion. Scope 
of included literature was international, with papers from 16 differing countries. 
I detailed the study selection process in a PRISMA flow diagram.(Figure 3-1) 
The validation check suggested the initial search was appropriate, as all pre-
specified papers were found on first search. 
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Figure 3-2 PRISMA flow diagram detailing review process 
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3.3.1. Accuracy of screening tools for diagnosis of cognitive 
impairment  
From the papers identified in the original search using MESH terms, we screened 511 
abstracts and excluded 270 due to irrelevance to our chosen themes of diagnostic 
test accuracy and dementia. 
In total n=35 papers (n=3562 participants) were eligible. (164-166, 169, 187, 236, 
239, 246, 247, 266-289) I tabulated summary descriptors for studies employing 
clinical diagnosis reference standard (n=11 papers) (187, 236, 267, 275, 277-279, 
284, 286-288) and those using detailed neuropsychological assessment (n=21). (164-
166, 169, 239, 246, 247, 266, 268-274, 276, 280-283, 285)(Tables 3-3 and 3-4) 
There was considerable heterogeneity in study population; setting and test 
strategy. Twenty-three differing tests were described, commonest MMSE (n=16 
papers) and MoCA (n=8).(Tables 3-3 to 3-5). 
The various screening tests gave a spread of test accuracy, sensitivity range: 14-
100% and specificity range: 0-100% with “trade-off” between sensitivity and 
specificity. Where authors compared more than one test in the same population, 
the comparator was usually MMSE and for most papers MMSE was more specific and 
less sensitive than other tests.  Both the Executive Function Performance Test 
(EFPT) and the Repeatable Battery for Assessment of Neuropsychological Status 
(RBANS) showed strong correlations with scores on neuropsychological batteries but 
data were not suitable for pooled analysis.(266, 268, 270, 273)  
 
The recruitment strategy, demographics of stroke population included and the 
country in which this study was completed are detailed in table 3-6.
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Table 3-2 Test accuracy for individual studies: Limited to those studies 
where reference standard was a clinical diagnosis of dementia 
 
Study  “n” included 
“n”(%) with 
dementia 
Index test 
(cut-off 
Summary Results 
Sensitivity Specificity 
Brookes* (275) 152 N/A BMET Discriminates AD/SVD 
Cumming 2010 
(267) 
149 42 (28%) Cog4 53% 84% 
De Koning 2000 
(277) 
300 55 (19%) 
RCAMCOG 
(<33) 
91% 90% 
De Koning 2005 
(278) 
121 35 (29%) 
RCAMCOG 
(<33) 
66% 94% 
De Koning (288) 300 55 (19%) 
CAMCOG (<81) 
MMSE (<25) 
91% 
80% 
80% 
67% 
Dong 2012 (279) 300 60 (25%) 
MoCA (<21) 
MMSE (<24) 
88% 
88% 
64% 
67% 
Hershey(282) 63 13 (21%) CCCE (<20) 85% 87% 
Hobson* (236) 149 69 (46%) PNB (<55) 71% 93% 
Srikanth (187) 67 8 (12%) MMSE (<23) 14% 100% 
Tang (284) 142 10 (12%) 
MDRS (<22) 
MMSE (<18) 
82% 
80% 
90% 
88% 
Wu (286) 206 95 (46%) MoCA (<23) 65% 79% 
 
Where more than one test cut-off was described, we present the authors primary data.  
N/A=not applicable 
ASU=Acute Stroke Unit 
NPB=Neuropsychological battery  
BMET= Brief Memory and Executive Test; CSCSE=Cognitive Capacity Screening Examination; 
Cognistat=Neurobehavioral Cognitive Status Examination; Cog4=Cognitive components of the 
National Institutes of Health Stroke Scale; MMSE=Mini-mental State Examination; MoCA=Montreal 
Cognitive Assessment; PNB=Preliminary Neuropsychological Battery; CAMCOG= Cambridge Cognitive 
Examination; R-CAMCOG=Rotterdam Cambridge Cognitive Examination; MDRS=Mattis Dementia 
Rating Scale 
*=case-control study, data not included in any pooled analyses 
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Table 3-3 test accuracy data for individual studies: Limited to those 
studies where reference standard was diagnosis of cognitive impairment 
based on detailed, multi-domain neuropsychological battery 
Study “n” included 
“n” (%) 
with 
dementia 
Index test 
(cut-off) 
Summary Results 
Sensitivity Specificity 
Agrell* (246) 64 N/A MMSE (<23) 56% 24% 
Baum* (266) 73 N/A EPFT Correlates with NPB 
Blake (239) 112 31 (28%) MMSE (<24) 62% 88% 
Bour (271) 194 22 (11%) MMSE (<23) 96% 83% 
Cartoni (276) 30 27 (90%) MEAMS (≥3) 52% 100% 
Cumming 2013 
(164) 
60 39 (65%) MMSE (<24) 
MoCA(<24) 
54% 
97% 
81% 
52% 
Desmond*(272) 72 6 (8%) TICS (25) MMSE (<24) 
100% 
83% 
83% 
87% 
Dong 2010 
(280) 100 60 (60%) 
MMSE (<24) 
MoCA (<21) 
86% 
90% 
82% 
77% 
Godefroy (165) 95 64 (67%) MMSE (<24) MoCA (<24) 
70% 
92% 
94% 
58% 
Grace (281) 70 32 (46%) MMS (<79) MMSE (<24) 
69% 
44% 
79% 
84% 
Green (268) 60 N/A RBANS (<84) 84% 90% 
Jodzio (283) 44 25 (55%) WCST PPV 21 NPV 75 
Larson (273) 158 N/A RBANS Correlates with NPB 
Morris (169) 101 51 (84%) MMSE (<24) ACE-R (<88) 
58% 
94% 
77% 
0% 
Nokleby (287) 49 28 (60%) 
COGNISTAT 
(<59) 
SINS (>2) 
CDT(9) 
59% 
71% 
63% 
 
67% 
67% 
67% 
Nys* (247) 72 N/A MMSE (<28) 100% 40% 
Pendlebury 
(166) 91 19 (21%) 
MoCA (<25) 
MMSE (<24) 
ACE-R (<88) 
100% 
56% 
84% 
46% 
96% 
85% 
Pendlebury 
(telephone) 
(274) 
91 19 (21%) T-MoCA (<19) 
TICSm (<25) 
89% 
85% 
46% 
56% 
Salvadori (269) 80 47 (59%) MoCA (<21) 91% 76% 
Wolf (270) 20 N/A EPFT Correlates with NPB 
Wong* (285) 68 N/A MoCA (<21) 73% 75% 
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Where more than one test cut-off was described, we present the authors primary data.  
N/A=not applicable 
ASU=Acute Stroke Unit 
NPB=Neuropsychological battery  
CDT=Clock drawing test; CSCSE=Cognitive Capacity Screening Examination; 
Cognistat=Neurobehavioral Cognitive Status Examination; Cog4=Cognitive components of the 
National Institutes of Health Stroke Scale; EPFT=Executive Performance Function Test; 
MEAMS=Middlesex Elderly Assessment Mental State; MMSE=Mini-mental State Examination; 
MMS=Mini-Mental State; MoCA=Montreal Cognitive Assessment; T-MoCA: Telephone Montreal 
Cognitive Assessment;  PNB=Preliminary Neuropsychological Battery; RBANS=Repeatable Battery for 
Assessment of Neuropsychological Status; SINS=Screening Instrument Neuropsychological 
impairments in Stroke; TICS=Telephone Interview Cognitive Status; TICSm=Modified Telephone 
Interview Cognitive Status; WCST= Wisconsin Card Sorting Test 
*=case-control study, data not included in any pooled analyses 
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Table 3-4 Summary of included studies: Limited to "acute” settings 
Study Setting Time since stroke 
Includes 
aphasia 
Index 
test(s) 
Index test 
rater 
Diagnostic 
test(s) 
Diagnostic 
test rater 
Bour 2010 
(271)  
Neurology 
ward Acute no MMSE Psychologist NPB Psychologist 
Cumming 
2013 
(164)  
Not 
Specified  Acute 
Not 
specified 
MMSE, 
MoCA Not specified NPB Not specified 
Dong 
2012 
(279) 
ASU Hyperacute no MoCA, MMSE Not specified NPB Psychologist 
Dong 
2010 
(280) 
ASU Hyperacute no MoCA, MMSE Not specified Clinical Not specified 
Godefroy 
2011 
(165) 
ASU Acute Yes MoCA, MMSE 
Not 
Specified NPB Not specified 
Green 
2013 
(268) 
ASU Acute Not specified RBANS Researcher NPB Researcher 
Jodzio 
2010 
(283) 
Neurology 
ward Acute  No WCST Not specified NPB Not specified 
Morris 
2012 
(169) 
ASU Acute Yes (mild) ACE-R, MMSE 
Physician, 
Psychologist NPB Psychologist 
Nys 2005 
(247) ASU Acute Yes  MMSE Not specified NPB Not specified 
Salvadori 
2013 
(269) 
ASU Hyperacute* Yes (mild) MoCA Researcher NPB Not specified 
Wu 2013 
(286) ASU Not specified No MoCA Physician Clinical  Not specified 
Where more than one test cut-off was described, we present the authors primary data.  
N/A=not applicable 
ASU=Acute Stroke Unit 
NPB=Neuropsychological battery  
ACE-R=Addenbrooke’s Cognitive Examination Revised; MMSE=Mini-mental State Examination; 
MoCA=Montreal Cognitive Assessment; NPB=Neuropsychological Battery; RBANS=Repeatable Battery 
for Assessment of Neuropsychological Status.  
*=case-control study, data not included in any pooled analyses 
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Table 3-5 Summary of included studies: Limited to "non acute" settings 
Study Setting 
Time 
since 
Stroke 
Include 
Aphasia 
Index 
test(s) 
Index 
test rater 
Diagnostic 
test(s) 
Diagnostic 
test rater 
Agrell  
2000 (246) 
Rehabilitation Post acute No MMSE Physician NPB Psychologist 
Baum  
2008 (266) 
Community Post acute 
Not 
specified EFPT 
Not  
specified 
NPB 
Not 
Specified 
Blake  
2002 (239) 
Hospital  
(other) 
Not 
specified 
Not 
specified 
MMSE  
SST 
RCPM 
Not  
specified 
NPB 
Not 
Specified 
Brookes 
2012 (275) 
Rehabilitation Post acute 
Not 
specified 
BMET 
MMSE 
CDRS 
Not  
specified 
Clinical 
Not 
Specified 
Cartoni  
2005 (276)  
Rehabilitation Not specified No MEAMS OT NPB Psychologist 
Cumming  
2010 (267) 
Community Long term Yes 
MMSE 
Cog4 
Physician 
Psychiatrist Clinical 
Physician 
Psychiatrist 
de Koning 
 2000 (277) 
Neurology  
Ward 
Medium 
term No 
(R)-
CAMCOG 
Physician 
Psychologist 
Clinical 
Adjudication  
Panel 
de Koning 
 2005 (278) 
Hospital 
(other) 
Medium 
term No 
R-
CAMCOG Researcher Clinical 
Adjudication  
Panel 
de Koning 
 1998 (288) 
Outpatients Post acute 
Yes 
(mild) 
CAMCOG 
MMSE 
Not  
specified 
Clinical 
Adjudication  
Panel 
Desmond  
1994 (272) 
Outpatients  Not specified 
Not 
specified TICS 
Not  
specified 
NPB 
Not 
Specified 
Grace  
1995 (281) 
Rehabilitation Not specified No 
MMSE 
3MS 
Not  
specified 
NPB 
Not 
Specified 
Hershey  Outpatients  
Not 
No CCSE Mixed Clinical Physician 
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1987 (282) specified FAQ 
Larson  
2005(273) 
Rehabilitation Medium term 
Yes 
(mild) RBANS 
Not  
Specified 
NPB 
Not 
Specified 
Nokleby  
2008 (287) 
Rehabilitation Post acute  Yes 
Cognistat 
SINS 
CDT 
Physician 
Psychologist 
NPB Psychologist 
Pendlebury  
2012 (166) 
Outpatients  Long term No 
MMSE 
MoCA 
ACE-R 
Physician NPB Mixed 
Srikanth 
2006 (187) Outpatients  
Post 
acute Yes S-MMSE 
Not  
Specified 
Clinical 
Not 
Specified 
Tang 
2005 (284) 
Outpatients  Post acute  
Not 
specified 
MDRS 
MMSE 
Researcher Clinical Psychiatrist 
Wolf 
2010 (270) 
Rehabilitation Hyper-acute  Yes EFPT 
Not  
Specified 
NPB 
Not 
Specified 
Wong 
2009 (285) 
Rehabilitation Post acute  
Not 
specified MoCA Researcher NPB Researcher 
N/A=not applicable 
MCI=Mild Cognitive Impairment; NPB=Neuropsychological battery; ASU=Acute Stroke Unit 
BMET= Brief Memory and Executive Test; CDRS=Clinical Dementia rating Scale; CCSE=Cognitive 
Capacity Screening Examination; Cognistat=Neurobehavioural Cognitive Status Examination; 
Cog4=Cognitive components of the National Institutes of Health Stroke Scale; EPFT=Executive 
Performance Function Test; MEAMS=Middlesex Elderly Assessment Mental State; MDRS=Mattis 
Dementia Rating Scale; MMSE=Mini-mental State Examination; MMS=Mini-Mental State; 
3MS:Modified Mini-Mental State; S-MMSE=Standardised Mini-Mental State Examination; 
MoCA=Montreal Cognitive Assessment; RBANS=Repeatable Battery for Assessment of 
Neuropsychological Status; RCPM=Raven’s Coloured Progressive Matrices; CAMCOG=Cambridge 
Cognitive Examination; R-CAMCOG=Rotterdam Cambridge Cognitive Examination; SST=Stop Signal 
Task; SINS=Screening Instrument Neuropsychological impairments in Stroke; TICS=Telephone 
Interview Cognitive Status; TICSm=Modified Telephone Interview Cognitive Status; WCST= Wisconsin 
Card Sorting Test 
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Table	  3-­‐6	  Study	  demographic	  details	  
Study  Country  Recruitment 
method  
Time since 
stroke  
(weeks) 
Aphasics 
included  
Mean Age  
(years) 
Agrell  
2000 (246) 
Sweden Consecutive 2 to 8 No 77 
Baum  
2008 (266) 
USA Selected 24 Unspecified 64.5 
Blake  
2002 (239) 
UK Research 
population 
Unspecified Unspecified 70.8 
Bour 2010 
(271)  
Netherlands  Consecutive 4 No 68.3 
Brookes 
2012 (275) 
UK Case control >12 Unspecified 69.7 
Cartoni  
2005 (276)  
UK Consecutive Unspecified No 75.8 
Cumming  
2010 (267) 
Australia Unspecified 12 Unspecified 80.3 
Cumming 
2013 (164)  
Australia Research 
population 
72 Yes 72.1 
de Koning 
 2000 (277) 
Netherlands Research 
population 
12 to 36 No 69.2 
de Koning 
 2005 (278) 
Netherlands Research 
population 
12 to 36 No 70 
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de Koning 
 1998 (288) 
Netherlands Consecutive 12 to 36 Yes 69.2 
Desmond  
1994 (272) 
USA Research 
population 
Unspecified  Unspecified 72.3 
Dong 2010 
(280) 
Singapore Unspecified <2 No 61.2 
Dong 2012 
(279) 
Singapore Consecutive  <2 No 60.2 
Godefroy 
2011 (165) 
France Consecutive <3 Yes 68.2 
Grace  
1995 (281) 
USA Consecutive Unspecified No Unspecifie
d 
Green 2013 
(268) 
UK Consecutive  Unspecified 
 
Yes 67.7 
Hershey  
1987 (282) 
USA Research 
population 
Unspecified No 66.2 
Hobson 2003 
(236) 
UK Consecutive Unspecified Unspecified 72.8 
Jodzio 2010 
(283) 
Poland Convenience <4 No 56 
Johnson-
Greene 2009  
USA Convenience <2 no 70.4 
Larson  
2005(273) 
USA Consecutive ≤24 Yes 63.7 
Lees 2013 UK Consecutive  <1 Yes 74 
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Morris 2012 
(169) 
UK Consecutive  2 Yes 76 
Nokleby  
2008 (287) 
Norway Selected  9.5 Yes 62 
Nys 2005 
(247) 
Netherlands Consecutive  <1 yes 64.7 
Pendlebury  
2012 (166) 
UK Research 
populations 
consecutive 
>52 No 72 
Salvadori 
2013 (269) 
Italy Unspecified  Unspecified  Unspecified  68.2 
Srikanth 
2006 (187) 
Australia Research 
population 
4 and 52 Yes 69 
Tang 
2005 (284) 
Hong Kong Consecutive  12 Unspecified 71 
Wolf 
2010 (270) 
USA Research 
population 
1 yes 58.8 
Wong 
2009 (285) 
Hong Kong Random 
selection 
Unspecified  Unspecified 70 
Wong 2004 Hong Kong Prospective selection  
12 Unspecified 72.9 
Wu 2013 
(286) 
China  Consecutive  unspecified Unspecified 68.14 
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Meta-analysis 
I was able to pool test accuracy data for four tests: ACE-R (cut-off score <88); MMSE 
(cut-offs≤24 and ≤26), MoCA (cut-offs<26 and <22) and R-CAMCOG (cut-off<33).  No 
test had sensitivity and specificity that were significantly different from others.  
MoCA at “traditional” cut-off was sensitive at cost of specificity; specificity 
improved if cut-offs were adjusted.(Table 3-8, Figures 3-4 to 3-11)   
Table 3-7 Pooled test accuracy for four cognitive screening tests against a 
reference standard of "cognitive impairment" 
Test
(threshold)
Papers
Patients
Cognitive 
impairment 
n (%)
Sensitivity
(95%CI)
Specificity
(95%CI)
Positive 
Likelihood 
Ratio
(95%CI)
Negative 
Likelihood 
Ratio
(95%CI)
ACE-R 
(<88/100)
2
(192)
52 (27%) 96.2
(0.90-1.0)
0.70
(0.59-0.80)
3.19
(2.24-4.54))
0.06
(0.01-0.22)
MMSE 
(<25/30)
12
(1639)
483 (30%) 0.71 
(0.60-0.80)
0.85 
(0.80-0.89)
4.73
(3.63-6.17)
0.34
(0.25-0.47)
MMSE 
(<27/30)
5
(445)
195 (44%) 0.88 
(0.82-0.92)
0.62 
(0.50-0.73)
2.33 
(1.72-3.17)
0.19 
(0.13-0.29)
MoCA 
(<22/30)
6
(726)
289 (39%) 0.84 
(0.76-0.89)
0.78 
(0.69-0.84)
3.75
(2.77-5.08)
0.20
(0.15-0.29)
MoCA 
(<26/30)
4
(326)
131 (40%) 0.95 
(0.89-0.98)
0.45 
(0.34-0.57)
1.73 
(1.43-2.10)
0.10 
(0.04-0.23)
R-CAMCOG
(<33/49)
2
(421)
90 (21%) 0.81
(0.57-0.93)
0.92
(0.87-0.95)
10.18
(6.41-16.18)
0.20 
(0.07-0.52)
 
ACE-R=Addenbrookes Cognitive Examination (Revised); MMSE=Folstein’s Mini Mental state 
Examination; MoCA=Montreal Cognitive Assessment; R-CAMCOG=Rotterdam CAMCOG 
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Morris 2012
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Figure 3-3 Forest plot of ACE-R (cut-off 88) for diagnosis of 
dementia/cognitive impairment (n=2 studies) 
	  
	  
Study
de Koning A
de Koning B
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0.94 [0.87, 0.98]
Sensitivity (95% CI)
0 0.2 0.4 0.6 0.8 1
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Figure 3-4 Forest plot of R-CAMCOG (cut-off 33) for dementia/cognitive 
impairment (n=2 studies) 
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Figure 3-5 Summary ROC curve and forest plot describing test accuracy 
studies of Folstein’s Mini-Mental State Examination (MMSE) at a  test cut-
off of <25/30 
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Figure 3-6 Summary ROC curve and forest plot describing test accuracy 
studies of Folstein's Mini-Mental State Examination (MMSE) at a test cut-
off of <27/30 
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Figure 3-7 Summary ROC curve and forest plot describing test accuracy 
studies of the Montreal Cognitive Assessment (MoCA) at a test cut-off of 
<22/30 
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Figure 3-8 Summary ROC curve and forest plot describing test accuracy 
studies of the Montreal Cognitive Assessment (MoCA) at a test cut-off of 
<26/30 
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3.3.2. Quality and reporting  
One paper was graded “low risk” for all QUADAS2 domains.(269) Common issues of 
concern were use of case-control methodology (n=7 papers) and potential lack of 
blinding (n=12).(Figure 3-2 and 3-3). Five papers attempted to include patients with 
moderate to severe aphasia.(165, 187, 269, 270)  
STARDdem assessment suggested consistent areas of poor reporting, particularly 
around the handling of missing data (n=22 papers) and descriptions of training and 
expertise of assessors (n=25 papers).(Table 3-8) 
 
Due to the modest sample size of the papers relevant to this research question, 
post-hoc analysis based on study quality or sample size was not performed.  I chose 
to describe quality at an individual paper level using standardised measures 
(QUADAS2 and STARDdem).   
 
 
Figure 3-9 Assessment of risk bias and applicability concerns using the 
revised Quality Assessment of Diagnostic Accuracy Studies tool (QUADAS-
2)
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Table 3-8 Risk of bias and applicability concerns assessed at study level 
using the revised Quality Assessment of Diagnostic Accuracy Studies tool 
(QUADAS-2) 
Pa
tie
nt
 S
ele
cti
on
Agrell 2000 –
Baum 2008 –
Blake 2002 ?
Bour 2010 ?
Brookes 2012 –
Cartoni 2007 ?
Cumming 2010 –
Cumming 2013 ?
de Koning 1998 –
de Koning 2000 –
de Koning 2005 –
Desmond 1994 –
Dong 2010 ?
Dong 2012 –
Godefroy 2011 +
Grace 1995 –
Green 2013 +
Hershey 1987 –
Hobson 2003 –
Jodzio 2010 –
Larson 2005 +
Morris  2012 +
Nokleby 2008 –
Nys 2005 –
Pendlebury 2012 +
Salvadori 2013 +
Sodring 1998 +
Srikanth 2006 –
Tang 2005 ?
Wolf 2010 –
Wong 2009 –
Wu 2013 –
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Methods Results
Participants Test Methods Stats Participants Test Results Estimates
STARDdem item 
STUDY AUTHOR 1 2 25 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Agrell 2000 N Y Y Y N Y Y Y Y Y Y Y Y N Y Y Y Y Y N N Y N Y N
Baum 2008 Y Y Y Y Y N Y Y Y Y N N Y Y N Y Y Y Y N N N N Y Y
Blake 2002 N Y Y Y N Y Y Y Y Y Y N Y N N Y N Y Y N N Y N Y N
Bour 2010 N Y Y Y N Y Y Y Y Y Y Y Y N Y Y Y Y Y Y Y Y N Y N
Brookes 2012 N Y Y Y Y N Y Y Y Y Y N Y Y N Y N Y Y Y N N N Y Y
Cartoni 2007 Y Y Y Y N Y Y Y Y Y Y N Y N Y Y Y Y Y Y N Y N Y N
Cumming 2010 N Y Y Y Y N Y Y Y Y Y N Y N Y Y Y Y Y Y N Y N Y N
Cumming 2013 N Y Y Y N Y Y Y Y Y Y N Y Y Y Y Y Y Y Y Y Y Y Y Y
de Koning 2000 N Y Y Y N Y Y Y Y Y N N Y N Y Y Y N Y Y Y Y Y Y N
de Koning 2005 N Y Y Y N Y Y Y Y Y N N Y N Y Y N Y Y N Y Y Y Y N
de Koning 1998 N Y Y Y N Y Y Y Y Y Y Y Y N Y Y Y Y Y N N Y Y Y N
Desmond 1994 Y Y Y Y N Y Y Y Y Y N N N Y N Y Y Y Y N N Y Y Y Y
Dong 2012 N Y Y Y Y Y Y Y Y Y Y Y Y N Y Y Y Y Y Y N Y Y Y N
Dong 2010 N Y Y Y Y Y Y Y Y Y N N Y N N Y N Y Y N N Y Y Y N
Godefroy 2011 N Y Y Y N Y Y Y Y Y N N Y N Y Y N Y Y N N Y N Y N
Grace 1995 Y Y Y Y N Y Y Y Y Y N N Y N N Y N Y Y N N Y N Y N
Green 2013 N Y Y Y N Y Y Y Y Y Y Y Y N N Y Y Y Y Y N Y N Y N
Hershey 1987 N Y Y Y Y N Y Y Y Y Y Y Y N N Y N N Y N N Y N Y N
Hobson 2003 N Y Y Y N Y Y Y Y Y N N Y Y Y Y Y Y Y N N Y N Y Y
Jodzio 2010 N Y Y Y Y Y Y Y Y Y N N Y N Y Y Y Y Y N N Y N Y N
Larson 2005 N Y Y Y N Y Y Y Y Y N N Y N N Y Y Y Y N N Y Y Y N
Morris 2012 N Y Y Y N Y Y Y Y Y Y Y Y N N Y Y Y Y N N Y Y Y N
Nkleby 2008 N Y Y Y Y N Y Y Y Y Y N Y N N Y Y Y Y Y N Y Y Y N
Nys 2005 N Y Y Y N Y Y Y Y Y N N Y N N Y N Y Y N N Y N N N
Pendlebury 2012 N Y Y Y Y Y Y Y Y Y Y Y Y N Y Y Y Y Y N N Y N Y N
Salvadori 2013 N Y Y Y N Y Y Y Y Y Y Y Y N Y Y Y Y Y Y N Y N Y N
Srikanth 2006 N Y Y Y N Y Y Y Y Y N Y Y N Y Y Y Y Y N N Y N Y N
Tang 2005 N Y Y Y Y Y Y Y Y Y Y Y Y Y N Y Y Y Y N N Y N N Y
Wolf 2010 N Y Y Y Y N Y Y Y Y N N Y N N Y Y Y N N N Y N N N
Wong 2009 N Y Y Y Y N Y Y Y Y N Y Y Y N Y N Y Y N N Y N N Y
Wu 2013 N Y Y Y Y N Y Y Y Y Y Y Y N Y Y N Y Y N N Y N Y N
Pendlebury 2013 N Y Y Y N Y Y Y Y Y N N Y N Y Y Y Y Y N N Y N Y N
 
Figure 3-10 STARDdem reporting guidance as applied to included studies  
 
	  91	  
3.3.3. Heterogeneity 
I assessed effect of timing and reference standard using MMSE data. Comparing six 
“acute” studies(236, 246, 265, 269, 277, 278) and six “non-acute”; (166, 247, 267, 
274, 275, 279) relative sensitivity:0.73 (95%CI:0.58-0.93) and relative 
specificity:1.12 (95%CI:1.01-1.25) suggesting that accuracy varies with assessment 
timing. (Figure 3-10) Comparing “clinical dementia” reference standard, (187, 269, 
280, 284, 288) against neuropsychological battery; (164, 166, 169, 239, 279, 281, 
293) suggested no difference with relative sensitivity:0.86 (95%CI:0.67-1.11) and 
relative specificity:1.05 (95%CI:0.95-1.16). (Figure 3-11)  
 
3.3.4. Accuracy of brief tools 
I found three suitable papers (n=294 participants). (289, 290, 292) (Table 3-9)  The 
4AT test is a brief delirium assessment.  However, it was included here as a brief 
assessment of cognition as delirium can be a trigger to the development of longer-
term cognitive impairment, as discussed previously in the introduction chapter (p5).  
Two papers were graded high risk of bias and applicability concerns due to case 
control-methodology and patient inclusion. (289, 292) 
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Figure 3-11 Summary ROC curve exploring the effect of time since 
stroke on test accuracy: comparing "acute" testing with "non-acute" 
testing 
Acute 
Non-­‐Acute 
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Figure 3-12 Summary ROC curve exploring the effect of reference 
standard employed: comparing "clinical" diagnosis of dementia against 
diagnosis made using "neuropsychological battery" 
Clinical	  dementia	  diagnosis
Multi-­‐domain	  impairment
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Table 3-9 Summary of studies describing brief (less than 5 minutes 
administration time) cognitive assessments 
Study 
“n” 
Included 
Setting 
(Timing) 
Index 
Tests 
Reference 
Standard(s) 
Summary results 
Johnson-
Greene 2009 
115 
ASU 
(Hyperacute) 
TCT MMSE, 
HVLT 
TCT correlates with HVLT and 
MMSE and discriminates cases 
from controls 
Lees 2013 111 
ASU 
(Hyperacute) 
4AT, AMT, 
CDT, Cog-4 MoCA 
4AT performs well at standard 
MoCA cut-offs. 
CDT performs well at lower 
MoCA cut-offs 
Wong 2004 68 
Outpatients  
(Unspecified) 
CDT MMSE, WCST 
CDT correlated with MMSE and 
WCST and discriminates cases 
from controls 
 
ASU=Acute Stroke unit 
4AT=4 A test; AMT=Abbreviated mental test;Cog-4=Cognitive components of the National Institute 
of Health Stroke Scale; CDT=Clock drawing test; TCT=Three Cities Test 
HVLT=Harvard Verbal Learning Test; MMSE=Mini Mental State Examination; MoCA=Montreal 
Cognitive Assessment; WCST=Wisconsin Card Sorting Test 
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3.4. Discussion 
The aim was to provide a synthesis of screening tool properties to allow evidence-
based recommendations on cognitive testing. I was partially successful in this aim. 
Although there is an extensive literature describing cognitive testing in stroke, 
number of papers using the classical test accuracy paradigm of index test versus 
reference (gold) standard was limited. Eligible papers were characterised by 
heterogeneity and risk of bias and the potential to describe summary analyses at 
individual test level was limited. 
Accepting these caveats, I can still offer conclusions from the pooled analysis. 
There was no clearly superior cognitive screening test. Given the relative 
consistency in accuracy data across the tests, choice of test strategy should be 
informed by purpose of testing and other factors such as feasibility; acceptability 
and opportunity cost. Recent guidance and practice has tended to favour novel 
tests over the traditionally popular MMSE.(22, 255, 291) Although there may be 
good reasons to favour other tests, the data I present do not suggest that MMSE is 
inferior for the diagnosis of multi-domain impairment, albeit MMSE may lack 
sensitivity for single domain impairment.(166, 259, 291) There was a trend towards 
better clinical utility for R-CAMCOG but the small number of studies and 
corresponding wide confidence intervals precludes definitive recommendation. 
Preferred test properties will depend on the assessment setting and on test 
purpose, particularly the level of cognitive impairment to be detected. High 
sensitivity may be desired but this will be at the expense of lower specificity: false 
positives will rise.  These patients may have to undergo further testing and may 
over burden services preventing true positives from receiving help.  On the other 
hand, favouring specificity will raises the false negative rate, and some patients 
will miss out on support and treatments, perhaps impacting negatively on patient 
recovery.  Therefore, it may be argued that for initial screening, sensitivity should 
be preferred over specificity. In this case MoCA may be preferred. The high false 
positive rate for multi-domain impairment obtained at a cut-off of MoCA<26 is to be 
expected since this cut-off was chosen for detection of single domain 
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impairment/MCI.(166, 259) This study findings suggest that an adjusted cut-off of 
<22 has improved properties for multi-domain impairment. 
I was pragmatic in choice of index test and reference standard. The screening test 
rubric ranged from relatively short assessments (MoCA) through to fairly lengthy 
batteries (RBANS). I did not find significant improvements in sensitivity/specificity 
comparing shorter and longer screens (e.g. MoCA and ACE-R). This may suggest that 
increasing the length of screening tools does not necessarily improve the test 
accuracy. 
There is no universally accepted gold standard for dementia. Clinical diagnosis is 
most in keeping with current practice, but I acknowledge the inherent inter-
observer variability.(260) Including multi-domain impairment based on 
neuropsychological assessment is potentially problematic. A-priori Dr Quinn and I 
decided on this approach, to maximise potential for pooled analysis and recognising 
that a clinical diagnosis is not always feasible or appropriate. I used multi-domain 
impairment as this is closest to current operational classifications of dementia; I did 
not specify the contents of the neuropsychological assessment and recognise 
substantial heterogeneity in batteries employed.(259) It is reassuring that subgroup 
analyses suggested no significant difference between the approaches to reference 
standard.  
Brief assessment tools are attractive for use in busy stroke settings but only if they 
have acceptable accuracy. In this regard the limited number of studies looking at 
brief assessments is unfortunate. Based on data available, screening using clock 
drawing test or AMT may have a role for initial assessment; but with their focus on 
select cognitive domains they should not be considered a substitute for subsequent 
multi-domain testing.  However, The 4AT assessment is a brief delirium assessment.  
However it may have potential for brief cognitive assessment.  It embodies items 
pertaining to orientation, memory (both long and short term) and attention, which 
can be commonly affected following stroke.  Thus, the 4AT assessment could 
provide credible information of the patients’ current and future cognitive ability, 
hence its inclusion here.(290, 294)  However, the 4AT is an extremely brief 
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assessment and therefore not likely to give an accurate global assessment of 
cognition (i.e. covering areas of executive function, abstract reasoning or visual 
spatial ability which are all affected by stroke and impact on cognition long term).  
 
3.4.1. Limitations of included studies 
This review highlights issues in the design and reporting of cognitive test accuracy 
studies.  There was little reporting of missing or indeterminate data, however we 
know that substantial numbers of stroke patients are unable to complete multi-
domain screening tools.  The same concern holds for a reference standard based on 
an extensive neuropsychological battery.  Limiting test accuracy data to those able 
to complete testing will bias results, tending to inflate test accuracy.  I would 
encourage use of the “intention to diagnose” approach, where the traditional “2x2” 
test accuracy table is expanded with cells representing those unable to complete 
index test and/or reference standard.(295)   
A related issue is around generalisability of the included subjects.  In the quality 
assessment we (Dr Selvarajah and I) scored several papers as “inappropriate 
exclusion” including the studies that excluded patients with moderate to severe 
aphasia or inability to consent.  I recognise the challenges of cognitive testing in 
this group, who by definition have at least single domain impairment, however 
excluding patients with communication problems or frank confusion from test 
accuracy research will limit external validity.  
I would encourage greater consistency in reporting of methods and results.  Use of 
the recently published STARDdem guidance may improve reporting.(Table 3-2) 
 
3.4.2. Strengths and limitations of review 
I offer a comprehensive review with highly sensitive search strategy; following best 
practice in conduct and reporting and with multiple embedded internal and 
external validity checks. The review has limitations, the focussed question excluded 
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potentially informative papers, for example where screening tests are compared 
against each other,(163, 296)  and I did not assess other important test metrics such 
as responsiveness to change. I recognise that cognitive assessment in stroke is 
evolving, 15 (47%) of included papers in the primary review were published since 
2010. Novel, stroke specific(297) and generic cognitive screening tools (ACE version 
three) have been described but no accuracy data were available at the time of 
review.  We are limited in our analyses by the modest number of papers describing 
only a limited range of available tests.  We used those cut-offs described in the 
papers.  Access to source data and pooling in an individual patient level meta-
analysis would allow for a more robust assessment of how varying thresholds may 
perform. 
 
3.4.3. Future research  
The subgroup analysis suggests that test accuracy will vary depending on time since 
stroke but could not suggest an optimal time for assessment.  Early assessment in 
the ASU has practical advantages and could allow for timely intervention.  However 
few studies assessed patients in the very acute period. Given the issues with 
generalisability and missing data, future studies may wish to describe feasibility and 
acceptability of testing as well as classical test accuracy metrics. 
 
3.4.4. Conclusion 
As studies have focussed on using one assessment versus a reference standard, a 
meta-analysis comparing the same assessments across similar populations provides 
the best way to analyse assessment performance within stroke cohorts.  There is no 
clearly superior cognitive screening test approach. If sensitivity is favoured, then 
MoCA may be the preferable test, although test cut-offs may need adapted for use 
in stroke. All of our results must be interpreted with caution as included studies had 
substantial heterogeneity and potential for bias. I would also acknowledge that 
multi-domain cognitive impairment is part of, but is not the same as, a diagnosis of 
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dementia. A diagnosis of dementia requires evidence of both impairment in 
activities of daily living, progression and a lack of reversibility.  Importantly, none 
of these are measured by the cognitive screening tools described in this work and 
thus there are inherent limitations in using any form of cognitive screening to 
predict future dementia.  I recognise that our reference standard contains two 
approaches that are not synonymous.  The true gold standard is clinical assessment.  
To make a diagnosis of dementia using usual classification systems requires 
evidence of a) impairment in functional ability, b) progression, c) lack of 
reversibility and d) impairments in more than one cognitive domain.  Multi-domain 
cognitive assessment (and screening tools) only assesses the last of these four 
criteria. 
 
 
3.4.5. Research in context 
There is an extensive, cross-disciplinary literature on cognitive screening in stroke. 
Previous systematic reviews of cognitive test accuracy have focussed on older 
adults with narrative results only. My review provides a contemporary synthesis of 
the rapidly evolving field of cognitive screening in stroke and uses novel statistical 
techniques to allow summary analyses. My pooled data suggest that no cognitive 
test is clearly superior, R-CAMCOG has potential and MoCA has favourable 
sensitivity. Sub-analyses suggest that timing of assessment will impact on test 
properties and that screening test diagnostic cut-offs should be altered for stroke-
survivors and where purpose of testing is to detect dementia versus single domain 
impairments. 
Although in practice the results of cognitive screening would be interpreted as part 
of a multidisciplinary assessment that includes other functional and investigational 
data, it can help put results in context to model the effect of test property data. 
From the annual incidence of all strokes (152,000) in the UK(298), Glasgow has an 
annual stroke survival of 2,257.(299) Assuming a one-year prevalence of all-cause 
post-stroke dementia of around 40%, at traditional cut-offs MoCA as sole screening 
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tool would miss 45 patients with dementia and would wrongly give a probable 
dementia diagnosis to 745 patients.  If the MoCA cut-off is adjusted to <22/30, 
multi domain cognitive impairment/dementia could be missed in 144 patients and 
298 would be given an erroneous dementia label. However, the outcome of any 
assessment is vulnerable to other external factors i.e. assessor experience and 
setting administered.  This is further discussed in chapter 7. 
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Chapter 4 Feasibility and diagnostic 
accuracy of early mood screening to 
diagnose persisting clinical depression 
or anxiety disorder post-stroke 
Building on evidence presented in previous chapters 
My systematic review suggested that cognitive screening assessments at the acute 
stage post-stroke is feasible but with limited data on accuracy and where data were 
available accuracy differed between tools.  
There is less research into standardised assessment of post-stroke mood than 
cognition.  Like cognition, mood can significantly impact on a patient’s outcome 
across several areas of recovery. This work follows the previous chapter and 
explores the feasibility and predictive accuracy of mood measures administered to 
acute stroke patients.  
 
4.1. Introduction 
Post-stroke depression usually starts within the first year, with around a third 
developing within 3 months.  With that said half of those that develop depression 
within the first year also recover. Despite this the impact on recovery within this 
time may still impact beyond the first year.(87)  It is therefore important to screen 
for potential depression early as it would allow for timely support, education and 
treatment to reduce risk of hindering recovery.   
In addition, early assessment for neuropsychological disorders is a pertinent issue as 
many stroke survivors are discharged direct from the acute ward and if 
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depression/anxiety is not assessed during this stay it may not be assessed 
thereafter.  Stroke-survivors often report that their physical needs are prioritised 
over psychological.(300)  
Depressed stroke survivors are more passive in their approach to rehabilitation and 
show reduced functional ability on admission and discharge.(146) Mood impacts on 
both their ability to perform activities of daily living(143) and on their rate of 
functional recovery during rehabilitation.(202) Effects persist during follow up: 
depressed patients show a decrease in some areas of functional ability.(149) 
Association does not imply causation.  There is a clear link between mood and 
function but research to date can only tell us that one increases the risk and 
predicts the severity of the other.(145, 301, 302)  
Mood assessment in the first few days after stroke may be complicated by 
impairments of speech; cognitive and physical function.  Communication deficits 
can lead to depression post-stroke(96), but also can limit the assessment measures 
that are feasible and may predispose to inaccurate diagnosis(214, 215)   However, 
stroke patients may also demonstrate changes in mood due to the realisation of a 
potentially catastrophic life event.  Psychological adjustment to stroke often 
involves depression and/or anxiety symptoms, which do not persist long-term and 
significantly affect recovery.(303, 304)  By using predictive accuracy, it might be 
possible to find an assessment that can identify those individuals who fail to adjust 
psychologically, and go on to develop more chronic mood disorder. 
Studies of early (first weeks) screening have tended to focus on cross-sectional 
prevalence with no follow-up.(305, 306)  However, with transient problems 
affecting results(15, 307), illustrated by the findings of chapters 3 and 4, an acute 
screening strategy could overburden services by detecting problems that require no 
follow-up or intervention.    
Given this uncertainty, this pragmatic clinical study was designed to:  
(i) Investigate feasibility of brief screening tests for depression/anxiety 
assessment in an acute stroke setting. 
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(ii) To determine the stability and diagnostic accuracy of early screening for 
clinically significant depression/anxiety problems at one month post-stroke. 
It is recognised the one month follow-up is a short period of time in terms of 
psychological recovery, post-stroke.  However, we adopted this time frame in an 
attempt to explore the earliest time post stroke in which interventions to aid 
adjustment and minimise likelihood of mood disorder could be feasibly addressed, 
thus limiting the potential long term affects on recovery. 
 
4.2. Methods  
4.2.1. Participants  
I assessed consecutive adult (≥18 years) stroke patients admitted to a teaching 
hospital acute stroke unit (ASU).  This ASU directly admits all suspected stroke with 
no exclusions on the basis of pre-stroke impairments.  For this assessment of 
feasibility, I was deliberately inclusive, but did not include subjects with active 
diagnosis of major psychiatric disorder (i.e. disorders which would affect consent 
and understanding such as schizophrenia, bipolar disorder). I included stroke 
(ischaemic and haemorrhagic) and transient ischaemic attack (TIA) but not 
subarachnoid haemorrhage.  Final cerebrovascular diagnosis was clinical, based on 
all available data, and made by adjudication panel comprising stroke physicians and 
radiologists. 
Recruitment took place between December 2012 and April 2013.  Patients were 
initially assessed for suitability, including capacity to consent, by the treating 
clinical team.  This medical assessment did not follow a protocol, rather the 
treating clinical team made an initial decision of whether the patient was medically 
stable for an attempt at depression/anxiety screening.  Suitable patients were 
approached and consented by myself.  I aimed to perform assessments on day of 
ASU admission. 
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4.2.2. Assessor  
I collected screening and follow-up assessment data.  I was trained prior to the 
study in test delivery by a consultant Stroke Psychologist (Dr Niall Broomfield).  This 
involved: familiarisation, informal practice with the assessments and instructions 
alongside supervised administration of the assessments to establish a 
standardisation in their execution.   
   
4.2.3. Assessments  
I used depression/anxiety-screening tools validated for use in stroke-survivors.  My 
choice of tool was based on the previous review work (chapter 2), perceived 
suitability for the acute setting and availability within the trust.  The primary focus 
was mood.  I used two depression/anxiety screening tools, one standard 
depression/anxiety assessment: Hospital Anxiety and Depression Scale (HADS)(197) 
[GL Assessment] and one potentially suitable for patients with aphasia: Depression 
Intensity Scale Circles (DISCS)(308). 
HADS is a self-report multiple-choice measure of depression and anxiety.  The 
structure and purpose of HADS is discussed in chapter 1.   
The DISCS test was developed to screen for depression in patients with cognitive or 
communication impairment following brain injury.  It has been validated within a 
hospital setting, including stroke.(308, 309) The test comprises a vertical scale of 
six circles (controlling for visual-spatial disturbances) with increasing levels of 
shading, representing participant depression levels.  Scoring is from 0 “no 
depression” to 5 “severe depression”.  A score of ≥2/5 is defined as “screen 
positive depression”.(308)   
The reference standard for HADS and DISCS was one-month follow-up assessment 
clinical diagnosis of depression/anxiety disorder.  I employed the Mini International 
Neuropsychiatric Interview (MINI), a multi-component, semi-structured psychiatric 
questionnaire(310) based on the Diagnostic Statistical Manual of Mental Disorders 
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(DSM)(121) and International Classification of Diseases (ICD)(311) diagnostic 
criteria.  Telephone administration has been previously validated.(312)  I assessed 
only the mood components of MINI: major depressive disorder and dysthymia 
(classified together as depression); panic disorder with/without agoraphobia; social 
anxiety disorder; generalised anxiety disorder (classified together as anxiety) and 
no mood disorder.  
 
4.2.4. Cognition 
Recognising the complex relationship between cognition and depression/anxiety, 
and how cognition can affect screening, I also assessed patients’ cognitive function 
using a single cognitive screen, the MoCA(161), at baseline and follow-up. A 
modified MoCA for telephone use (274) is described and showed promise in my 
systematic review.  I used this telephone MoCA (TMoCA) for my telephone follow-up 
assessments.  The TMoCA excludes assessment of visuospatial skills and naming 
visual cues and score is modified accordingly.  The full MoCA rather than the 
visually impaired version was employed at baseline to allow a full assessment of 
patient’s abilities and to consider the feasibility of administering a multimodal 
cognitive assessment, which included motor and visual skills  Total MoCA<26 was 
recorded as “screen positive cognitive impairment”(161); (<18/22 for TMoCA).(274)  
To allow direct comparison of MoCA and TMoCA I described scores as a percentage 
of total score.  In relation to prior findings in previous chapters, I planned to 
investigate the effect of varying MoCA cut-offs on predicting follow-up cognitive 
impairment. 
 
4.2.5. Data Collection 
I kept a log of total numbers of admissions and reasons why participants were 
inappropriate for assessment.  I also recorded baseline demographic and clinical 
details to a pre-specified and piloted proforma.  Order of testing DISCS or HADS was 
randomised (coin toss).  Scores for HADS; DISCS and MoCA were shared with 
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patient’s clinical team and General Practitioner.  Assessments were not modified 
for patients with specific impairments.  Problems that impeded or prevented test 
completion and instances where I had to provide assistance were noted.  
I performed follow-up telephone based assessments at one month post-stroke.  
Patients gave a preference to morning or afternoon calls at time of consent. 
Contact was attempted 3 times maximum.  Times and reasons for disrupted 
response was recorded.  In the event of no response, the hospital database was 
checked to ensure the participant was not currently an inpatient.  For participants 
still in-patient, assessment was completed face-to-face on the ward.  An option for 
face-to-face assessment was also given for subjects with no telephone access or 
who were uncomfortable using the telephone.  Order of telephone assessment was 
fixed: MINI; HADS; TMoCA.  I decided to administer the MINI over the telephone to 
reduce patient burden and following previous research adopting this approach.  
MINI employs a simple yes or no response format incorporating additional questions 
to any positive screen responses.  Thus, piloting and subsequent experience 
suggested it lended itself well to use via the telephone. 
 
4.2.6. Analysis 
Outcomes of interest were feasibility; stability and test accuracy. 
To assess feasibility I described proportions completing screening tests (aided and 
unaided) and reasons for non-completion, illustrated by flow diagram (Figure 5-1).  
As my study was designed to test feasibility, I did not pre-specify a target number 
for inclusion, rather I specified a fixed time period for data collection (4 months).  
Our primary test accuracy analyses compared acute depression/anxiety screening 
tests against one-month clinical diagnosis of depression/anxiety disorder.  I created 
standard 2x2 tables and calculated sensitivity, specificity, positive and negative 
predictive values with corresponding 95% confidence intervals (95%CI).   
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I assessed agreement between HADS and DISCS at baseline by comparing proportions 
assessed as screen positive for depression using a chi-squared analysis.  
To assess temporal change in screening tests over time I created a plot of values for 
repeated measure on vertical axis against time on horizontal axis (“spaghetti plot”) 
and with Wilcoxon paired tests.(313) 
Although not conforming to the classical index test/reference standard paradigm I 
assessed “accuracy” of early MoCA against “diagnosis” of cognitive impairment 
using follow-up TMoCA and described results with usual test accuracy metrics.  My 
systematic review has suggested that the standard <26/30 MoCA cut point may be 
unsuitable for stroke cohorts.(165, 166, 280)  I explored the effect of varying MoCA 
cut-offs on prevalence of “screen positive” cognitive impairment at baseline and 
follow-up.  
All statistical analyses were performed using SPSS version 18.0 (IBM, USA) and 
Statsdirect software version 2.7.9 (Stats Direct Ltd, UK).   
My study was adopted by the Scottish Stroke Network and approved by our local 
research ethics committee (West of Scotland Research Ethics Committee 1: 
12/WS/0275) (Appendix F). 
 
4.3. Results  
4.3.1. Participant characteristics 
Over the four month recruitment period, 146 patients were admitted to the acute 
stroke unit; 39 were too unwell to approach; 5 violated inclusion criteria; 102 were 
approached with 33 refusing screening and 69 recruited.(Figure 4-1). 
Recruited subjects were: n=41 (59%) male; median age:71 (IQR:61-81); median 
NIHSS:3 (IQR:2-5); 41% (n=28) prior stroke; 13% (n=9) prior depression.  All subjects 
with prior depression were prescribed antidepressants, mostly selective serotonin 
reuptake inhibitors (Fluoxetine (n=6); Dosulepin (n=1); Imipramine (n=1); Setraline 
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(n=1) and Trazodone (n=1)).  Stroke classifications in recruited patients were LACS 
(n=15, 22%); PACS (n=32, 46%); POCS (n=6, 9%); TACS (n=5, 7%); TIA (n=8, 12%)  
Median time to screening assessment was 2 days post admission (IQR:1-4).(Table 4-
1) 
I described selected demographics (sex and stroke subtype) of those who did not 
agree to testing by using monthly aggregate data that is collected as part of the 
Scottish Stroke Care Audit (SSCA) and NHS performance targets (HEAT targets) . 
Both are national quality improvement programmes that collect data to allow 
‘systematic, comprehensive audit of management and outcome providing feedback 
through regular reporting and annual review of performance against national stroke 
care standards’.(314)  Monthly data are collated and shared with treating clinical 
teams.  My clinical supervisor was able to derive certain descriptors by subtracting 
data for those involved in the project from the aggregate figures.   
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146	  CONSECUTIVE	  STROKE	  ADMISSIONS	  TO	  ASU	  WIG
N=102	  Patients	  approached	  
N=44	  Unsuitable	  patients	  
N=39	  Too	  unwell
N=5	  Inclusion	  criteria	  violated
N=69	  Recruited	  
N=33	  Refusals	  
Baseline	  testing	  completed	  
N=69	  HADS	  
N=68	  DISCS	  
N=66	  MoCA
N=63	  Appropriate	  to	  follow-­‐up
N=61	  Participated	  in	  follow-­‐up
N=1	  Disability	  prevented	  assessment	  
N=5	  Violation	  of	  criteria	  post	  baseline	  assessment
N=1	  Deceased
N=8	  Unable	  to	  fully	  complete	  all	  
parts	  of	  baseline	  assessment
N=2	  Motor	  disability	  
N=4	  Visual
N=1	  Speech	  
N=1	  Concentration/withdrawal	  
N=58	  Full	  MINI	  assessment	  
N=4	  MINI	  depression	  section	  only
N=57	  HADS	  completion
N=56	  MoCA completion	  
N=4	  Withdrew	  (3	  HADS,	  4	  MoCA)
N=1	  Violated	  criteria
 
Figure 4-4-1 Flow chart of patient recruitment and assessment 
WIG: Western Infirmary General; ASU: Acute Stroke Unit; HADS: Hospital Anxiety and Depression 
Scale; DISCS: Depression intensity Scale Circles; MoCA: Montreal Cognitive Assessment; MINI:  Mini 
International Neuropsychiatric Interview 
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Table 4-4-1 Baseline clinical and demographic information 
 
*= significant difference between recruited/not included groups at a significance level of 
p<0.0001 
# = Data of non-included patients were calculated from aggregate ward data collected as part of 
the national stroke audit  
† IQR: Inter Quartile Range; TACS: Total Anterior Circulation Stroke; TIA: Transient Ischemic 
Attack. 
 
 Total Admitted Recruited Not Included 
Total  
n(%) # 
146 
- 
69 
(47%) 
77 
(53%) 
Age  
Median (IQR) 
75 
(63-83) 
71 
(61-81) 
- 
Males  
n(%group) # 
81 
(55%) 
41 
(59%) 
41 
(53%) 
Ischaemic stroke  
n(%) # 
112 
(77%) 
57 
(83%) 
55 
(71%) 
Left hemisphere  
n(%) 
64 
(44%) 
25 
(36%) 
- 
TACS  
n(%)* 
30 
(21%) 
5 
(7%) 
- 
TIA  
n(%) 
18 
(12%) 
8 
(12%) 
- 
NIHSS 
Median (IQR)* 
4 
(3-8) 
3 
(2-5) 
- 
Prior strokes  
n(%) 
- 
28 
(41%) 
- 
Prior depression 
n(%) 
- 
9 
(13%) 
- 
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4.3.2. Feasibility 
All (n=69) participants completed HADS at baseline, n=36 (52%) were able to self-
complete the test; n=31 (45%) requested verbal administration and required my 
input for completion; n=2 (3%) required that I mark answers only.  One patient was 
unable to complete DISCS due to visual impairment with all others able to self-
complete.  Two did not attempt MoCA (n=1 withdrew after consent; n=1 unable due 
to stroke impairments).  Certain subjects could only partially complete MoCA (n=8, 
12%) due to impairments of: vision n=4 (6%); motor skills n=2 (6%) and language n=1 
(2%).(Figure 4-1). 
 
4.3.3. Baseline depression/anxiety 
Using standard cut-offs (≥11), HADS described an anxiety presence of n=11 (16%) 
and depression n=9 (13%); DISCS described depression in n=25 (37%), with 
differences between proportions screening positive for depression comparing HADS 
and DISCS (p=0.021). 
 
4.3.4. Follow-up depression/anxiety 
Of 69 recruited at baseline: n=63 (91%) were appropriate to contact at one month, 
with n=61 (97%) participating in follow-up assessment.  I collected MINI data from 
n=58 (95%) (n=4 [6%] completed depression questions only).  I collected follow-up 
HADS data from n=57 (93%).  Median time from stroke to follow-up assessment was 
36 days (IQR:30-43).(Figure 4-1).         
Using standard diagnostic cut-offs MINI defined n=12 (20%) with depression; n=6 
(10%) with anxiety disorder. 
HADS anxiety and depression subscales both showed poor sensitivity but good 
specificity for prediction of relevant depression/anxiety disorders at one month.  
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DISCS demonstrated good sensitivity and specificity for predicting clinical 
depression at one month.(Table 4-2). 
I assessed accuracy of follow-up HADS against corresponding depression/anxiety 
disorders.  One month HADS anxiety and depression subscales had low sensitivity 
and high specificity (0.92, 95%CI:0.82-0.97; 0.96, 95%CI:0.86-0.99).   
Comparing baseline and follow-up HADS anxiety (HADS-A) and depression (HADS-D) 
scores showed decrease in anxiety (Median:-4, 95%CI:1.20-3.72, p<0.0001) and 
depression scores with time (Median:-2, 95%CI:0.28-2.85, p=0.04).(Figures 4-2 and 
4-3). 
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Table	  4-­‐2	  Accuracy	  of	  screening	  tests	  for	  one	  month	  mood	  disorder	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MINI: Mini International Neuropsychological Interview; 95% CI: 95% Confidence Interval; HADS-A: 
Hospital Anxiety and Depression Scale Anxiety subscale; HADS-D: Hospital Anxiety and Depression 
Scale Depression subscale; DISCS: Depression intensity Scale Circles; PPV: Positive Predictive Value; 
NPV: Negative Predictive Value. The grey shaded rows represent accuracy of HADS performed at 
one-month follow up. 
 
 Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
HADS-A  
Baseline  
≥11 
0.17 
(0.03-0.56) 
0.85 
(0.73-0.92) 
0.11 
(0.02-0.44) 
0.90 
(0.78-0.96) 
HADS-D 
Baseline  
≥11 
0.25 
(0.09-0.53) 
0.94 
(0.84-0.98) 
0.50 
(0.19-0.81) 
0.84 
(0.72-0.91) 
DISCS  
Baseline  
≥2 
0.92 
(0.65-0.99) 
0.78 
(0.64-0.87) 
0.50 
(0.31-0.69) 
0.97 
(0.87-1.00) 
HADS-A  
Follow-up  
≥11 
0.33 
(0.10-0.70) 
0.92 
(0.82-0.97) 
0.33 
(0.10-0.70) 
0.92 
(0.82-0.97) 
HADS-D 
Follow-up  
≥11 
0.33 
(0.12-0.65) 
0.96 
(0.86-0.99) 
0.60 
(0.23-0.88) 
0.89 
(0.77-0.95) 
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Figure 4-4-2 Graphical display of HADS anxiety scores at baseline and 
follow-up 
Measurement point 1= baseline HADS-A score; measurement point 2= follow-up HADS-A score, the 
bold line represents the screen positive cut-off.  
HADS-A: Hospital Anxiety and Depression Scale Anxiety subscale 
 Case positive (diagnostic cut off ≥11/21): baseline n=11 (16%); follow-up n=6 (11%) 
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Figure 4-4-3 Graphical display of HADS depression scores at baseline and 
follow-up 
Measurement point 1= baseline HADS-D score; measurement point 2= follow-up HADS-D score, the 
bold line represents the screen positive cut-off 
HADS-D: Hospital Anxiety and Depression Scale Depression subscale. 
Case positive (diagnostic cut off ≥11/21): baseline n=9 (13%); follow-up n=5 (9%) 
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4.3.5. Effects of varying HADS cut-off  
At baseline, my detection rate for mood problems using the HADS was lower (n=9 
depression and n=11 anxiety) than described in other studies.  Along with a low 
sensitivity and high specificity (compared to MINI outcome at one month) of 
baseline measures, this suggests that perhaps the cut-off for HADS (as discussed in 
chapter 1), in such an acute stroke setting is too high.  I investigated the effect of 
varying the screening cut-off for ELEVATED depression and anxiety symptoms.    
For baseline HADS-D and HADS-A a cut off of ≥7/11 appears to have the best 
sensitivity, specificity and predictive values to MINI detection of clinical mood 
problems at one month. (Tables 4-3 and 4-4)   
For HADS measured at one-month follow-up in comparison to MINI outcome at one 
month: the HADS-D subscale with a cut-off point of ≥8, ≥9 or ≥10/11 has the same 
accuracy.  However, performance is best for ≥8/11 for HADS-A subscale.(Tables 4-3 
and 4-4).   
Overall sensitivity is still lower than specificity in HADS at both baseline and follow-
up measurements.   
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Table 4-3 HADS-D baseline and follow up subscale test positive vs. MINI 
depression case positive for various cut points 
Cut point 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
HADS-D Baseline 
≥7 
0.583 
(0.32-0.81) 
0.755 
(0.62-0.85) 
0.368 
(0.19-0.59) 
0.881 
(0.75-0.95) 
≥8 
0.50 
(0.25-0.75) 
0.857 
(0.73-0.93) 
0.462 
(0.23-0.71) 
0.875 
(0.75-0.94) 
≥9 
0.333 
(0.14-0.61) 
0.878 
(0.76-0.94) 
0.40 
(0.17-0.69) 
0.843 
(0.72-0.92) 
≥10 
0.333 
(0.14-0.61) 
0.878 
(0.76-0.94) 
0.40 
(0.17-0.69) 
0.843 
(0.72-0.92) 
HADS-D Follow-up 
≥7 
0.667 
(0.35-0.88) 
0.875 
(0.75-0.94) 
0.50 
(0.25-0.75) 
0.933 
(0.82-0.98) 
≥8 
0.556 
(0.27-0.81) 
0.938 
(0.83-0.98) 
0.625 
(0.31-0.86) 
0.918 
(0.81-0.97) 
≥9 
0.556 
(0.27-0.81) 
0.938 
(0.83-0.98) 
0.625 
(0.31-0.86) 
0.918 
(0.81-0.97) 
≥10 
0.556 
(0.27-0.81) 
0.938 
(0.83-0.98) 
0.625 
(0.31-0.86) 
0.918 
(0.81-0.97) 
 
95% CI: 95% Confidence Interval; HADS-A: Hospital Anxiety and Depression Scale Anxiety 
subscale; HADS-D: Hospital Anxiety and Depression Scale Depression subscale; PPV: 
Positive Predictive Value; NPV: Negative Predictive Value.  
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Table 4-4 HADS-A baseline and follow up subscale test positive vs. MINI anxiety case 
positive for various cut points 
Cut point 
 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
HADS-A Baseline 
≥7 
0.5 
(0.19-0.81) 
0.692 
(0.56-0.80) 
0.158 
(0.06-0.38) 
0.923 
(0.79-0.97) 
≥8 
0.333 
(0.10-0.70) 
0.769 
(0.64-0.86) 
0.143 
(0.04-0.40) 
0.909 
(0.79-0.96) 
≥9 
0.333 
(0.10-0.70) 
0.769 
(0.64-0.86) 
0.143 
(0.04-0.40) 
0.909 
(0.79-0.96) 
≥10 
0.167 
(0.03-0.56) 
0.827 
(0.70-0.92) 
0.10 
(0.02-0.40) 
0.896 
(0.78-0.96) 
HADS-A Follow-up 
≥7 
0.667 
(0.30-0.90) 
0.824 
(0.70-0.90) 
0.308 
(0.13-0.58) 
0.955 
(0.85-0.99) 
≥8 
0.667 
(0.30-0.90) 
0.882 
(0.77-0.95) 
0.40 
(0.17-0.69) 
0.957 
(0.86-0.99) 
≥9 
0.50 
(0.19-0.81) 
0.882 
(0.77-0.95) 
0.333 
(0.12-0.65) 
0.938 
(0.83-0.98) 
≥10 
0.50 
(0.19-0.81) 
0.902 
(0.79-0.96) 
0.375 
(0.14-0.69) 
0.939 
(0.84-0.98) 
 
95% CI: 95% Confidence Interval; HADS-A: Hospital Anxiety and Depression Scale Anxiety subscale; 
HADS-D: Hospital Anxiety and Depression Scale Depression subscale; PPV: Positive Predictive Value; 
NPV: Negative Predictive Value. 
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4.3.6. Cognition 
At baseline, using the traditional cut-off <26, MoCA defined cognitive impairment 
was seen in n=54 (82%).  At follow-up TMoCA data was collected from n=55 (92%) 
with n=26 (46%) found to be cognitively impaired.(Figures 4-1 and 4-4). 
Baseline MoCA demonstrated good “sensitivity” (0.96, 95%CI:0.81-0.99) and poor 
“specificity” (0.35, 95%CI:0.20-0.53) for predicting enduring cognitive impairment 
at one month.  The proportion with MoCA defined cognitive impairment using the 
standard cut-off of MoCA <26 was high at baseline.  As there are no available stroke 
norms, I performed post-hoc exploratory analyses varying the screen positive cut-
point of MoCA.  With lower-cut points, numbers with screen positive cognitive 
impairment at baseline decreased.  Varying the diagnostic cut-off for MoCA defined 
cognitive impairment altered the sensitivity/specificity.(Table 4-3). 
Wilcoxon paired test of baseline and follow-up MoCA, showed a significant increase 
in percentage score from baseline to follow-up (Median:4%, 95%CI:-7.12 to-0.52, 
p=0.014).(Figure 4-4-4) 
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Table 4-5 Effects of varying MoCA test positive cut-off for predictive 
accuracy at one month follow up of TMoCA 
 
Cut point 
Baseline case 
positive 
n(%) 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
<26 54 (82%) 
0.96 
(0.81-0.99) 
0.35 
(0.20-0.53) 
<25 47 (71%) 
0.92 
(0.76-0.98) 
0.52 
(0.34-0.69) 
<24 45 (68%) 
0.89 
(0.71-0.96) 
0.55 
(0.38-0.72) 
<23 38(58%) 
0.73 
(0.54-0.86) 
0.55 
(0.38-0.72) 
<22 34 (52%) 
0.69 
(0.50-0.84) 
0.72 
(0.54-0.85) 
<21 22 (33%) 
0.54 
(0.36-0.71) 
0.93 
(0.78-0.98) 
<20 21 (32%) 
0.54 
(0.36-0.71) 
0.93 
(0.78-0.98) 
 
*MoCA: Montreal Cognitive Assessment; TMoCA: Telephone Montreal Cognitive Assessment; 95% CI: 
95% Confidence Interval. 
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Figure 4-4-4 Graphical display of MoCA baseline and follow-up 
Measurement point 1= baseline MoCA; measurement point 2= follow-up TMoCA with the bold line 
representing the line of best fit. 
MoCA: Montreal Cognitive Assessment; TMoCA: Telephone Montreal Cognitive Assessment 
Case positive: baseline (diagnostic cut off <26/30) n=54 (82%); follow-up (<18/22) n=26 (46%) 
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4.4. Discussion 
This work sought to explore feasibility, stability and diagnostic test accuracy of 
depression/anxiety screening in the first days following stroke.   
These data suggest that screening all hyperacute stroke admissions is not feasible.  
Less than half of all admitted “medically stable” stroke admissions took part in 
assessments.  I found poor agreement between the acute screening tools and 
evidence of substantial change over the first weeks post-stroke.  Thus commonly 
used screening tools (HADS) may not be useful for suggesting sustained and 
clinically important depression/anxiety disorders.  However, by lowering the cut-
offs for HADS subscales, sensitivity, specificity and predictive values improved in 
both baseline and follow-up measurements.  Thus, HADS may require a lower cut-
off in stroke cohorts of ≥8/11 for depression and anxiety subscales, in order to be 
able to detect clinically important mood problems. The HADS cut offs of 7/8 
adopted were based on a-priori decision-making, and guided by the psychiatric 
literature standard, and local clinical practice.  I acknowledge the lower stroke 
adjusted cut-offs highlighted as appropriate for stroke use in some of the extant 
literature, but also recent work examining prevalence of post-stroke depression and 
anxiety which relied on 7/8 cut off approach employed here.  There has also been 
evidence that factorial analysis of HADS cut-off from 8-11 is recommended for 
identifying probable abnormal levels of anxiety and depression symptoms in brain 
injury populations.(203, 204, 315) 
Assessment feasibility is an important metric if screening is introduced to a busy 
clinical service.  Of the total population, a substantial number were deemed 
unsuitable for assessment.  This is not a concern as the utility of attempting direct 
screening assessments in medically unwell patients is limited.  Those suitable for 
assessment were mostly able to complete screening tests, although many required 
assistance.  Thus, even using self-completion tests, stroke screening may require 
input from staff, bringing associated opportunity cost.  The proportion of stable 
patients approached who did not want to participate was unexpectedly high, 
reminding me not to assume that screening is acceptable to all, however as 
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mentioned before, this could be due to the lack of benefits from research 
participation.  Future work should focus on qualitative descriptors of patient and 
staff opinions on neuropsychological screening.  
My analyses suggest that tools may have differing properties; with poor agreement 
between my two screening test strategies.  DISCS appears to have most favourable 
accuracy for predicting clinically important depression at one month.  The ease of 
DISCS administration may explain why it performs well in the acute stage where 
cognitive impairment is prevalent.  My analysis of baseline and one month 
depression/anxiety scores shows change over time.  Generally the trend is for 
improvement.  However there is substantial heterogeneity with some participants 
improving and some worsening.  This pattern makes intuitive sense, diagnosis of a 
major illness may cause substantial, transient depression/anxiety symptoms for 
some while others may not develop depression/anxiety problems until they return 
home and realise the extent of impairments.   
MoCA defined cognitive impairment was highly prevalent at the acute stage.  As 
there are no clearly defined norms for acute stroke cohorts, I used the standard 
cut-point for baseline MoCA (<26).  These data suggest that MoCA scores may 
improve over the first weeks post-stroke.  This is consistent with previous research 
in the post-acute phase where, cognition improves over time and recovery varies 
across domains.(15, 73, 74)  My data suggest that MoCA acute impairment may be 
transient and lowering the MoCA cut-point may be required to detect clinically 
important cognitive problems.  
As MoCA defined cognitive impairment was significant at the acute stage, this may 
explain poorer HADS to DISCS performance.  Integrating four-choice responses, 
HADS places a larger demand on working memory than DISCS.   
The novelty of this work derives from not only the acute administration of the 
assessments but from the comparison of the verbal multiple-choice test with non-
verbalised one question pictorial test (an assessment designed and validated for 
brain injured patients).  I can therefore look into what is an appropriate format of 
test at the acute stage, taking into account other complications of the stroke.       
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Feasibility of administration and within subject performance of these formal 
screening assessments has not been investigated previously.  In addition, by 
following patients up at one month with a structured interview, I can track changes 
or improvements, to make inferences about effects of the acute stage post-stroke 
on the tests and on their ability to be administered to patients.   
This work is different from other papers in that most published studies have 
assessed index test and reference standard concurrently.  In contrast, I delay the 
reference standard to one month and repeat the index test at that point.  
Therefore it is both a predictive and a one-point test accuracy study.  I chose this 
format to investigate feasibility during the acute stage and to gauge persistent 
mood disorders.  A follow-up assessment with a clinically structured interview at 
one month allows for this.  I can compare assessment outcome at the acute stage 
with repeated scores at follow up.  I can also consider accuracy versus the 
structured clinical reference standard.  In doing so, the potential for transient 
issues causing ‘white noise’ to assessments can be accounted for.       
I acknowledge limitations of this work.  The sample may not be entirely stroke 
representative; more severe strokes were less likely to be included.  However it is 
debatable whether very severe stroke patients would be included in early 
depression/anxiety screening programmes.  Unavailable during study design was a 
DISCS equivalent for anxiety, although recently one has been published.(316) I 
recognise that MINI is not a substitute for clinical (neuro)psychological 
assessment.  For this study I did not seek to describe potential diagnosis underlying 
a mood disorder rather we collated all within the rubric of “depression” or 
“anxiety”. Although I was not blinded to individual test scores, a long period had 
passed before I reassessed patients and I did not have access to scores at the time 
of doing the follow up assessments, which decreases potential bias.  I recognise that 
the one month follow-up is still relatively early and depression/anxiety may 
continue to change, however it mirrors other protocols(238) and allowed timely 
study completion.   
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This study’s strength is the acute assessment paradigm, measuring patient 
characteristics at a very early stage post-stroke and using commonly employed 
screening tools.  My methodology was necessarily pragmatic and I hope these data 
may help inform service planning around depression/anxiety screening in stroke.  
My inclusive recruitment should ensure generalisability and my follow-up rates were 
relatively high for a prospective observational study.    
Future research is required to build on this pilot work.  It will be important to 
observe whether other brief depression/anxiety assessments with minimal cognitive 
load are feasible for use in acute settings.  There is evidence to support brief scales 
post-stroke, such as the Yale Single Question(208) and Patient Health 
Questionnaire(317),  although not at the acute stages.   
Based on these findings, I recommend when assessing mood at the acute stage that 
a simple assessment wherein cognitive demand is low (e.g. DISCS) be used. I also 
suggest that MoCA may require a lower cut-off, if used to screen for sustained 
cognitive problems in stroke.   
In addition, given the poor level of acceptability, uptake amongst stable stroke 
patients and changing test values over the first weeks, adopting a delayed 
depression/anxiety screening strategy (several weeks post-stroke) when a more 
stable measure can be made and a higher level of assessment tolerance ensured 
would be preferred.  Our study had an acute assessment focus.  National and local 
guidance recommends assessment during the hospital admission with stroke, which 
can often be only a few days.  In terms of ease of access to patients and availability 
of staff to perform assessment, the acute setting seems attractive for early 
assessment of cognition and mood.  However, as our results demonstrate there are 
feasibility issues with acute testing and initial scores on test are highly variable 
over the first days to weeks.    If mood assessment was delayed to the patients’ 3-
month review, it is likely to have recovered from cofounding impairments affecting 
assessments such as poor concentration, impaired executive function and fatigue.  
This may allow for patients to complete more of the assessments themselves and 
give more accurate responses, assuming that providing a verbal response would lead 
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to patients giving a more positive response so as not to feel judged.  Through 
helping patients complete assessments and reassuring them throughout completion, 
this should have minimised the impact this had on these assessments for this study.  
Nevertheless the benefits of assessing patients at such a hyper acute stage is likely 
to allow for more patients to be screened allowing for potential problems impacting 
on recovery.  As HADS has demonstrated poor predictability at this stage, other 
assessments may be more accurate, such as the GDS, which has validated shorter 
versions.   With a significant number of patients refusing to take part, this poor 
apparent acceptability to assessments might be more towards taking part in 
research rather than the assessments themselves.  Separation between 
acceptability to research and assessments themselves would be difficult to 
investigate out with the research setting until assessments are performed as part of 
usual care.  Investigations into the feasibility and accuracy of cognitive and mood 
assessments are needed to further support this work.   
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Chapter 5 Test accuracy of a short 
cognitive screening test: The Cog-4 
Building on evidence presented in previous chapters 
Findings from chapter 2 show preference for brief screening assessments in 
research and usual practice.  In contrast chapter 3 demonstrated few studies 
investigating very brief measures.  Furthermore, each of the previous chapters has 
demonstrated a need for accurate acute assessments.  Chapter 3 found that as 
specific assessment the Cog-4 test for dementia and had reasonable accuracy for 
detecting dementia in stroke cohorts.(267) This laid the foundation for assessing its 
accuracy in an acute stroke setting. 
I therefore aimed in this chapter of work to directly investigate the accuracy as and 
validity of this assessment in the acute stroke setting.   
 
5.1. Introduction 
Stroke-survivors with cognitive deficits may have improved outcomes if diagnosis is 
made at an early stage. Timely diagnosis of potential cognitive issues will allow for 
appropriate intervention and follow-up.(67)  It would be beneficial to both the 
health professional and the patient if assessments routinely administered could 
have a multiple purpose.  
Few cognitive assessment tools have been specifically designed or validated for use 
in acute stroke settings as there are many other challenges to overcome.  
Cognitive assessment in acute stroke can be complicated by speech disturbance(96) 
physical impairments and concomitant medical complications including 
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delirium.(214, 215, 318)   A valid assessment of the test properties of the Cog-4 as a 
screening tool must include subjects’ who are representative of those stroke 
patients likely to be assessed in routine clinical practice.  My intention with this 
work was to mirror “usual practice” through comparison of Cog-4 as a brief tool 
with a clinically accepted measure in a representative sample of patients examined 
in the acute stage of stroke.    
The National Institutes of Health Stroke Scale (NIHSS) is an impairment scale 
commonly employed in stroke care. NIHSS assesses neurological function through 
measurement of; consciousness, language, neglect, visual fields, eye movement, 
facial symmetry, motor strength, sensation and coordination.(Appendix N)(319) 
Selected elements of the NIHSS: (1b) orientation, (1c) executive function, (9) 
language and (11) inattention have been suggested for use together as a short 
cognitive screening test - the Cog-4. (Appendix O)(267)   
The Cog-4 has been shown to provide some indication of cognitive impairment at 18 
months post-stroke and superficially assesses cognition after 90 days.(320)  Despite 
these short-comings, there is a possibility that if this brief assessment can be used 
as a substitute for a screening tool then cognitive implications could be taken from 
a routine assessment.   There is nevertheless evidence that the Cog-4 performs less 
well than the more detailed screening tool of MMSE.(267)  However, the MMSE may 
not be the ideal comparator, as it has limited ability to describe the executive 
impairments commonly seen in stroke cohorts.(247, 271)  Studies of responsiveness 
of Cog-4 has suggested that Cog-4 assesses only a limited range of possible cognitive 
outcomes with a marked ‘floor’ effect (320, 321) and lacks sensitivity depending on 
the hemisphere affected.(320, 322)  However, other aspects of the Cog-4 are 
desirable for the acute stroke setting; the assessment is short in duration, does not 
add to test burden and can be derived from routinely collected data. 
I aimed to describe test accuracy and validity of the Cog-4 against a multi-domain, 
cognitive assessment recommended for all cause vascular cognitive impairment, the 
MoCA.(22, 161, 166).  In specific relation to my study, MoCA was chosen as a 
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cognitive assessment as its test domains allow for individual component analysis of 
Cog-4 items, while still offering a valid global test of cognitive function.(166)   
The primary aim was to test the accuracy of Cog-4 for detection of MoCA defined 
cognitive impairment and to describe correlation of individual Cog-4 items and 
broadly corresponding MoCA cognitive domains. 
 
5.1.1. Methods  
The study was devised in line with methodological (i.e. assessment administration) 
and reporting guidance for diagnostic test accuracy studies, including the dementia 
specific guidance STARDdem(293, 323) and Quality Assessment of Diagnostic 
Accuracy Studies - QUADAS2.(262)  Although my reference standard was cognitive 
impairment on MoCA rather than clinical dementia, the best practice described in 
STARDdem is still applicable to this study.   
The Cog-4 is a brief assessment and is unlikely to provide a good alternative to a 
neuropsychological assessment.  However, in order to determine if it can provide 
meaningful information on basic cognitive function, I chose to compare each item 
with a corresponding domain on a preferred cognitive assessment tool.  This was 
relatively easy for subscales other than subscale 1c.  Although the item is 
‘commands’, it can be justified to assess basic executive function domain based on 
definitions of executive function. Being able to process verbal information, plan 
and execute a goal is part of executive processing and thus the command item can 
arguably be used as a simplistic test of executive function.(324, 325)   
  
5.1.1.1. Data sources  
The primary data source was the baseline data collected as part of the acute test 
study presented in Chapter four.  From this study I had access to NIHSS (from which 
Cog-4 is derived) and contemporaneous MoCA data.  To increase my sample size I 
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pooled my acute test study data with an existing data set that was provided by my 
supervisor. 
This second dataset comprised anonymised data from a previous audit of stroke 
practice that has been performed as part of the European Hypertension Society 
(EHS) audit of secondary prevention in stroke.  I played no part in collection of the 
EHS data.  A full description of the EHS audit data that was available is in Appendix 
G and H.  In brief, sequential stroke admissions to two acute stroke units (Glasgow 
Royal Infirmary and Western Infirmary) were included in the audit; trained assessors 
by took data from retrospective case note review.  Training was performed by 
senior physicians and consisted of implementing and marking assessments as well as 
reading and extracting data from medical case notes.  The EHS included baseline 
descriptors of NIHSS and MoCA (both were standard measures in participating units 
at time of the audit).  The NIHSS and MoCA data had been collected with scoring of 
each individual component and so these data were suitable to be pooled with my 
trial data.   
Ethical approvals for the acute mood study are described in Chapter Four.  The EHS 
audit had appropriate approvals from the relevant Caldicott guardian and 
agreements from clinical leads at both sites.  Agreement from the Caldicott 
guardian that I could use the audit data for a secondary purpose was confirmed 
(relevant paperwork is included in Appendix G and H)  
 
5.1.1.2. Assessments 
The index tests were the subscales of the NIHSS (orientation, executive function, 
language and inattention) that make up the Cog-4.(267)  Each component is scored 
from 0 to 2 or 3 with >0 being considered abnormal (Appendix N); increasing scores 
describe greater severity of impairment within that domain.(320)  The reference 
standard was the MoCA.  Component domain scores range from 2 to 6 and include: 
visuospatial/executive function; animal naming; short and long term memory; 
attention; language; abstraction and orientation.   
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In Cog-4 elements of the NIHSS are taken as proxies of cognitive domains: NIH 1b 
orientation; NIH 1c executive function; NIH 9 language and NIH 11 (visual) 
inattention.  I compared with corresponding domains of MoCA.  Cog4 and MoCA had 
certain domains that purported to measure the same construct, orientation, 
executive function and language; the Cog4 domain of (visual) inattention had no 
direct equivalent within MoCA and I chose visuospatial function as being closest in 
nature.(326)       
The recommended standard test cut-points of ≥1 for Cog-4(327) and <26/30 for the 
MoCA(161) were employed as testing positive for cognitive impairment.  
Assessments were not modified for patients with specific impairments; however, 
disabilities that may have impeded scores were noted.   
Where no score data were available for the Cog-4 or MoCA, these participants were 
removed from analysis.  The total scores were calculated and classified from 
available data, where participants were unable to complete a particular section of 
the test this was scored as 0.  
 
5.1.2. Analysis 
My primary analysis was the test accuracy of total Cog-4 for the binary outcome 
cognitive impairment/no cognitive impairment based on MoCA scores.  Secondary 
analyses described correlation between individual components of the Cog-4 and the 
corresponding domains of the MoCA.  Because of the ordinal nature of these data I 
used a Pearson correlation to compare domains. I created a 2x2 and 3x3 data table 
for primary analyses.  The 3x3 table allows for those unable to complete testing to 
be considered in the analysis and should give a better reflection of how the test 
performs in clinical practice.(295)  From these I calculated sensitivity, specificity, 
positive and negative predictive values with corresponding 95% confidence intervals 
(95% CI). 
I recognised that NIHSS scores favour dominant hemisphere and anterior lesions. 
The effect of hemisphere on Cog-4 properties has previously been described.  On 
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advice from reviewers I performed post-hoc subgroup analyses, repeating the 
analysis limited to those with TACS/PACS.   
For ease of understanding I collated the data and present all data as pooled (acute 
study and EHS audit unless otherwise stated).  
Statistical analyses were performed using SPSS (IBM, version 19.0, USA), Minitab 
(Minitab Inc, windows version 15, USA) and Statsdirect software (Stats Direct Ltd, 
version 2.7.9, UK). 
	  
5.1.3. Results 
Useable data were available for 173 (n=66 acute mood study; n=107 EHS audit).  
The majority of participants were able to complete the screening assessments: 166 
had Cog-4 data and 148 MoCA (Table 5-1).  Some participants were only able to 
score part of the MoCA, in this instance those domains that could not be scored 
were coded as zero; this was required in n=12 (7%).  
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Table 5-1 Test accuracy of Cog-4 and MoCA as "3x3" table 
 MoCA +’ve MoCA –‘ve MoCA untestable 
Cog-4 +’ve 45 1 17 
Cog-4 –‘ve 79 23 1 
Cog-4 untestable 0 0 7 
 
Cog-4= 4 cognitive areas of the National Institute of Health Stroke Scale, diagnostic cut-off used 
was ≥1/12 
MoCA= Montreal Cognitive Assessment, diagnostic cut-off used was <26/30 
+’ve = case positive for cognitive impairment  
-‘ve = case negative for cognitive impairment  
	  134	  
Stroke classifications by OCSP were: LACS (n=38, 22%); PACS (n=54, 31%); POCS 
(n=12, 7%); TACS (n=27, 16%); TIA (n=10, 6%); other/unclassified (n=32, 18%).  
Median total NIHSS was 3 (IQR: 2-6; range: 0-24) and median Cog-4 was 0 (IQR: 0-1; 
range: 0-8).  There were various risk factors for cognitive impairment within 
subjects: 16 (9%) had a previous diagnosis of dementia; 15 (8.7%) had depression 
and 26 (15%) had pre-stroke visual or hearing impairments. (Table 5-2)         
The MoCA recorded 82% (n=124) of participants with data available, as having 
cognitive impairment at standard diagnostic cut-off and the Cog-4 recorded 37% 
(n=62). Test accuracy is described in Table 5-3. 
In the individual domain analyses: significant (Pearson) correlations were found for 
orientation (p<0.0001), language (p<0.0001) and inattention (p=0.02), albeit 
strength of association was modest r= -0.44, -0.37 and -0.19 respectively (Table 5-
4).   
My post-hoc subgroup analysis suggested test properties of Cog-4 were not improved 
when the test was limited to those with anterior strokes (TACS, PACS): sensitivity 
0.53 (95%CI:0.41-0.65), specificity 0.50 (95%CI:0.46-0.99), PPV 0.99 (95%CI:0.87-
1.00), NPV 0.13 (95%CI:0.06-0.28)   
As prevalence of MoCA defined cognitive impairment was higher than anticipated, I 
performed post-hoc analyses describing test properties of Cog-4 at two other cut-
off MoCA scores that have been suggested for use in stroke populations.  Sensitivity 
improved with lower MoCA cut-offs but remained suboptimal (Table 5-5). 
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Table 5-2 Clinical and demographic information of participants 
 
 
  Participants n(%) Median IQR Range 
 Participant demographics 
All Data 
Data set 1 
Data set 2 
Males 
92 (53%) 
41 (59%) 
55 (50%) 
- - - 
All Data 
Data set 1 
Data set 2 
Age 
- 
- 
- 
74 
75 
71 
63-83 
63-83 
64-85 
28-97 
 
28-97 
All Data 
Data set 1 
Data set 2 
Prior Stroke 
70 (40.5%) 
28 (41%) 
n/a 
- - - 
 OCSP Classification 
All Data 
Data set 1 
Data set 2 
LACS 
38 (22%) 
17 (25%) 
25 (23%) 
- - - 
All Data 
Data set 1 
Data set 2 
PACS 
54 (31%) 
31 (45%) 
28 (25%) 
- - - 
All Data 
Data set 1 
Data set 2 
POCS 
12 (7%) 
6 (7%) 
8 (7%) 
- - - 
All Data 
Data set 1 
Data set 2 
TACS 
27 (16%) 
5 (7%) 
18 (16%) 
- - - 
All Data 
Data set 1 
Data set 2 TIA 
10 (6%) 
8 (12%) 
4 (4%) 
 
- - - 
All Data 
Data set 1 
Data set 2 
Unclassified 
32 (18%) 
3 (4%) 
27 (24%) 
- - - 
 Cognitive Impairment Risk Factors 
All Data 
Data set 1 
Data set 2 
Dementia 
16 (9%) 
0 
14 (13%) 
- - - 
All Data 
Data set 1 
Data set 2 
Depression 
15 (8.7%) 
9 (13%) 
7 (6%) 
- - - 
All Data 
Data set 1 
Data set 2 
Visual/hearing 
impairment 
26 (15%) 
n/a 
14 (13%) 
- - - 
 Assessments 
All Data 
Data set 1 
Data set 2 
NIHSS 
- 3 
3 
5 
2-6 
2-5 
1-5 
0-24 
1-23 
0-24 
All Data 
Data set 1 
Data set 2 
Cog-4 
- 0 
1 
1 
0-1 
0-1 
0-2 
0-8 
0-8 
0-8 
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*data set 1= chapter 4 data; data set 2 = chapter 5 data 
OCSP= Oxford Community Stroke project; LACS= Lacunar stroke; PACS= Partial anterior circulation 
stroke; POCS= Posterior circulation stroke; TACS= Total anterior circulation stroke; TIA= Transient 
Ischaemic Attack; NIHSS = National Institute of Health Stroke Scale; Cog- 4= 4 cognitive areas of the 
National Institute of Health Stroke Scale; n/a: data not collected 
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Table 5-3 Test accuracy comparisons between total Cog-4 and MoCA 
Data 
set Cog-4 Sensitivity Specificity 
Positive 
Predictive 
Value 
Negative 
Predictive 
Value 
Correlation 
(r) 
Significance 
(p value) 
All 
data  
 
 
1 
 
 
2 
 
 
Estimate 
(95% CI) 
0.36 
0.28 – 0.45 
 
0.26 
0.16-0.41 
 
0.58 
(0.45-0.69) 
0.96 
0.80 – 0.99 
 
0.92 
0.62-1.00 
 
0.6 
0.39-0.78 
0.98 
0.89 – 1.00 
 
0.23 
0.14-0.35 
 
0.53 
0.42-0.63 
0.23 
0.16 – 0.32 
 
0.77 
0.65-0.86 
 
0.47 
0.37-0.58 
-0.48 <0.0001 
 
*data set 1= chapter 4 data; data set 2 = chapter 5 data 
Cog-4= 4 cognitive areas of the National Institute of Health Stroke Scale, diagnostic cut-off used 
was ≥1/12 
MoCA= Montreal Cognitive Assessment, diagnostic cut-off used was <26/30 
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Table 5-4 Correlations and mean scores between sub-domains of Cog-4 
and MoCA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*data set 1= chapter 4 data; data set 2 = chapter 5 data 
Cog-4= 4 cognitive areas of the National Institute of Health Stroke Scale 
MoCA= Montreal Cognitive Assessment 
 
 
 
 
 
Cog-4 sub-
domain Correlation (r) 
Significance 
(p value) 
Cog-4 
Mean (SD) 
MoCA 
corresponding 
domain  
Mean (SD) 
All data 
1 
2 
Orientation 
-0.44 
-0.24 
-0.21 
<0.0001 
0.05 
0.04 
0.06 (0.35) 
0.41 (0.80) 
0 
1.99 (1,03) 
2.41 (0.51) 
1.90 (1.09) 
All data 
1 
2 
Executive 
Function 
-0.03 
-0.29 
-0.054 
0.72 
0.50 
0.60 
0.36 (0.68) 
0.35 (0.79) 
0.36 (0.66) 
2.53 (1.75) 
2.59 (1.37) 
2.52 (1.83) 
All data 
1 
2 
Language 
-0.37 
-0.21 
-0.61 
<0.0001 
0.083 
<0.0001 
0.21 (0.50) 
0.41 (0.80) 
0.17 (0.41) 
4.59 (1.74) 
5.00 (1.32) 
4.51 (1.82) 
All data 
1 
2 
Inattention 
-0.19 
-0.08 
-0.02 
0.02 
0.50 
0.85 
0.20 (0.52) 
0.59 (0.87) 
0.12 (0.37) 
4.06 (1.89) 
4.71 (1.36) 
3.93 (1.96) 
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Table 5-5 Test accuracy comparisons between the total Cog-4 and MoCA 
at different cut points 
Cog-4 
Sensitivity 
<20 
Specificity 
<20 
Sensitivity 
<24 
Specificity 
<24 
Estimate 
95% CI 
0.49 
0.37-0.60 
0.86 
0.76-0.92 
0.40 
0.31-0.50 
0.89 
0.77-0.95 
 
Cog-4= 4 cognitive areas of the National Institute of Health Stroke Scale, diagnostic cut-off used 
was ≥1/12 
MoCA= Montreal Cognitive Assessment, diagnostic cut-off used was <20/30 and <24/30 
 
 
5.2. Discussion	  
I have demonstrated suboptimal validity and test accuracy of Cog-4 as a brief 
cognitive screening assessment for acute stroke.  My analysis showed favourable 
specificity but at the expense of poor sensitivity. At this stage post stroke, 
sensitivity is favoured over specificity.  It is more important to detect all cases even 
at the risk of certain patients receiving unnecessary further cognitive assessments.  
Therefore the Cog-4 is not appropriate for screening with such a low sensitivity.  In 
addition, although total Cog-4 showed significant correlation with MoCA, association 
was modest.  Three individual Cog-4 domains were significantly correlated with 
corresponding cognitive domains (orientation, language and inattention) although 
again strength of association was at best modest.  My data suggest that many stroke 
survivors with potential cognitive problems would not be picked up by Cog-4 testing 
and other brief cognitive screening tests may be better suited to acute stroke.  The 
correlation data suggest that Cog-4 items may not robustly measure the cognitive 
domains it purports to measure. 
These test accuracy data are in keeping with previous research that has described 
reduced sensitivity of Cog-4 to detect cognitive impairment(267). My analysis was 
necessarily pragmatic.  I recognise that MoCA is not a definitive diagnostic test 
rather MoCA offers a more detailed multi-domain screening tool. As the Cog-4 is a 
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superficial measure, I chose the MoCA as the ‘reference standard’ for the Cog-4 as 
it is a validated screening tool for these domains in the stroke population.  
My reference standard, the MoCA, recorded 82% (n=124) of participants, as having 
cognitive impairment.  This is higher than previous study estimates; however 
previous studies were not performed in my very acute time frame.(280, 328, 329)  
In the absence of consensus agreement for MoCA diagnostic cut-off in the stroke 
setting, I used the standard cut-off described for MoCA.  The very high prevalence 
of cognitive impairment recorded suggests that this cut-off may be too high.  Other 
authors have investigated and suggested alternative cut-points(165, 280) which I 
explored in this chapter and chapter 3 and 4.  In agreement with chapter 3 and 4, 
my post hoc analysis of these data continued to show that lower cut-points in the 
MoCA improve the properties of the Cog-4 to an extent, but not sufficiently to 
recommend the use of the Cog-4.  The substantial early cognitive burden in acute 
stroke I have demonstrated is a factor to be mindful of in context of 
recommendations for cognitive screening in acute stroke and an area that would 
benefit from further research to describe the incidence and natural history of these 
early cognitive impairments.   
   
5.2.1. Strengths and limitations 
Although consecutive stroke unit admissions were assessed, the median NIHSS is low 
for an unselected acute stroke cohort as those with very severe stroke were 
excluded.  While this limits generalisability, in practice, standard cognitive 
assessment in the context of severe stroke or other medical emergency is unlikely 
to be feasible or clinically useful.  Rather I present data on a population 
representative of stroke survivors who may be considered for acute cognitive 
screening.   
Furthermore, patients approached were assessed under research conditions and not 
as a requirement for stroke care.  This could limit somewhat the generalisability of 
findings to the clinical population, as patients were able to withdraw or refuse at 
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any point of assessment. Further, it is possible some patients may not have shown 
their true capability due to fatigue or lack of interest.  Results may have been 
impacted by this, especially considering the limited scope of treatment/therapy 
available for cognitive impairment. Furthermore, the assessments were done at a 
time convenient for the patient and accommodating other MDT care.  The level of 
fatigue and concentration is likely to be affected by the patient having therapy just 
before or even just the time of day. No data to clarify this were collected.   
However, with a reasonable sized population involved in data analysis, we can 
assume that the effect on results will be limited.  
Accepting these limitations, I present data on an important, topical and relatively 
under researched area of stroke care.  The size of the dataset is comparable to 
other test accuracy studies, as seen from chapter 3.  As best as possible I took steps 
to follow best practice in methodology and reporting.  
 
5.3. Conclusions 
These data suggest that although cognitive screening within the acute stroke setting 
is generally feasible, Cog-4 may not be suited to this purpose.  In particular Cog-4 
may be insufficiently sensitive to detect cognitive impairment in stroke-survivors 
and certain domains of Cog-4 may not be valid measures of the cognitive constructs 
they purport to describe.   
I have shown that favourable diagnostic properties of “traditional” screening 
instruments should not be assumed.  Given current recommendations for routine 
cognitive assessments in stroke I would urge further test accuracy assessments of 
any proposed screening instruments to inform the choice of optimal assessment at 
various stages of the stroke survivor journey.   
	  142	  
Chapter 6 Ongoing research protocol: 
Feasibility and comparative test 
properties of three direct cognitive 
assessment tools in a stroke 
rehabilitation setting 
Comparison of the Addenbrookes’ Cognitive 
Examination- third edition, Montreal Cognitive 
Assessment and Mini Mental State Examination 
 
The preceding chapters have indicated that there are many obstacles to overcome 
in acute screening, in order for assessments to be both feasible and accurate for 
the majority of stroke patients.  Due to assessments being vulnerable to temporary 
post-stroke deficits, it suggests that screening may be more valuable if 
administered at a later time.  
Brief assessments, despite their appeal for reducing burden on patients and the 
clinical team, are vulnerable to the problems present at the acute stage.  This is 
the foundation for my on-going work; does brief screening tool feasibility and 
validity improve after the acute stage to identify impairments? Or is a longer test 
more appropriate?  The following chapter is the protocol to investigate this.  This 
has been approved by the Scottish A Research Ethics Committee (14/SS/0042) 
(Appendix I) and received a grant from GG&C NHS research endowments fund.  I 
took a leading role in writing this protocol and contributed to the writing of the 
grant application. 
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6.1. Feasibility and accuracy of cognitive assessments post-acute 
stroke 
The findings from previous chapters suggest that acute assessments, despite being 
preferred for initiation of potential early interventions, are likely to be inaccurate 
unless adjusted to acute stroke obstacles.  As demonstrated from chapter 3, 
screening assessments vary across setting.   
Community/outpatient stroke survivors are likely to have fewer cognitive and 
physical deficits, compared to inpatients on a rehabilitation ward.  Presence of 
physical, language, visuospatial impairments will affect administration and scoring 
of standard cognitive assessment tools.  It is important to understand if the 
problems with accuracy and feasibility are present in all stages of inpatient care.  
To address this question and make an informed decision about appropriate 
assessments and timing of screening post-stroke, I developed and initiated a study 
investigating cognitive assessments in a rehabilitation ward setting.  Not only will 
this compare short and longer cognitive assessments; it also investigates feasibility, 
concurrent sensory/physical deficits with the effect of stroke severity on 
administration and completion.  Data collection for this study is on-going and at 
time of writing I do not have final data to facilitate analyses. 
Delaying assessments to later in the stroke journey could diminish the effect of 
temporary impairments and allow for measures to correctly identify deficits 
without over adjusting for other impairments.   
   
6.2. Introduction 
Stroke cognitive screening is being adopted across many Scottish stroke sites and is 
required in England and Wales based on the dementia Commissioning for Quality 
and Innovation (CQUIN) report 2012/13.(30)  No stroke specific assessment tools are 
in common use and or have robust validation data.  Assessment in a stroke-survivor 
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population may pose unique challenges, for example aphasia; concomitant 
delirium; prevalent dementia; physical and sensory impairments. 
Validated and popular neuropsychological tests for assessing cognition within the 
cognitively impaired and stroke patient populations include: MMSE(22, 31, 158, 244, 
330), MoCA (161, 166, 280, 331) and the ACE-R(166, 168-170, 332, 333).  All of 
these tools are currently used in Greater Glasgow and Clyde stroke services, as 
shown by the questionnaire in chapter 2.  They take between 10-20 minutes to 
administer and can be used by any member of staff after brief training. 
Each tool has advantages and limitations.  MMSE has been the traditional favoured 
assessment for all hospital inpatients.  However, MMSE is not suitable for the 
executive problems seen post-stroke(239, 247) as it contains no specific sub-test to 
assess this domain and, perhaps more importantly, copyright issues are now being 
enforced that will require hospital trusts to pay for continued use of the scale.  As 
discussed in chapters 3 and 4, MoCA may be better suited to post-stroke assessment 
than MMSE, but cut-offs may need reviewed in stroke settings.(76) The ACE 
contained the MMSE and so has been revised in light of MMSE copyright issues.  The 
new ACE-III shows promise but experience is limited particularly in a stroke setting. 
We should not base policy on opinion or tradition; we need an evidence base to 
guide recommendations for cognitive assessment tool(s) in stroke.  Thus there is 
urgent need for studies describing and comparing properties of screening tools.  
The ideal tool should be quick, acceptable to patient and staff; feasible; reliable 
and accurate.  My aim with this study is to describe feasibility and comparative 
accuracy of the three assessment tools. 
This study will investigate properties of the newly updated ACE-III, the MoCA and 
the MMSE in stroke on rehabilitation settings (≥2 weeks post event).  Participants 
will be recruited from entry into rehabilitation services or ≥2 weeks post-stroke.   
The aims of the study are: to establish if assessments in usual clinical practice (as 
suggested by previous survey) can feasibility be employed in a rehabilitation 
setting, to describe the “cost” in terms of assessor and patient time and to 
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compare proportions “test positive” at various thresholds across the three 
commonly used multi-domain assessments.   
 
6.3. Aims and research questions 
My goal is to test the properties of ACE-III, MMSE and MoCA in a stroke rehabilitation 
setting. 
I wish to gain experience of testing cognitive assessments in a rehabilitation 
setting.  It is likely that rehabilitation will be representative of the most impaired 
post-stroke patients and thus will provide the most robust assessment of screening 
feasibility.  The anticipation is that these pilot data will inform an application for a 
more definitive prospective diagnostic study of various cognitive testing strategies.   
Specific aims of this project are: 
• To describe feasibility of ACE-III, MMSE and MoCA in a rehabilitation setting  
o How much time it took to administer assessments? 
o Which areas of assessment did patients struggle most in? i.e. what 
sections were they unable to complete? 
o Proportion of participants able to complete all assessments.  
o Average number of attempts required in order to assess patients  
• To “phenotype” confusion in a stroke rehabilitation setting and explore the 
effect of important confounders (aphasia, delirium, dementia, sensory 
impairment) on ACE-III, MMSE and MoCA. 
• To compare corresponding domains of ACE-III, MoCA and traditional MMSE 
assessment through correlation. 
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6.4. Plan, methods, expertise available and statistical power 
6.4.1. Overview 
Consecutive patients will be recruited across two rehabilitation sites (Western 
Infirmary Glasgow linked with Gartnavel General Hospital and Glasgow Royal 
infirmary linked with Stobhill Hospital).  Gartnavel has a rehabilitation ward 
comprising of 20 beds and Stobhill 24 beds.  The turnover in rehabilitation is 
between two and four patients per week.  Assessment for suitability, including 
ability to consent, will be made by the clinical team.  This information will be 
shared with the researchers at the weekly multidisciplinary team reviews.  The 
clinical team will check that patients are happy to be approached by the researcher 
before giving details to the research team.  Suitable patients will be approached by 
researchers (myself and fellow PhD student, Kirsty Hendry).  Data collection and 
assessments will be performed by both of us.  We are both psychology graduates 
with clinical research experience, and have been fully trained in use of all scales by 
stroke specialist clinical neuropsychologist, Dr Niall Broomfield. 
Stroke -survivors and their chosen informant will be provided with an information 
sheet (PIS) and a verbal explanation of the study (Appendices F-H).  If the patient 
and chosen informant understand and are willing to participate then written 
consent will be attained.  Baseline demographics and clinical details will be 
extracted from subject’s case-sheets.  Order of testing ACE-III, MoCA and MMSE will 
be randomised and split between two sessions to reduce patient burden.  Other 
assessments performed/collected by researchers will include: the Confusion 
Assessment Method (CAM) for delirium; National Institute of Health Stroke Scale 
(NIHSS) for neurological function; Patient Health Questionnaire (PHQ-9) and Yale 
Single Question for Depression; Informant Questionnaire of Cognitive Decline 
(IQCODE) and Commissioning for Quality and Innovation (CQUIN) single question for 
a measure of cognitive decline and dementia.  This combination will provide a 
comprehensive picture of the patient.  If patients express an interest in their 
results the researcher performing the assessment will refer the patient to the 
clinical team, with whom the results will be shared, and they can make a more 
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comprehensive assessment of performance.  In the event that a participant 
becomes distressed or frustrated and it is clear that they are unable to complete 
the testing, it will be stopped.  Any anxiety or distress from assessment will be 
handled through reassurance or ending of the assessment.  If we detect probable 
depression, we would advise the clinical team to consider referral to Stroke 
Neuropsychology service depending on patient preference.  If we detect suicidal 
ideation, the clinical team would be immediately informed and any required risk 
procedures/crisis management strategies put in place.  The researcher would be 
carefully trained in suicide risk assessment procedures by Dr Broomfield.  
Participants will have the right to withdraw at any time.   
All data will be kept on a password-protected spreadsheet on an encrypted NHS USB 
that will be kept in a locked cabinet within a clinical base.  Hard copies will also be 
kept within the locked cabinet and neither will leave the clinical premises.        
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Consecutive	  stroke	  survivors;	  rehabilitation	  entry	  or	  2	  
weeks	  post	  event
Exclusion:	  Non-­‐stroke	  diagnosis,	  no	  
spoken	  English,	  major	  psychiatric	  disorder.
Clinical	  team	  assesses	  patient’s	  suitability	  and	  capacity	  
to	  consent	  at	  the	  MDT	  weekly	  meeting.	  Potential	  
participants	  are	  first	  approached	  by	  the	  clinical	  team	  
before	  details	  are	  passed	  onto	  the	  researchers.
Potential	  participants	  are	  given	  an	  information	  sheet	  and	  
have	  the	  study	  explained	  verbally
Written	  consent/recruitment
Demographic	  and	  clinical	  details	  from	  case	  
sheets
• sex,	  age,	  education,	  previous	  stroke,	  
depression,	  dementia,	  hearing/visual	  
impairment,	  OCSPC,	  TOAST,	  	  NIHSS,	  	  time	  
since	  stroke,	  MRI/CT	  Free	  text	  radiology	  
report
Researcher	  Assessments	  
1. MoCA
2. ACE-­‐III
3. MMSE
4. CAM
5. Yale	  single	  question
6. PHQ-­‐9
7. IQCODE
8. CQUIN	  single	  question
Version	  2	  	   01/04/2014
 
Figure 6-1 Flow chart of study strategy 
MoCA: Montreal Cognitive Assessment; ACE-III: Adenbrookes’ Cognitive Examination – Third edition; 
MMSE: Folstein’s Mini Mental State Examination; CAM: Confusion Assessment Method; PHQ-9: 
Patient Health Questionnaire – 9 items; IQCODE: Informant Questionnaire of Cognitive Decline in 
the Elderly; CQUIN: Cognitive Informant Question; OCSPC: TOAST: NIHSS: National Institute of 
Health Stroke Scale; MRI: Magnetic Resonance Imaging; CT: Computer Tomography.
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6.4.2. Participants 
I am interested in stroke-survivors who still have active impairments but are 
medically stable, thus I will focus on rehabilitation units.  Participants will be adult 
(≥ 18 years) stroke-survivors (including subarachnoid haemorrhage) patients 
entering rehabilitation or two weeks from index event, whichever is longer.  
Participants will be recruited on a consecutive basis and include first and multiple 
stroke patients, with no limitation on hemisphere location.  Kirsty and I will recruit 
as many eligible stroke survivors as possible over a 5-month period (aiming to 
recruit around 50 survivors).  I have not pre-specified a sample size as one of the 
metrics of interest in this study is feasibility of recruitment in a rehabilitation 
setting.  
At the weekly multidisciplinary team reviews, the clinical team will identify 
potential participants and check that these patients are happy to be approached by 
the researcher before giving details to the research team. 
Stroke survivors will be given a patient information sheet (Appendices I, J and K) 
and verbal explanation of the study.  They will be given a minimum of 24 hours to 
consider the study.  Kirsty and I will assess eligible patients once weekly and seek 
formal consent.  Our only exclusions will be: non-stroke diagnosis; major psychiatric 
disorder; no spoken English. 
 
6.4.3. Standard assessment 
6.4.3.1. Primary Measures 
1. Addenbrooke’s Cognitive Examination 3rd version (ACE-III) 
The ACE-III is a slightly longer and more in-depth cognitive assessment compared to 
the MoCA and MMSE and is described in detail in the introduction. 
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2. Montreal Cognitive Assessment (MoCA) 
MoCA is a multi-domain assessment developed to detect MCI in community dwelling 
older adults; it has been discussed in detail within the introduction chapter and test 
accuracy was described in chapter 3.   
3. Folstein’s Mini Mental State Examination (MMSE) 
MMSE is a short cognitive assessment developed to replace neuropsychological 
batteries in determining the level of patient cognitive impairment. Contents and 
accuracy are discussed in the introduction and chapter 3.  
 
6.4.3.2. Secondary measures 
4. National Institute of Health Stroke Scale (NIHSS) 
The NIHSS is measure of neurological deficit after stroke.  It has 15 items covering; 
consciousness, vision (gaze and detection), facial palsy, motor function and ataxia 
(arms and legs), sensation, language (comprehension/expression, production) and 
attention.(319)  The NIHSS includes assessment of language and can be used as a 
screen for substantial communication difficulty.  If NIHSS is not documented; it will 
be derived from available information recorded in the case-sheet.  Previous work in 
our department validated this approach. 
1. Confusion Assessment method (CAM) 
The CAM is a short screening questionnaire for delirium.  It was developed to 
replace assessments that required specific psychiatric training.   
2. Patient Health Questionnaire for Depression (PHQ-9) 
The PHQ-9 is a multiple-choice questionnaire that screens for depression completed 
by the patient.  It has 9 items relating to behaviours and feelings with an additional 
rating of how much issues described affect their daily activities item, over the 
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previous 2 weeks, each scoring 0 (not at all) to 3 (nearly every day).  Scores of: 1 to 
4 indicate minimal depression; 5 to 9 mild depression; 10 to 14 moderate 
depression; 15 to 19 moderately severe depression; 20 to 27 severe 
depression.(334)  This takes about 5 minutes to complete.   
3. Yale Single Question (YSQ) 
The Yale single question (YSQ)(335) for depression was taken from the Yale-Brown 
Obsessive Compulsive Scale(336).  It is a single question: “Do you often feel sad or 
depressed?” with a ‘yes’ or ‘no’ outcome.  It requires little training and does not 
require the patient to read, write or have normal verbal capabilities.(337)  It takes 
less than 1 minute to complete.   
4. Informant Questionnaire on Cognitive Decline (IQCODE) 
The IQCODE is an indirect measure of patient cognitive decline over the past 10 
years.  It is used as a measure of prior function.  The details of this assessment are 
described within the introduction.  
5. Commissioning for Quality and Innovation single question (CQUIN SQ) 
The CQUIN SQ was developed to raise awareness of cognitive changes rather than as 
a screening tool to identify at risk patients.(338)  This is directed to a 
caregiver/relative: “Has the person been more forgetful in the last 12 months to 
the extent that it has significantly affected their daily life?” with the response 
either ‘yes’ or ‘no’.   
Assessments will be performed by Kirsty Hendry and I on the rehabilitation wards.  
 
6.4.4. Data collection 
A log will be kept of all admissions and reasons why stroke-survivors were 
considered ineligible.  Basic demographic and clinical details will be extracted from 
patient case notes and recorded on a standardised proforma.  If not available from 
case notes, a basic examination including screening for aphasia will be performed 
	  152	  
using the National Institutes of Health Stroke Scale (NIHSS) and supplemented by 
screening tests for visual acuity and hearing impairments. 
The cognitive assessments will be MMSE, MoCA and ACE-III.  Other screening tests 
included are: for delirium the CAM; cognitive decline or prevalent dementia the 
IQCODE and CQUIN SQ; neurological function the NIHSS; depression the PHQ-9 and 
YSQ.  At MDT review the team will be asked the question “does this patient have 
important cognitive impairments?” with a dichotomised yes/no response.  All 
assessments will be paper based and transferred to electronic media.  All 
assessments are currently used and recommended in NHS GG&C, assessment scores 
will be shared with the treating clinical team. 
Assessments will be split between the two sessions; order of assessment and 
assessor will be randomised.  One session will include ACE-III, YSQ and PHQ-9; 
session two will consist of MMSE and MoCA.  The CQUIN SQ and IQCODE are paper-
based questionnaires given to family or carers. 
Identifiable patient information will not be collected as part of the research.  This 
includes date of birth, contact details or CHI number.  Names of participants will 
only be on consent forms.  Assessments will be collated and labelled using 
participant numbers, no name being recorded.  Assessment scores will be recorded 
in the patients’ medical notes (on the same day of administration) which only the 
clinical team have access to.  All data will be entered to an electronic database, 
stored on a password-protected document on encrypted USBs that will be kept in a 
locked cabinet within the clinical base when not in use.  Hard copies will also be 
stored in the locked cabinet and neither will leave the clinical premises.    
In addition to the above clinical measures we will collect relevant clinical and 
social demographic details.   
• Sex 
• Age  
• Education/schooling – based on level reached i.e. secondary school, 
university etc.  
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• Stroke classification (oxford community stroke project classification – OCSP)  
• Visual  and hearing impairment 
• History  
o Prior stroke 
o Alcohol dependence  
• Days since stroke – based on day of admission  
• Hemisphere affected 
• Radiological information (reports of any brain imaging performed) 
• Neurological function on admission (described using NIHSS) 
• Time taken to complete assessments 
• Assistance required to complete assessments 
 
 
6.4.5. Statistical power 
For this pilot study I have not performed a sample size calculation; rather I will use 
data from this study to inform sample size calculations for a future definitive study.  
Using mean assessment scores, numbers able to provide data for each assessment, 
participation rate alongside pooled accuracy estimates from chapter 3, I can 
estimate how many patients will be required to approach, how much time will be 
required to reach this goal, for future studies in similar populations.   
Based on bed numbers, ward turnover and previous recruitment rates a 
conservative estimate is that we will recruit n=50 over five months. 
I will assess feasibility by describing numbers of inpatients; numbers eligible; 
numbers completing assessments and reasons why assessments not completed.  We 
will compare clinic-demographic details of those completing and not completing 
assessments.  During assessments, researchers will time completion of each test 
and record if the stroke-survivor needed any assistance to complete. 
Using usual diagnostic cut-offs we will describe numbers “testing positive” for each 
of the three scales and then describe the effect of varying the diagnostic cut-off.  I 
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will specifically test whether domains assessed in the MMSE can be derived from the 
copyright free tests of ACE-III +/- MoCA.  I will describe the accuracy of MDT 
informal assessment and single question assessments against formal tests. 
 
6.5. Limitations, risks and recommendations 
We are assessing a highly selected patient population, stroke survivors requiring 
patient rehabilitation.  This cohort is suited to a study of feasibility.  If cognitive 
testing strategies are feasible in this group with substantial impairments, they 
should be feasible in any group of stroke survivors.  We have struck a balance 
between information available from test and patient burden.  We have chosen to 
restrict our study to the most commonly used cognitive screening tests.  We believe 
our data will help shape future policy and recommendations regarding cognitive 
assessment in stroke.  Cognitive assessment is recommended for all stroke 
survivors, so we are not performing unnecessary assessments.  I will share all our 
data with the treating clinical team.   
There was also no public involvement in this research design.  With no patient input 
I could have potentially missed important factors around the patient experience of 
testing.    
 
6.6. Potential impact and dissemination of results 
This work is novel in that I am looking into both the feasibility of assessment 
(completion and administration but also the time required to do so on each 
participant) in those that are likely to have a mix of physical and cognitive 
problems but also the feasibility of assessment of participants without capacity 
through permission of their legal representative, an important concept to look into 
especially when attempting to generalise about post-stroke recovery. 
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I anticipate that this work will help inform practice regarding cognitive screening.  
My meta-analysis of test accuracy suggested that diagnostic accuracy is similar 
across the commonly used multi-domain cognitive assessment tools.  Thus choice of 
test should be based on other metrics and the most practically important 
consideration is feasibility and test burden.  There is some research considering 
these issues (37, 41) and when is suitable to intervene and begin rehabilitation.(42) 
Comparing results between the tests adds to our knowledge of the properties of 
these tests but may have further utility – given the copyright restrictions on MMSE 
an important practical question is whether MMSE data can be derived from other 
sources such as MoCA.   
I recognise that these data are pilot in nature and in particular acknowledge that 
we do not have a gold standard assessment to compare our tests against.  I hope 
that this study will allow us to work towards a grant application for a more 
definitive study.  In which, assessments based on feasibility can be chosen and 
administered within the rehabilitation setting, cut points altered based on pilot 
data means and put up against long term follow up (potentially 2 years).  The 
follow-up would consist of a gold-standard neuropsychological assessment as well as 
daily independence and any scan information already available.  This larger based 
study could provide valuable information on characteristics of those likely to 
develop dementia or multi-domain cognitive impairments that impact on daily 
functioning and quality of life. These characteristics can help to identify at risk 
stroke survivors earlier and therefore provide these patients to potentially benefit 
from interventions, support or planning for the future. Critical evaluation of the 
evidence base for cognitive screening tests is of major importance as discussed 
throughout this thesis. 
The results will be shared with practicing stroke clinicians, allied health 
professionals through the managed clinical networks.  In addition the results will be 
put forward for journal publication and conference presentation.   
In my previous work I have established links with stroke Managed Clinical Network 
and contacts for various local specialist societies (such as the Scottish Stroke Nurses 
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Forum, Scottish Stroke Neuropsychologists, British Geriatric Society (Scotland), 
British Association Stroke Physicians, Stroke Allied Health Professionals and 
Association of Chartered Physiotherapists Interested in Neurology).  In addition 
these works have involved interaction and coordination with various members of 
the multidisciplinary team.  Involving the ward staff in implementation has 
improved the research as it reduces clashes with usual care and also in finding 
appropriate times and patients to approach.  This gives me a unique opportunity to 
disseminate these results in a timely and efficient manner.  
 
6.7. Preliminary results 	  
Over the first 3 months we have recruited 34 patients from n=55 medically stable 
strokes approached (3 refusals, 2 discharged, 14 no capacity and proxy absent with 
n=34 assessed). The mean number of attempts to speak to consenting patients was 
1(IQR: 1-2).  
Recruited participants’ demographics are: age mean 69years (IQR: 62-84); n=14 
males; n=13 left hemisphere; OCSP: n=14 TAC, n=4 POC, n=6 PAC, n=8 LAC, n=1 
inconclusive; n=6 haemorrhage; NIHSS mean: 9; mean days since stroke: 44days. 
From those assessed n=15 had fully completed ACE-III, n=16 MoCA, n=17 MMSE. 
(Table 6-1) 
Common impairments restricted mainly completion/attempt of drawing tasks 
especially in the MoCA and ACE-III. The majority of patients were able to complete 
the MMSE, which also had the lowest completion time.  There was a low response 
rate for informant-based questions due to lack of presence during assessment.  The 
majority of those who responded found their family member to have improved 
(n=6). 
Cognitive assessment in the rehabilitation setting has difficulties in direct 
administration and completion mainly due to physical impairments preventing 
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drawing, as well as indirect administration as informants are not regularly available 
to answer questions. 
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Table 6-1 Preliminary results of cognitive assessments in rehabilitation 
*ACE-II= Addenbrookes’ Cognitive Examination 3rd Edition; MoCA= Montreal Cognitive Assessment; 
MMSE= Folstein’s Mini mental State Examination 
	  
Cognitive 
Assessment  
Mean 
Score  
Mean 
time to 
complete 
(minutes)  
Fully 
completed 
assessment  
n(% of all 
recruited) 
Unable to 
complete 
sections n(% 
of all 
recruited) 
Unknown/not 
completed or 
attempted 
n(% of all 
recruited) 
ACE-III 55 21 15 (44%) 5 (15%) 14(41%) 
MoCA 14 10 16 (47%) 9 (26%) 9 (26%) 
MMSE 21 7 17 (50%) 6 (18%) 11 (32%) 
IQCODE 35 n/a 7 (21%) n/a 27 (79%) 
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Chapter 7 Discussion 
Stroke is a prevalent problem.  It is responsible for a significant proportion of 
physical and psychological problems in adults.  As psychological issues are not as 
immediately obvious as physical disabilities, especially among the elderly, 
assessments that can accurately depict and describe various cognitive domains are 
needed to allow us to target clinical interventions and effective rehabilitation.   
 
7.1.1. Current application of cognitive and mood assessments 
In Chapter two, I aimed to describe the cognitive and mood assessments currently 
employed in stroke research and in usual practice within stroke care.  I 
hypothesised that as guidelines urge health professionals to assess stroke patients 
for cognitive and mood problems yet provide no stipulation as to how or when this 
should be done, there would be a lack of consistency in both research and usual 
practice over the choice of test. 
The data collected supported my hypothesis: not only did I find relatively few 
stroke publications that included cognitive and mood instruments, but also there 
was considerable heterogeneity across the measures that were employed within 
research settings.  Thus, as practice should mirror evidence-based research, which 
provided no clear consensus of test choice, stroke care settings also had poor 
agreement over which assessment to perform.  
Wide variation in assessment poses difficulties when it comes to comparison and 
description of cognitive and mood impairments across diverse stroke cohorts.  Our 
inability to compare groups reduces our potential knowledge about the true impact 
of a stroke, including psychological impact, and limits how improvements to 
recovery can be addressed.   
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A second relevant finding from the usual practice questionnaire concerned the 
scheduling of cognition and mood assessment.  Cognition testing took priority, was 
concentrated in the acute stages post-stroke and generally used some form of 
formal assessment.  Formal assessment of mood was deferred until later.  It is 
understandable that mood problems seem easier to observe at the early stages than 
cognitive deficits; however, as mentioned in chapter one, many mood problems 
including adjustment affect stroke patients and may manifest with only subtle 
signs.  An incorrect diagnosis/formulation is likely if formal assessment is not 
employed and has been highlighted in the introduction, neuropsychological (mood 
and cognition) factors, if undetected, may adversely impact rehabilitation efforts, 
stroke recovery and patient quality of life.  
These findings set a strong foundation towards a need for consensus in 
measurements.  A good area to start would be in test accuracy analysis.  An 
assessment that is not valid, sensitive or specific in identifying impairment is 
limited in clinical utility.  With a strong base of evidence for an accurate 
assessment, a better understanding of the course/impact of cognitive and mood 
disorders after stroke could be assembled.  In building a fuller picture of stroke 
recovery, potential interventions can be investigated and a fuller view of their 
influence on outcomes compared.   
Stroke researchers and clinicians are unlikely to be surprised by the findings, it has 
long been suspected that the stroke clinical community are failing to capitalise on 
the potential of cognitive and mood assessments.(148, 153)  My data provides 
evidence to support this view and hope it provides further incentive to look towards 
standardising assessments across studies.  I would recommend that stroke 
researchers produce guidance on preferred outcome measures for cognitive and 
mood disorders, informed by robust descriptions of test accuracy and clinometric 
properties of scales in stroke cohorts.  This will help to inform this guidance or at 
least highlight where original research is still needed.   
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7.1.2. The accuracy of common measures in research 
In Chapter 3, I reviewed the published data on common cognitive assessments in 
order to describe screening tool accuracy for detection of dementia and multi-
domain cognitive impairment post-stroke.  Based on my findings in chapter 2, I was 
aware that there may be few papers able to be included in any meta-analysis. 
From pooled analysis the data showed that commonly used screening tests 
performed similarly across studies in terms of accuracy.  In addition, pooled 
analysis did not indicate any significantly superior screening measure to identify all 
types of dementia or multi domain cognitive impairment.  Not surprisingly, I found 
that according to the cut-offs chosen to identify impairment, sensitivity and 
specificity varied.  As stroke patients have a high prevalence of transient cognitive 
problems post-stroke, and are usually older with some premorbid deficits, it is 
likely that sensitivity increases (providing a higher level of those found to be 
impaired) and specificity decreases (miscategorising patients) when higher cut-offs 
are employed.  I found an improvement of specificity when cut-offs were lowered.  
This could be because of the effect of potential transient problems affecting 
performance at the acute stage or stoke patients have a different range of norms 
than other patient cohorts when testing for cognitive impairments.  In support, 
when the data were split into ‘acute’ and ‘non-acute’ settings for comparison, the 
assessments in the acute settings showed high sensitivity and lower specificity.  
Within the reverse pattern in the non-acute settings the sensitivity, despite being 
low, was higher than for the acute settings.   
Collection of the entirety of assessment was found to be a crucial issue that would 
influence measures of test accuracy.  Missing sections within tests led to the 
removal of that patient’s assessment from analysis.   Poor levels of completion are 
not only from disability and other impairments but also the extent to which 
participants are unwilling to complete part or all of the tests.  Inability to complete 
sections due to a confounding disability that does not affect understanding (i.e. 
difficulty holding a pen) or to a wish to withdraw will lower test score and inflate 
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estimates of impairments.  Feasibility of test administration to patients with 
varying disabilities should be corrected for when accuracy is being described.   
Therefore, these data demonstrated how it is vital for accuracy that cognitive 
assessments are selected and performed with a particular purpose in mind.   The 
assessments have to be robust in the face of co-existing impairments if we are to 
gain a clear view of whether deficits will exert a long- or short-term impact.  
 
7.1.1. The prognosis and feasibility of mood assessments in acute 
stroke  
The data from chapters 3 and 4 have indicated that accuracy and feasibility of 
cognitive assessment performance are susceptible to factors present mainly during 
the acute stage post-stroke.  With potential factors unrelated to impairments 
preventing patient acceptance for cognitive assessments, it was important for me 
to investigate if this was also the case with mood assessments.  Comparison of 
verbal and non-verbal assessment allowed me to remove the effect of temporary or 
lasting cognitive/communication dysfunctions on assessment.   
Here again, I demonstrated that not all eligible patients accepted an approach at 
such an early stage.  With the assessments requiring a high level of input from 
myself for test completion I infer that patients may have concerns around being 
unable to do a task.   
In contrast, the simple non-demanding mood assessment was completed by a higher 
number of participants and was also more accurate in prediction of mood at one-
month follow-up.  Cognitive demands appear to play an important role in 
measurement accuracy across the acute stroke stage.   
 
7.1.2. Accuracy of a regularly administered severity assessment to 
identify cognitive impairment in acute settings  
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The results from Chapter 3 suggested that there are limited data not only in acute 
stroke settings but also regarding very brief screening assessments.  Measures of 
accuracy appear to vary depending on the setting in which screening tests are 
performed. This may arise perhaps from improvement in impairments over time or 
in ability to complete the assessment itself (as seen in chapter 4). 
Based on the findings of chapter 3, I investigated in chapter 5 how feasible and 
accurate a cognitive screening tool derived from a regularly administered stroke 
severity assessment may be in identifying cognitive impairment.   
The Cog-4 proved to have modest correlation with corresponding MoCA domains, 
suggesting that it is not accurate in terms of specific cognitive domain assessment.  
Although more acute stroke patients had more completed Cog-4 data than MoCA 
scores, this argument of feasibility and brevity does not allow for accurate 
assessment of cognitive function.      
As discussed within the introduction, there are other confounding deficits that may 
affect administration of assessment. Therefore some physical deficits may have had 
an impact on our ability to identify impairments, probably because they influence 
patients’ ability to perform assessment tasks.    
Furthermore when considering feasibility, the majority of patients were more likely 
to complete the shorter less cognitively demanding assessment, the Cog-4.  Despite 
a large response rate to screening, there were still a moderate number of eligible 
patients who refused to participate or withdrew in the middle of testing without 
specific reason.  This demonstrates that irrespective of potential cognitive, 
delirium or other deficits, there are other factors at play that affect the feasibility 
of comprehensive screening within an acute sample.  With fatigue commonly 
affecting stroke patients, along with their potential anxiety of finding another 
problematic area, these may be one of the reasons why so many refused/withdrew.   
 
7.2. Conclusions  
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These data have investigated the use of cognitive and mood screening within stroke 
cohorts.  Finding poor consensus in published research and usual practice due to 
lack of evidence, I investigated common assessments.  I found that screening tools 
had a tendency to vary in accuracy depending on which type of impairment they 
were being used to detect (i.e. multi-domain cognitive impairment versus 
dementia) and on the setting in which they were administered.  
Furthermore, patient acceptability of assessments was not uniform and the reasons 
for this were unclear.  This could reflect an underlying adjustment problem, an 
avoidance of potential problematic diagnoses or just poor timing in approaching the 
patient.  Investigation of this could help to improve participation and choice of 
assessment.   
Administration of most assessment tools may achieve greater acceptance during the 
rehabilitation phase of care but even here the results may be affected by other 
deficits related to stroke.  The study described in chapter 6 is the first step towards 
investigating this possibility.  Through addressing the queries surrounding the 
balance between appropriate timing and effect of other impairments, the results 
from chapter 6 could contribute to the expansion of post-stroke cognitive and mood 
assessment knowledge.  The data will hopefully help to lay the foundations for 
future works of outcome or interventions as a fuller and more accurate picture of 
patient capabilities can be measured.   
Development of protocols (based on these findings) for selecting assessments to 
detect various deficits and for selecting their timing will render impairment data 
more comparable across diverse populations.  This would greatly strengthen 
research underpinning future clinical and interventional trials.  Comparison of 
several patient populations using the same intervention improves knowledge of the 
true effect of that treatment and may let us target interventions toward those who 
would derive greatest benefits.  This will help both individuals and the health care 
service in terms of time, money and efficient use of limited resources.     
As screening is potentially the key to intervention, my findings have importance in 
the understanding of impairments in cognitive and mood domains and of their 
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progression post-stroke.  However, as discussed in the introduction, there is an 
argument to be made for screening causing more harm than good in the absence of 
established treatments for cognitive impairment or dementia.  On top of this, 
current screening tools are far from accurate and it may cause great distress if a 
patient is stigmatised by being labelled with a deficit or impairment.   
From the data that I have collected, conclude that although screening is possible, it 
may not be accurate during the acute stage unless an appropriate assessment (in 
terms of administration and format of response required) is chosen.  Other 
researchers recommend various cut-offs for the same assessment across different 
settings.  My data in chapter 3 also reflected this where sensitivity and specificity 
change between acute and non-acute setting assessment.  The assessment also has 
to be administered when it is acceptable to the patient.  The results from this 
thesis demonstrate that assessments should either be adapted to account for post-
stroke impairments which may inaccurately categorise patients, or assessments be 
chosen based on the patient capabilities.  For example a patient unable to move 
their dominant hand can give verbal responses or a verbally impaired patient 
provide motor response whether it be pointing or other movements to provide a 
response.  These data should be collaborated and formatted into a flow-chart or 
similar which allow health care professionals to select appropriate test modalities 
or the best assessment available for their patient’s ability.    
From prior studies my acute works show that we are currently finding a higher level 
of cognitive impairment and mood disorders than previously reported.  This could 
be due to the assessments themselves, the timing or the lack of patients involved in 
research due to their inability to consent.  I was limited to an extent in my clinical 
research by what kind of patient I could approach and who the MDT thought were 
appropriate to ask to consent to my research.  If there were more 
treatments/therapies available for cognitive or mood impaired patients at the 
acute stage, my study design could have been different and included all patients, 
which would have given a more generalizable view of patient impairment.  Although 
this not an issue for my literature and meta-analysis studies, inclusion for these 
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data were also limited by what the various authors reported as well as the 
variability in how, when and what they used in their works.         
Therefore, in order for screening to overcome transient problems in the cognitive 
and mood domains, use of a detailed multi-domain assessment should be better 
implemented and more meaningful if conducted at a later stage after stroke onset.  
This may be at follow up appointments, in clinics or in the rehabilitation settings 
(as I demonstrated with cognitive/mood improvements over one month in chapter 
4).  These later assessments could be done by any trained member of the clinical 
team and therefore could represent the beginning of stepped care implementation 
for psychological services to try and prevent services, to limit overburdening of 
services.   
Cognitive assessments should be administered with a specific impairment in mind to 
identify either transient short-term impairments (such as delirium) or longer lasting 
deficits.  Our search for mood disorders should also use simple screening 
assessments to attempt to distinguish between the wide ranges of problems.  This 
would hopefully allow positive screens to be directed to psychological services, 
when appropriate, for a more detailed assessment for disorders that could impact 
on recovery.  
For future research, this thesis demonstrates the need for either a global 
assessment across all patients in cognition/mood or assessments tailored to a 
patient’s impairments.  In order for data to be comparable across all patient 
cohorts and with prior research demonstrating the importance of processing speed 
in patients’ recovery, I would suggest investigating and measuring processing speed 
for all patients regardless of impairments/severity of stroke.  Furthermore, in order 
to assess specific domains in cognition, I think future research should concentrate 
on developing guidance, which allows health care staff to select an appropriate 
assessment for their patient.   
Mood problems assessment is slightly more complex to generalise across stroke.  
Based on the research completed I would maintain a simple assessment for 
depression and anxiety at early stages (i.e. DISCS and an anxiety equivalent) then at 
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a later stage implement more detailed assessment for separation of symptoms and 
clear clinical problems affecting daily life.   
However, despite these suggestions, these assessments will only become useful 
when we develop interventions that can help improve patient outcome.  Therefore, 
research should also look into potential treatments that the patient/caregiver can 
easily practice/implement to improve mood and cognitive function.   
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Appendices 
Appendix A – Email correspondence for 
ethical approval for usual practice 
questionnaire 
 
Hi 
  
Yes, if there is no patient identifiable data on the form, then Caldicott approval is 
not required. 
  
Isobel 
  
Isobel Brown 
Information Governance Manager 
Administration Building, 
Western Infirmary 
Dumbarton Road 
Glasgow G11 6NT 
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0141 211 (5) 1790 
  
 
________________________________________ 
From: Terence Quinn [mailto:Terry.Quinn@glasgow.ac.uk]  
Sent: 15 November 2011 19:44 
To: Brown, Isobel 
Cc: Rosalind Lees; Broomfield, Niall 
Subject: RE: advice / support with European audit 
  
Dear Isobel 
  
Thanks for help and advice with my recent EHS audit. 
  
I have another quick information governance question. 
My group has some funding from Chest Heart and Stroke Scotland to conduct a 
questionnaire audit of usual practice in mood and cognitive assessment in stroke 
units. 
The questionnaire is voluntary, intended to be completed by senior staff and has no 
identifiable information other than hospital site. 
I assume this would not require Caldicott Guardian approval - could you confirm? 
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Best wishes 
  
Terry  
  
  
Dr T J Quinn MD, MRCP, MBChB (hons), BSc MedSci (hons) 
Lecturer in Geriatric Medicine 
  
Cardiovascular and Medical Sciences, Walton Building 
Glasgow Royal Infirmary, G4 0SF 
Tel: +44 141 2114976  
Fax +44 141 211 4033 
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Appendix B - Usual Practice 
Questionnaire 
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Appendix C - Systematic review protocol 
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Appendix D Chapter 3 search strategy 
Concept a) Stroke 
1.Brain Ischemia.ti,ab (exploded) 
2.Cerebrovascular*ti,ab (exploded) 
3.Stroke.ti,ab (exploded) 
4. or/1-3 
Concept b) Cognitive disorders and tests 
1.3-stage commands.ti,ab 
2.Abbreviated mental test.ti,ab 
3.AMT.ti,ab 
4.Addenbrooke’s cognitive examination revised.ti,ab  
5.ACE-R.ti,ab 
6.Arizona battery for communication disorders of dementia.ti,ab  
7.Assessment of motor and processing skills.ti,ab  
8.AMPS.ti,ab 
9.Block tapping.ti,ab 
10.Brixton tests.ti,ab  
11.California verbal learning test.ti,ab  
12.CVLT.ti,ab 
13.Cambridge cognitive examination revised.ti,ab 
14.CAMCOG.ti,ab 
15.Chessington occupational therapy Neurological assessment battery.ti,ab 
16.COTNAB.ti,ab 
17.Clock drawing.ti,ab  
18.Cognitive linguistic quick tester.ti,ab 
19.CLQT.ti,ab 
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20.Cognistat.ti,ab 
21.Doors and people test.ti,ab  
22.Galveston orientation and amnesia test.ti,ab  
23.GOAT.ti,ab 
24.Hayling test.ti,ab  
25.Intersecting pentagons.ti,ab  
26.Loewenstein occupational therapy cognitive assessment.ti,ab  
27.LOTCA-G.ti,ab 
28.Lothian aphasia stroke cognitive assessment.ti,ab  
29.LASKA.ti,ab 
30.Mental status questionnaire .ti,ab 
31.MSQ.ti,ab 
32.Mini mental state examination.ti,ab 
33.MMSE.ti,ab 
34.Montreal cognitive assessment.ti,ab 
35.MoCA.ti,ab 
36.Measure of cognitive linguistic ability,ti,ab 
37.MCLA.ti,ab 
38.OT cognitive screening tool.ti,ab  
39.Perceive, recall, Plan and Perform.ti,ab 
40.PRPP.ti,ab 
41.Picture cards.ti,ab  
42.Repeatable battery for the assessment of the neuropsychological status.ti,ab 
43.RBANS.ti,ab 
44.Rivermead behavioural memory test.ti,ab 
45.RBMT.ti,ab 
46.Rivermead perceptual assessment battery.ti,ab 
47.RPAB.ti,ab 
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48.Screening Instrument for neuropsychological Impairments in Stroke.ti,ab 
49.SINS.ti,ab 
50.Short orientation memory and concentration test.ti,ab 
51.SOMC.ti,ab 
52.Verbal fluency test .ti,ab 
53.Wessex head injury matrix.ti,ab 
54.WHIM.ti,ab 
 
55..Alzheimer Disease.ti.ab (exploded) 
56..Cognition.ti.ab 
57..Cognition Disorders.ti,ab (exploded) 
58..Dementia.ti,ab (exploded) 
59.Memory.ti,ab (exploded) 
60.Vascular dementia.ti,ab 
 
61. or/1-54 
62. or/55-60 
63. 61 or 62 
Concept c) cognitive screening 
1.Mass Screening.ti,ab (exploded) 
2.Mental Status Schedule.ti,ab 
3.Neuropsychological Tests.ti,ab (exploded) 
4.Predictive Value of Teststi,ab 
5.Psychiatric Status Rating Scales.ti,ab (exploded) 
6.Psychological Tests.ti,ab 
7.Reproducibility of Results.ti,ab  
8.ROC Curve.ti,ab 
9.Sensitivity.ti,ab (exploded)  
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10.Specificity.ti,ab (exploded) 
11.Severity of Illness Indexti,ab (exploded) 
12. or/1-11 
 
(Concept b OR concept c) AND concept a 
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Appendix E – STARDdem reporting 
guidance  
(For studies with a dementia/cognitive impairment 
reference standard) 
Section and 
Topic and item 
No. 
STARD checklist item Points of particular relevance to dementia 
Title/Abstract/ 
Keywords 
  
1 Identify the article as a study of 
diagnostic accuracy (recommend 
MeSH heading 'sensitivity and 
specificity') 
Studies reporting a sensitivity/specificity or 2x2 
data derivable, fall within the scope of 
STARDdem and should be indexed accordingly. 
Introduction   
2 State the research questions or 
study aims, such as estimating 
diagnostic accuracy or comparing 
accuracy between tests or across 
participant groups 
Some studies describing aims related to 
'prognosis' or 'prediction' may also fall within the 
remit of STARDdem. 
 
Report test purpose: 'stand-alone' test or as an 
addition to other tests or clinical criteria. 
Methods   
Participants:   
	  183	  
3 The study population: The 
inclusion and exclusion criteria, 
setting and locations where data 
were collected 
 
See also Item 4 on recruitment 
and Item 5 on sampling 
Key inclusion criteria: (a) demographic, 
especially age; (b) cognition- or disease-related 
criteria. 
 
Report referral pathways, precise locations of 
patient recruitment, where index test and 
reference standard were performed. For 
secondary/tertiary settings helpful to report the 
medical subspecialty or hospital dept (e.g. 
psychiatry, neurology). 
 
Diagnostic accuracy studies in dementia are 
often nested within larger cohort studies. If this 
is the case, then the targeted population for the 
cohort study and the method of cohort selection 
should be described and/or the parent study 
cited. 
4 Participant recruitment: Was 
recruitment based on presenting 
symptoms, results from previous 
tests, or the fact that the 
participants had received the 
index tests or the reference 
standard? 
 
See also Item 5 on sampling and 
Item 16 on participant loss at 
each stage of the study 
For case-control design, report whether those in 
intermediate categories (e.g. possible AD or 
possible DLB) were excluded.  
5 Participant sampling: Was the 
study population a consecutive 
series of participants defined by 
the selection criteria in item 3 
and 4? If not, specify how 
participants were further selected 
 
See also Item 4 on recruitment 
and Item 16 on participant loss 
Planned analyses showing how characteristics of 
the subgroup entering the study differ from the 
eligible population are strongly recommended 
(i.e. if a convenience sample has been used due 
to invasive nature of test/s). 
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6 Data collection: Was data 
collection planned before the 
index test and reference standard 
were performed (prospective 
study) or after (retrospective 
study)? 
Authors should report the timing of the analysis 
plan with respect to data collection: was the 
analysis plan set out in a protocol before index 
and reference standards were performed? If not, 
when was the analysis plan created? 
Test methods:   
7 The reference standard and its 
rationale 
For neuropathological and clinical reference 
standards the diagnostic criteria used should be 
specified. Where relevant, reference should be 
made to studies validating the criteria. 
 
Report if standard consensus clinical criteria 
incorporate the index test (incorporation bias 
rendering blinding of index test impossible). 
8 Technical specifications of 
material and methods involved 
including how and when 
measurements were taken, 
and/or cite references for index 
tests and reference standard 
 
See also Item 10 concerning the 
person(s) executing the tests 
Use of scales: specify details of administration, 
which version. 
Clinical diagnostic criteria: what information was 
available to inform the diagnoses; how the 
criteria were applied (e.g. by individual 
clinicians, by consensus conference, by semi-
automated algorithm). 
   
Imaging and laboratory tests: specify materials 
and instruments, including sample handling and 
concordance with any harmonisation criteria. In 
new assays describe all steps in detail. Any 
particular preparation of participants should be 
described. 
9 Definition of and rationale for the 
units, cut-offs and/or categories 
of the results of the index tests 
and the reference standard 
Explanation of any cut-off used is warranted; 
depending on clinical setting a more sensitive or 
more specific test is required.  
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10 The number, training and 
expertise of the persons 
executing and reading the index 
tests and the reference standard 
 
See also Item 8 
 
Especially where subjective judgments are 
involved, e.g. the interpretation of neuroimaging 
results. 
 
Report inter- and intra-rater agreement.  
 
Reference or describe the content of training 
materials used. 
 
Reference or describe details of lab certification 
and harmonised biomarker assays. 
11 Whether or not the readers of the 
index tests and reference 
standard were blind (masked) to 
the results of the other test and 
describe any other clinical 
information available to the 
readers 
 
See also Item 7 
Also, the index test may form a part of the 
reference standard. This is often referred to as 
incorporation bias and renders blinding of the 
index test impossible.  
Statistical 
methods: 
  
12 Methods for calculating or 
comparing measures of diagnostic 
accuracy, and the statistical 
methods used to quantify 
uncertainty (e.g. 95% confidence 
intervals) 
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13 Methods for calculating test 
reproducibility, if done 
Applies to the reference standard as well as to 
the index test. Both should be 
reported/adequately referenced.  Recommend 
reporting inter-rater and test-retest reliability of 
reference standard as applied in the study being 
reported, rather than simply referring to other 
studies where reproducibility has been 
established. 
 
The training which image readers receive should 
be carefully described.  Studies in which the 
accuracy of ‘majority’ judgements are reported 
should also report data for the minority 
judgements.  Reports of the impact of training 
should clearly describe the population 
characteristics of the training group and whether 
it is representative of the group to which the test 
will be applied. 
Results   
Participants:   
14 When study was performed, 
including beginning and end dates 
of recruitment 
Pertinent particularly to longitudinal (delayed 
verification) studies, authors should report 
recruitment dates of the study (not to be 
confused with recruitment dates of the wider 
cohort study from which it might be drawn), and 
the beginning (first participant) and end (last 
participant) dates of the periods during which 
index test/s and reference standard were 
performed. 
 
Report the period for the index test and period 
for the reference standard separately if it is not 
clear. 
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15 Clinical and demographic 
characteristics of the study 
population (at least information 
on age, gender, spectrum of 
presenting symptoms) 
 
See also Item 18 
Report key demographic variables: age, sex and 
education. 
Report age distribution of sample in detail.  
Ethnicity and genetic factors (e.g. APOE 
genotype) may also be particularly important. 
The cognitive characteristics are covered in Item 
18. 
 
16 The number of participants 
satisfying the criteria for inclusion 
who did or did not undergo the 
index tests and/or the reference 
standard; describe why 
participants failed to undergo 
either test (a flow diagram is 
strongly recommended) 
 
See also Item 3, Item 4 and 
Item 5 
Test results:   
17 Time-interval between the index 
tests and the reference standard, 
and any treatment administered 
in between 
Specify the follow-up period for all subjects in 
relation to their outcomes. It should be specified 
whether or not participants had received any 
treatments which might affect disease 
progression. 
18 Distribution of severity of disease 
(define criteria) in those with the 
target condition; other diagnoses 
in participants without the target 
condition 
Include a description of the severity of the target 
condition at the time the index test is 
performed. Usually captured by a cognitive score 
and/or duration of symptoms. 
 
For delayed verification studies report 
distribution of severity of disease and the degree 
of certainty (such as probable/possible) about 
the diagnosis at time of case ascertainment.  
 
Report other diagnoses (not target condition). 
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19 A cross tabulation of the results 
of the index tests (including 
indeterminate and missing 
results) by the results of the 
reference standard; for 
continuous results, the 
distribution of the test results by 
the results of the reference 
standard 
20 Any adverse events from 
performing the index tests or the 
reference standard 
Report all adverse events, even if unlikely to be 
related to the diagnostic test performed. 
Estimates:   
21 Estimates of diagnostic accuracy 
and measures of statistical 
uncertainty (e.g. 95% confidence 
intervals) 
 
See also Item 12 
22 How indeterminate results, 
missing data and outliers of the 
index tests were handled 
23 Estimates of variability of 
diagnostic accuracy between 
subgroups of participants, readers 
or centers, if done 
24 Estimates of test reproducibility, 
if done 
 
See also Item 13 
Discussion   
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25 Discuss the clinical applicability 
of the study findings 
Key to clinical applicability are differences in age 
and comorbidity between the study population 
and the patients typically seen in clinical 
practice. 
 
Discuss issue of the 'added’ or ‘incremental’ 
value of the index test if appropriate. 
 
Emphasise: 1. Stage of development of the test 
(e.g. proof of concept; defining accuracy in a 
typical spectrum of patients); 2. The further 
research needed to be done to make test 
applicable to population in whom likely to be 
applied in practice; 3. Whether sample was 
representative of the population in whom the 
test would be applied in practice. 
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Appendix F Methodology for developing 
dementia diagnosis QUADAS-2 anchoring  
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Appendix G Local ethics committee 
approval – Chapter 5  
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Appendix H – Caldlcott Gardian 
approval: audit data collection – 
Chapter  5 
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Appendix I – Email correspondence for 
use of audit data for another project – 
Chapter 5 
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Appendix J - National ethics committee 
approval – Chapter 6 rehabilitation 
study 
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Appendix K – Patient Information sheet 
and consent form – Chapter 6  
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Appendix L – Preferred carer/friend 
information sheet and consent form – 
Chapter 6 
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Appendix M – Legal representative 
information sheet and consent form – 
Chapter 6 
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Appendix N - Opinion article 
Stroke cognitive screening: The good, 
the bad and the unknown 
 
This	  opinion	  article	  was	  commissioned	  by	  the	  editors	  of	  the	  journal	  International	  Journal	  of	  
Therapy	   and	   Rehabilitation,	   in	   response	   to	   an	   original	   research	   article	   on	   cognitive	  
assessments	   in	   stroke	   settings.	   	   In	   the	   context	   of	   rising	   publicity	   surrounding	   dementia	  
assessment	  and	  polarised	  opinion	  on	  the	  utility	  of	  cognitive	  screening	  for	   impairments,	  this	  
article	  was	  written	   to	  point	  out	   the	   issues	   and	  potential	   benefits	   of	   cognitive	   screening	   as	  
well	   as	   what	   is	   missing	   from	   research.	   	   With	   multi-­‐domain	   cognitive	   impairment	   and	  
dementia	   prevalent	   in	   stroke	   survivors	   and	   a	   push	   for	   screening	   in	   guidelines	   despite	   few	  
interventions	  available,	  this	  article	  attempts	  to	  help	  clarify	  our	  current	  understanding	  of	  the	  
role	  of	  cognitive	  screening	  in	  stroke.	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Post-stroke cognitive screening:  
The good, the bad and the unknown
Cognitive impairment is highly prevalent following stroke and has significant func-tional impact (Tatemichi et al, 
1994; Patel et al, 2003). Implementing 
an early cognitive screening strategy 
to identify problematic patients and 
implement interventions should reduce 
the long-term impact of cognitive def-
icits on functional recovery (Duits et 
al, 2008). Stroke cognitive screening 
can therefore provide invaluable data to 
improve stroke rehabilitation.  
A number of organisations recom-
mend routine cognitive screening 
of all stroke survivors (e.g. National 
Stroke Strategy, Scottish Intercollegiate 
Guideline Network, National Institute 
for Health and Care Excellence. 
Hospitals are increasingly implementing 
stroke cognitive screening and it may 
become a UK national audit standard. 
However, a lack of consensus remains 
around when and how to screen for cog-
nitive function (Lees et al, 2012). This 
piece discusses five of the main ques-
tions around screening.  
Should stroke cognitive 
screening occur?
Cognitive deficits following stroke 
are associated with negative treatment 
response and functional outcome. Stroke 
cognitive screening should help deter-
mine the presence (and nature) of cog-
nitive impairments, to enable a more 
individualised stroke rehabilitation 
approach that accounts for specific cog-
nitive deficits (Green et al, 2013). 
However, care must be taken. Stroke 
patients often have a variety of disabili-
ties that affect the cognition assessment 
process and the chosen screening tool’s 
value; this includes cognitive function 
itself (Quaranta, 2008). Many stroke 
patients suffer from impaired atten-
tion, executive function, mental speed 
and language. Achieving a true measure 
of cognitive function can be problem-
atic when the assessment itself requires 
a high level of cognitive demand and/
or verbal response. Transient cognitive 
dysfunction, aphasia and physical dis-
ability can give false positives for long-
term cognitive impairment. Due to these 
disabilities, patients screened early could 
score poorly on assessments, despite 
higher levels of actual cognitive function 
(Lees et al, 2013). Thus, it is important 
that cognitive screening programmes are 
carefully designed, to ensure early co-
morbid stroke disabilities do not signifi-
cantly interfere with the process. 
When should stroke cognitive 
screening occur?
Following stroke, cognitive func-
tion often improves over time, and 
across domains (Hurford et al, 2013). 
Depending on stroke severity, patients 
may reach peak cognitive performance 
early or later post ictus, with recovery 
occurring in peaks and troughs or more 
gradually and continuously. 
Two questions surround the implemen-
tation of an early stroke cognitive screen-
ing programme: (i) can it accurately 
measure the level of cognitive function 
post-stroke? (ii) can it accurately predict 
the peak functional level in recovery? 
The best way to determine an opti-
mum assessment point for stroke cogni-
tive screening is for research to assess 
cognition at regular intervals over the 
first year in stroke cohorts to describe 
trends. If we can clarify when the major-
ity of stroke survivors reach cognitive 
potential, we can then prospectively 
determine the most accurate timing for 
prediction. If this issue is not addressed 
and an early approach adopted then the 
majority of stroke survivors could screen 
positive for cognitive impairment. This 
could overload stroke services with 
patients who are not suitable for follow-
up neuropsychological assessment.
While an early screening strat-
egy aimed at implementing early 
intervention(s) might seem appealing, it 
may be impracticable and confer unfa-
vourable psychological and organisa-
tional outcomes. An inaccurate early 
diagnosis of cognitive impairment that 
spontaneously improves could be dis-
tressing to the patient and family. It 
could also lead to unnecessary medi-
cal investigations and treatments with 
unknown side effects, added organisa-
tional costs, and resources diverted from 
patients in actual need (Le Couteur et al, 
2013). Arguably, until we better under-
stand how patients’ cognition improves 
over time, and until an accurate, reliable 
cognitive impairment measure is identi-
fied, cognitive screening after transient 
problems resolve may be preferable. 
The majority of stroke patients are fol-
lowed up medically after a few months, 
either by a specialised stroke service or 
their general practitioner. In the author’s 
opinion, this would be an opportune time 
for screening assessments as the patient 
is likely back to a routine and more 
aware of what they can and cannot do.
Which psychometric measure(s) 
should be used?  
Patients may be screened either directly, 
or indirectly using proxy questionnaires. 
Direct assessments tend to be favoured 
as it is assumed these provide a more 
accurate measure of specific cognitive 
domains. However, debate remains over 
which assessment approach is most reli-
able. Very few published works include 
neuropsychological measures and those 
that do are often not recognised as suit-
able for the stroke population. The lack 
of data surrounding norms across stroke 
patients at various stages in recovery in 
assessments makes it difficult to select 
a clinically appropriate assessment tool. 
Available domain-based meas-
ures that show promise include the 
Repeatable Battery for the Assessment 
of Neuropsychological Status (RBANS)
(Green et al, 2013), the Montreal 
Cognitive Assessment (MoCA) (Doong 
et al, 2010) and the Oxford Cognitive 
Screen (OCS). Difficulties can occur in 
	  
	  217	  
Opinion
International Journal of Therapy and Rehabilitation, January 2014, Vol 21, No 1 9
©
 2
01
3 
M
A
 H
ea
lth
ca
re
 L
td
determining appropriate cut-off points 
that distinguish ‘normal’ cognitive func-
tion from a long-term cognitive deficit, 
even with detailed batteries, due to the 
lack of data on norms (Green et al, 2013). 
Indeed, the long-term effect of cog-
nitive impairment following stroke, 
although associated with negative out-
come and poor recovery, is still under 
researched. Difficulties surrounding 
administration of cognitive assessment, 
poor understanding of the potential of 
the data collected, and time restraints in 
practice lie behind this lack of research.
If direct patient early screening is inap-
propriate due to transient or other issues 
interfering, a proxy screening strategy is 
necessary. Informant questionnaires pro-
vide details on patients’ pre-stroke cog-
nitive function and the extent of change 
post-stroke. Proxy questionnaires: are 
observational; can be more forgiving in 
the presence of other disabilities, such 
as aphasia; may reduce patient burden; 
and can be observed over time. A good 
assessment to determine patient cogni-
tion that accounts for previous capa-
bilities is the Informant Questionnaire 
of Cognitive Decline in the Elderly 
(IQCODE). This short questionnaire can 
be filled in by any proxy in regular con-
tact with the patient and gives a good 
feel for patient cognitive change over 
time, and it can screen for dementia.   
Who should be responsible for 
stroke cognitive screening?
Although cognitive screening is impor-
tant, uncertainty remains over the impli-
cations of gathered information for 
further care and personal responsibility. 
Cognitive assessment has to be consist-
ent in its application to provide meaning-
ful and comparable results across stroke 
cohorts. NHS improvement reports state 
that cognitive assessments have to be 
administered by an assessor with spe-
cific training in using those tool(s). This 
is a reasonable request but a lack of guid-
ance, training and protocols for cognitive 
screening has left clinical teams with-
out recommended assessments. Lack of 
available, trained assessors can lead to 
inaccurate administration or may result 
in the absence of screening. 
Individual stroke services should 
ensure several members of the treat-
ing clinical team are trained in selected 
cognitive screening tools and have a 
protocol in place stating who is respon-
sible for administering assessment(s). 
Training and oversight of cognition 
screening is arguably best handled by 
a clinical psychologist/neuropsycholo-
gist specialising in stroke although such 
individuals remain scarce. Clear defini-
tion by services of who is responsible 
for supervising and delivering cognition 
assessments should ensure more patients 
are screened. Stroke cognitive screening 
should, of course, involve all patients.
 
How should stroke screening 
data be interpreted?
Information extrapolated from cognitive 
screening can be useful to inform reha-
bilitation and/or grounds for referral to 
specialised services. It may allow thera-
pists to modify a patient rehabilitation 
programme, and can provide useful data 
to help explain to patients and their fami-
lies why some patients, while progress-
ing physically, may still be struggling to 
complete basic activities of daily living. 
It is important to understand that stroke 
cognitive screening data not only cap-
tures problematic areas requiring stroke 
rehabilitation team focus. Findings may 
also have significant implications for 
long-term care plans, support, and educa-
tion to caregivers to enable a patient to 
live a maximally independent life post-
discharge (Duits et al, 2008). Stroke cog-
nitive screening assessments can be used 
to distinguish patients at high risk of fur-
ther cognitive decline (vascular dementia) 
from those likely to make a reasonable 
cognitive recovery and resume pre-stroke 
function. By establishing which patients 
are at high risk of further cognitive 
decline, interventions to improve qualiy 
of life, allow planning and to slow down 
the rate of decline can be made available. 
CONCLUSIONS
Stroke cognitive screening is complex 
and much remains to be determined. 
Domain-based cognitive measures that 
show promise are available (Doong et al, 
2010; Green et al, 2013) and can help 
guide rehabilitation. However, the opti-
mum point in the care pathway at which 
to introduce stroke cognitive screen-
ing is unknown and longitudinal obser-
vation research is needed to determine 
this. Over-diagnosis due to screening too 
early could overload services and prove 
financially, medically, psychologically, 
and socially detrimental. There is sparse 
evidence currently that early neuropsy-
chological interventions assist although 
inter-disciplinary cognitive rehabilitation 
frameworks for stroke now exist (Taylor 
and Broomfield, 2013).   
Better implementation of consistent 
cognitive assessments in research and 
practice should extend our understand-
ing of which cognitive domains are usu-
ally affected early following stroke and 
which domain deficiencies predict long-
term cognitive decline.  
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Appendix O – The National Institutes of 
Health Stroke Scale 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 = no stroke, 1-4 = minor stroke, 5-15 = moderate Stroke, 15-20 = moderate to severe stroke, 21-42 
= severe stroke 
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Appendix P – The Cog-4 assessment, 
domains and scoring 
Cog-­‐4 Score
1(b) Level	  of	  consciousness	  -­‐ questions	  (month	  and	  age)
Answers	  both	  correctly	  
Answers	  one	  question	  correctly
Answers	  neither	  questions	  correctly	  
0
1
2
1	  (c) Level	  of	  consciousness	  – commands	  (open	  and	  close	  eyes;	  grip	  and	  release	  hand)	  
Performs	  both	  task	  correctly
Performs	  one	  task	  correctly	  
Performs	  neither	  task	  correctly	  
0
1
2
9 Best	  language
No	  aphasia	  
Mild	  to	  moderate	  aphasia
Severe	  aphasia
Mute	  and	  global	  aphasia
0
1
2
3
11 Extinction	  and	  inattention
No	  inattention
Mild	  inattention
Severe	  inattention
0
1
2
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Appendix Q – The 4 ‘A’s Test (4AT) for 
delirium screening 
 Assessment Domain  Domain Subsections Score 
ALERTNESS 
This includes patients who may be markedly 
drowsy (e.g. difficult to rouse and/or 
obviously sleepy during assessment) or 
agitated/hyperactive.  Observe the patient.  
If asleep attempt to wake with speech or 
gentle touch on shoulder.  Ask the patient to 
state their name and address to assist rating. 
 
Normal (fully alert, but not agitated, 
throughout assessment) 
Mild sleepiness for <10 seconds after 
waking, then normal 
Clearly abnormal 
 
0 
0 
4 
AMT 4 
Age, date of birth,place (name of the 
hospital or building), current year. 
 
No mistakes  
1 mistake 
2 or more mistakes/untestable 
 
0 
1 
2 
ATTENTION 
Ask the patient: “Please tell me the months 
of the year in backwards order, starting at 
December.”  To assist initial understanding 
one promt of “what is the month before 
December?” is permitted. 
 
Achieves 7 months or more correctly 
Starts but scores <7months/refuses to 
start 
Untestable (cannot start because 
unwell, drowsy, inattentive) 
 
0 
1 
2 
ACUTE CHANGE OR FLUCTUATING COURSE 
Evidence of significant change or fluctuation 
in: alertness, cognition, other mental 
function (e.g. paranoia, hallucinations) 
arising over the last two weeks and still 
evident in the last 24 hours. 
 
Yes 
No 
 
0 
4 
4AT SCORE TOTAL  
 
4 or above: possible delirium +/- 
cognitive impairment 
1-3: possible cognitive impairment  
0: delirium or severe cognitive 
impairment unlikely (but delirium still 
possible if [4] information incomplete) 
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GUIDANCE NOTES    Version 1.1. Information and download: www.the4AT.com 
The 4AT is a screening instrument designed for rapid initial assessment of delirium and cognitive 
impairment. A score of 4 or more suggests delirium but is not diagnostic: more detailed assessment 
of mental status may be required to reach a diagnosis. A score of 1-3 suggests cognitive impairment 
and more detailed cognitive testing and informant history-taking are required. A score of 0 does 
not definitively exclude delirium or cognitive impairment: more detailed testing may be required 
depending on the clinical context. Items 1-3 are rated solely on observation of the patient at the 
time of assessment. Item 4 requires information from one or more source(s), e.g. your own 
knowledge of the patient, other staff who know the patient (e.g. ward nurses), GP letter, case 
notes, carers. The tester should take account of communication difficulties (hearing impairment, 
dysphasia, lack of common language) when carrying out the test and interpreting the score.  
Alertness: Altered level of alertness is very likely to be delirium in general hospital settings. If the 
patient shows significant altered alertness during the bedside assessment, score 4 for this item. 
AMT4 (Abbreviated Mental Test - 4): This score can be extracted from items in the AMT10 if the 
latter is done immediately before. Acute Change or Fluctuating Course: Fluctuation can occur 
without delirium in some cases of dementia, but marked fluctuation usually indicates delirium. To 
help elicit any hallucinations and/or paranoid thoughts ask the patient questions such as, “Are you 
concerned about anything going on here?”; “Do you feel frightened by anything or anyone?”; “Have 
you been seeing or hearing anything unusual?” 
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Appendix R – The Abbreviated Mental 
Test (AMT) 
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Appendix S – The Short form of the 
Informant Questionnaire on Cognitive 
Decline in the Elderly (IQCODE) 
 
Short Form of the Informant Questionnaire On Cognitive Decline in the Elderly 
(IQCODE) 
 
Informant ID:  
Date Completed:       Researcher: 
 
Now we want you to remember what your friend or relative was like 10 years ago and to 
compare it with what he/she is like now.  
 
On the next page are situations where this person has to use his/her memory or 
intelligence and we want you to indicate whether this has improved, stayed the same or 
got worse than in that situation over the past 10 years. Note the importance of comparing 
his/her present performance with 10 years ago.  
 
So if 10 years ago this person always forgot where he/she had left things and he/she still 
does this, then this would be considered ‘Not much change’. Please indicate the changes 
you have observed by ticking the appropriate box. 
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Much 
improved 
 
A bit 
improved 
 
Not 
much 
change 
 
A bit 
worse 
 
Much 
worse 
1 Remembering things about family and 
friends, e.g. occupations, birthdays, 
addresses 
     
2 Remembering things that have 
happened recently 
     
3 Recalling conversations a few days 
later 
     
4 Remembering her/his address and 
telephone number 
     
5 Remembering what day and month it 
is 
     
6 Remembering where things are 
usually kept 
     
7 Remembering where to find things 
which have been put in a different 
place from usual 
     
8 Knowing how to work familiar 
machines around the house 
     
9 Learning to use a new gadget or 
machine around the house 
     
1
0 
Learning new things in general      
1
1 
Following a story in a book or on TV      
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1
2 
Making decisions on everyday matters      
1
3 
Handling money for shopping      
1
4 
Handling financial matters, e.g. the 
pension, dealing with the bank 
     
1
5 
Handling other everyday arithmetic 
problems, e.g. knowing how much 
food to buy, knowing how long 
between visits from family or friends 
     
1
6 
Using his/her intelligence to 
understand what’s going on and to 
reason things through 
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Appendix T – The Montreal Cognitive 
Assessment (MoCA) 
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Appendix U – The Confusion Assessment 
Method (CAM) 
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Appendix V – Depression Inventory Scale 
Circles (DISCS) 
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Appendix W - Addenbrookes’ Cognitive 
Examination III (ACE-III) 
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Appendix X - Good clinical practice 
certificate 
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Appendix Y – Rankin scale clinical trials 
1st training certification 
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Appendix Z - Addenbrokes’ Cognitive 
Examination-III training certificate 
 
	  239	  
 
Bibliography 
1.	   World	  Health	  Organisation	  (WHO).	  Annex	  Table	  2:	  Deaths	  by	  cause,	  sex	  and	  mortality	  
stratum	   in	   WHO	   regions,	   estimates	   for	   2002.	   In:	   Organisation	   Wh,	   editor.	   Geneva	   World	  
Health	  Organisation	  2004.	  
2.	   Feigin	  VL.	  Stroke	  epidemiology	  in	  the	  developing	  world.	  Lancet.	  2005;365(9478):2160-­‐
1.	  
3.	   Chiu	  D,	  Peterson	  L,	   Elkind	  MS,	  Rosand	   J,	  Gerber	   LM,	  Silverstein	  MD.	  Comparison	  of	  
outcomes	   after	   intracerebral	   hemorrhage	   and	   ischemic	   stroke.	   J	   Stroke	   Cerebrovasc	   Dis.	  
2010;19(3):225-­‐9.	  
4.	   Rathore	   SS,	   Hinn	   AR,	   Cooper	   LS,	   Tyroler	   HA,	   Rosamond	   WD.	   Characterization	   of	  
incident	   stroke	   signs	   and	   symptoms:	   findings	   from	   the	   atherosclerosis	   risk	   in	   communities	  
study.	  Stroke.	  2002;33(11):2718-­‐21.	  
5.	   Andersen	  KK,	  Olsen	  TS,	  Dehlendorff	  C,	  Kammersgaard	  LP.	  Hemorrhagic	  and	  ischemic	  
strokes	  compared:	  stroke	  severity,	  mortality,	  and	  risk	  factors.	  Stroke.	  2009;40(6):2068-­‐72.	  
6.	   Bonita	   R,	   Beaglehole	   R.	   Recovery	   of	   motor	   function	   after	   stroke.	   Stroke.	  
1988;19(12):1497-­‐500.	  
7.	   European	  Cardiovascular	  Disease	  Statistics	  [Internet].	  British	  Heart	  Foundation	  Health	  
promotion	  Research	  Group	  2000.	  
8.	   Duncan	  PW,	  Goldstein	  LB,	  Horner	  RD,	  Landsman	  PB,	  Samsa	  GP,	  Matchar	  DB.	  Similar	  
motor	  recovery	  of	  upper	  and	  lower	  extremities	  after	  stroke.	  Stroke.	  1994;25(6):1181-­‐8.	  
9.	   Sturm	  JW,	  Dewey	  HM,	  Donnan	  GA,	  Macdonell	  RA,	  McNeil	  JJ,	  Thrift	  AG.	  Handicap	  after	  
stroke:	   how	   does	   it	   relate	   to	   disability,	   perception	   of	   recovery,	   and	   stroke	   subtype?:	   the	  
north	  North	  East	  Melbourne	  Stroke	  Incidence	  Study	  (NEMESIS).	  Stroke.	  2002;33(3):762-­‐8.	  
10.	   Lawrence	  ES,	  Coshall	  C,	  Dundas	  R,	  Stewart	  J,	  Rudd	  AG,	  Howard	  R,	  et	  al.	  Estimates	  of	  
the	  prevalence	  of	  acute	  stroke	  impairments	  and	  disability	  in	  a	  multiethnic	  population.	  Stroke.	  
2001;32(6):1279-­‐84.	  
11.	   Stroke	   Association.	   Stroke	   Statistics.	   A01R11	   [Internet].	   2013	   May	   2014:[13	   p.].	  
Available	  from:	  http://www.stroke.org.uk/resource-­‐sheet/stroke-­‐statistics.	  
12.	   Bueno	  VF,	  Brunoni	  AR,	  Boggio	  PS,	  Bensenor	  IM,	  Fregni	  F.	  Mood	  and	  cognitive	  effects	  
of	   transcranial	   direct	   current	   stimulation	   in	   post-­‐stroke	   depression.	   Neurocase.	  
2011;17(4):318-­‐22.	  
13.	   Moorhouse	   P,	   Rockwood	   K.	   Vascular	   cognitive	   impairment:	   current	   concepts	   and	  
clinical	  developments.	  Lancet	  neurology.	  2008;7(3):246-­‐55.	  
14.	   Tatemichi	   TK,	   Desmond	   DW,	   Stern	   Y,	   Paik	   M,	   Sano	   M,	   Bagiella	   E.	   Cognitive	  
impairment	  after	  stroke:	  frequency,	  patterns,	  and	  relationship	  to	  functional	  abilities.	  J	  Neurol	  
Neurosurg	  Psychiatry.	  1994;57(2):202-­‐7.	  
15.	   Hurford	   R,	   Charidimou	   A,	   Fox	   Z,	   Cipolotti	   L,	   Werring	   DJ.	   Domain-­‐specific	   trends	   in	  
cognitive	  impairment	  after	  acute	  ischaemic	  stroke.	  J	  Neurol.	  2013;260(1):237-­‐41.	  
16.	   Cumming	  TB,	  Marshall	  RS,	  Lazar	  RM.	  Stroke,	  cognitive	  deficits,	  and	  rehabilitation:	  still	  
an	   incomplete	   picture.	   International	   journal	   of	   stroke	   :	   official	   journal	   of	   the	   International	  
Stroke	  Society.	  2013;8(1):38-­‐45.	  
	  240	  
17.	   Leys	  D,	  Henon	  H,	  Mackowiak-­‐Cordoliani	  MA,	  Pasquier	  F.	  Poststroke	  dementia.	  Lancet	  
neurology.	  2005;4(11):752-­‐9.	  
18.	   Campbell	  Burton	  CA,	  Murray	  J,	  Holmes	  J,	  Astin	  F,	  Greenwood	  D,	  Knapp	  P.	  Frequency	  
of	   anxiety	   after	   stroke:	   a	   systematic	   review	   and	   meta-­‐analysis	   of	   observational	   studies.	  
International	  Journal	  of	  Stroke.	  2012;8(7):545-­‐9.	  
19.	   Broomfield	  NM,	  Laidlaw	  K,	  Hickabottom	  E,	  Murray	  MF,	  Pendrey	  R,	  Whittick	  JE,	  et	  al.	  
Post-­‐stroke	  depression:	   the	   case	   for	   augmented,	   individually	   tailored	   cognitive	  behavioural	  
therapy.	  Clin	  Psychol	  Psychother.	  2011;18(3):202-­‐17.	  
20.	   Andersen	  G,	  Vestergaard	  K,	   Ingemann-­‐Nielsen	  M,	   Lauritzen	   L.	   Risk	   factors	   for	   post-­‐
stroke	  depression.	  Acta	  Psychiatr	  Scand.	  1995;92(3):193-­‐8.	  
21.	   Allan	   LM,	   Rowan	   EN,	   Thomas	   AJ,	   Polvikoski	   TM,	   O'Brien	   JT,	   Kalaria	   RN.	   Long-­‐term	  
incidence	  of	  depression	  and	  predictors	  of	  depressive	  symptoms	  in	  older	  stroke	  survivors.	  Br	  J	  
Psychiatry.	  2013;203(6):453-­‐60.	  
22.	   Hachinski	   V,	   Iadecola	   C,	   Petersen	   RC,	   Breteler	   MM,	   Nyenhuis	   DL,	   Black	   SE,	   et	   al.	  
National	   Institute	   of	   Neurological	   Disorders	   and	   Stroke-­‐Canadian	   Stroke	   Network	   vascular	  
cognitive	  impairment	  harmonization	  standards.	  Stroke.	  2006;37(9):2220-­‐41.	  
23.	   Danovska	   M,	   Stamenov	   B,	   Alexandrova	   M,	   Peychinska	   D.	   Post-­‐stroke	   cognitive	  
impairment-­‐	   Phenomenology	   and	   prognostic	   factors.	   Journal	   of	   International	   Medical	  
Association	  Bulgaria.	  2012;18(Book	  3):8.	  
24.	   McManus	  J,	  Pathansali	  R,	  Hassan	  H,	  Ouldred	  E,	  Cooper	  D,	  Stewart	  R,	  et	  al.	  The	  course	  
of	  delirium	  in	  acute	  stroke.	  Age	  and	  ageing.	  2009;38(4):385-­‐9.	  
25.	   Shi	  Q,	  Presutti	  R,	  Selchen	  D,	  Saposnik	  G.	  Delirium	  in	  acute	  stroke:	  a	  systematic	  review	  
and	  meta-­‐analysis.	  Stroke.	  2012;43(3):645-­‐9.	  
26.	   Melkas	  S,	  Laurila	   JV,	  Vataja	  R,	  Oksala	  N,	   Jokinen	  H,	  Pohjasvaara	  T,	  et	  al.	  Post-­‐stroke	  
delirium	   in	   relation	   to	   dementia	   and	   long-­‐term	   mortality.	   Int	   J	   Geriatr	   Psychiatry.	  
2012;27(4):401-­‐8.	  
27.	   MacLullich	  AM,	  Beaglehole	  A,	  Hall	  RJ,	  Meagher	  DJ.	  Delirium	  and	  long-­‐term	  cognitive	  
impairment.	  Int	  Rev	  Psychiatry.	  2009;21(1):30-­‐42.	  
28.	   McManus	   J,	   Pathansali	   R,	   Stewart	  R,	  Macdonald	  A,	   Jackson	   S.	  Delirium	  post-­‐stroke.	  
Age	  and	  ageing.	  2007;36(6):613-­‐8.	  
29.	   Camus	  V,	  Gonthier	  R,	  Dubos	  G,	  Schwed	  P,	  Simeone	  I.	  Etiologic	  and	  outcome	  profiles	  in	  
hypoactive	   and	   hyperactive	   subtypes	   of	   delirium.	   Journal	   of	   geriatric	   psychiatry	   and	  
neurology.	  2000;13(1):38-­‐42.	  
30.	   England	  N.	  CQUIN	  Dementia	   In:	   Improvement	  IfIa,	  editor.:	  NHS	  England	  Institute	  for	  
Innovation	  and	  Improvement	  
;	  2012/13.	  
31.	   Wade	  DT.	  Measurement	   in	  neurological	   rehabilitation.	  Current	  opinion	   in	  neurology	  
and	  neurosurgery.	  1992;5(5):682-­‐6.	  
32.	   Siddiqi	  N,	  House	  AO,	  Holmes	  JD.	  Occurrence	  and	  outcome	  of	  delirium	  in	  medical	   in-­‐
patients:	  a	  systematic	  literature	  review.	  Age	  and	  ageing.	  2006;35(4):350-­‐64.	  
33.	   Young	  J,	  Inouye	  SK.	  Delirium	  in	  older	  people.	  Bmj.	  2007;334(7598):842-­‐6.	  
34.	   Henon	  H,	  Lebert	  F,	  Durieu	  I,	  Godefroy	  O,	  Lucas	  C,	  Pasquier	  F,	  et	  al.	  Confusional	  state	  
in	   stroke:	   relation	   to	   preexisting	   dementia,	   patient	   characteristics,	   and	   outcome.	   Stroke.	  
1999;30(4):773-­‐9.	  
	  241	  
35.	   Sheng	  A,	  Shen	  Q,	  Cordato	  D,	  Zhang	  Y,	  Yin	  Chan	  D.	  Delirium	  within	  three	  days	  of	  stroke	  
in	  a	  cohort	  of	  elderly	  patients.	  Journal	  of	  American	  Geriatric	  Society.	  2006;54(8):7.	  
36.	   Melkas	  S,	  HJokinen	  H,	  Hietanen	  M,	  Erkinjuntti	  T.	  Poststroke	  cognitive	  impairment	  and	  
dementia:	   prevalence,	   diagnosis	   and	   treatment.	   Degenerative	   Neurological	   and	  
Neuromuscular	  Disease.	  2014;4:7.	  
37.	   Bernhardt	  J,	  Dewey	  H,	  Thrift	  A,	  Collier	  J,	  Donnan	  G.	  A	  very	  early	  rehabilitation	  trial	  for	  
stroke	  (AVERT)	  phase	  II	  safety	  and	  feasibility.	  Stroke.	  2008;39(2):390-­‐6.	  
38.	   Rostamian	   S,	  Mahinrad	   S,	   Stijnen	   T,	   Sabayan	   B,	   de	   Craen	   AJ.	   Cognitive	   Impairment	  
and	   Risk	   of	   Stroke:	   A	   Systematic	   Review	   and	  Meta-­‐Analysis	   of	   Prospective	   Cohort	   Studies.	  
Stroke.	  2014.	  
39.	   Gauthier	  S,	  Reisberg	  B,	  Zaudig	  M,	  Petersen	  RC,	  Ritchie	  K,	  Broich	  K,	  et	  al.	  Mild	  cognitive	  
impairment.	  Lancet.	  2006;367(9518):1262-­‐70.	  
40.	   Feldman	  HH,	  Jacova	  C.	  Mild	  cognitive	   impairment.	  The	  American	   journal	  of	  geriatric	  
psychiatry	   :	   official	   journal	   of	   the	   American	   Association	   for	   Geriatric	   Psychiatry.	  
2005;13(8):645-­‐55.	  
41.	   Kwa	   VIH,	   Limburg	   M,	   Voogel	   AJ,	   Teunisse	   S,	   Derix	   MMA,	   Hijdra	   A.	   Feasibility	   of	  
cognitive	  screening	  of	  patients	  with	   ischaemic	  stroke	  using	  the	  CAMCOG	  -­‐	  A	  hospital-­‐based	  
study.	  Journal	  of	  Neurology.	  1996;243(5):405-­‐9.	  
42.	   Bernhardt	   J,	   Indredavik	   B,	   Langhorne	   P.	   When	   should	   rehabilitation	   begin	   after	  
stroke?	  International	  Journal	  of	  Stroke.	  2013;8(1):5-­‐7.	  
43.	   Chertkow	   H.	   Mild	   cognitive	   impairment.	   Current	   opinion	   in	   neurology.	  
2002;15(4):401-­‐7.	  
44.	   Ferro	  JM,	  Caeiro	  L,	  Verdelho	  A.	  Delirium	  in	  acute	  stroke.	  Current	  opinion	  in	  neurology.	  
2002;15(1):51-­‐5.	  
45.	   Petersen	  RC,	   Smith	  GE,	  Waring	   SC,	   Ivnik	  RJ,	   Tangalos	   EG,	   Kokmen	  E.	  Mild	   cognitive	  
impairment:	  clinical	  characterization	  and	  outcome.	  Archives	  of	  neurology.	  1999;56(3):303-­‐8.	  
46.	   DeCarli	   C.	   Mild	   cognitive	   impairment:	   prevalence,	   prognosis,	   aetiology,	   and	  
treatment.	  Lancet	  neurology.	  2003;2(1):15-­‐21.	  
47.	   Katzman	  R,	  Brown	  T,	  Fuld	  P,	  Peck	  A,	  Schechter	  R,	  Schimmel	  H.	  Validation	  of	  a	  short	  
Orientation-­‐Memory-­‐Concentration	   Test	   of	   cognitive	   impairment.	   The	   American	   journal	   of	  
psychiatry.	  1983;140(6):734-­‐9.	  
48.	   Research	   CfIPH.	   The	   Centre	   for	   Epidemiological	   Studies	   Depression	   Scale	   Revised	  
(CESD-­‐R)	  	  [cited	  2014	  10/07/14].	  Available	  from:	  http://cesd-­‐r.com/.	  
49.	   Woodford	   HJ,	   George	   J.	   Cognitive	   assessment	   in	   the	   elderly:	   a	   review	   of	   clinical	  
methods.	  QJM	  :	  monthly	  journal	  of	  the	  Association	  of	  Physicians.	  2007;100(8):469-­‐84.	  
50.	   Ferri	   CP,	   Prince	   M,	   Brayne	   C,	   Brodaty	   H,	   Fratiglioni	   L,	   Ganguli	   M,	   et	   al.	   Global	  
prevalence	  of	  dementia:	  a	  Delphi	  consensus	  study.	  Lancet.	  2005;366(9503):2112-­‐7.	  
51.	   Society	  As.	  Helping	  you	  to	  assess	  cognition:	  A	  practical	  toolkit	  for	  clinicians.	  In:	  Health	  
Do,	  editor.	  http://www.alzheimers.org.uk/cognitiveassessment:	  Alzheimer's	  Society;	  2013.	  p.	  
43.	  
52.	   World	   Health	   Organisation	   (WHO).	   The	   world	   health	   report:	   Shaping	   the	   future	  
Geneva	  WHO;	  2003.	  p.	  1-­‐204.	  
53.	   Pendlebury	  ST,	  Rothwell	  PM.	  Prevalence,	  incidence,	  and	  factors	  associated	  with	  pre-­‐
stroke	  and	  post-­‐stroke	  dementia:	  a	  systematic	  review	  and	  meta-­‐analysis.	  Lancet	  neurology.	  
2009;8(11):1006-­‐18.	  
	  242	  
54.	   van	  der	  Flier	  WM,	  Scheltens	  P.	  Epidemiology	  and	   risk	   factors	  of	  dementia.	   J	  Neurol	  
Neurosurg	  Psychiatry.	  2005;76	  Suppl	  5:v2-­‐7.	  
55.	   Hardy	   J,	   Allsop	   D.	   Amyloid	   deposition	   as	   the	   central	   event	   in	   the	   aetiology	   of	  
Alzheimer's	  disease.	  Trends	  in	  Pharmacological	  Sciences.	  1991;12(10):383-­‐8.	  
56.	   Mudher	   A,	   Lovestone	   S.	   Alzheimer's	   disease-­‐do	   tauists	   and	   baptists	   finally	   shake	  
hands?	  Trends	  Neurosci.	  2002;25(1):22-­‐6.	  
57.	   GomezIsla	  T,	  Hollister	  R,	  West	  H,	  Mui	  S,	  Growdon	  JH,	  Petersen	  RC,	  et	  al.	  Neuronal	  loss	  
correlates	   with	   but	   exceeds	   neurofibrillary	   tangles	   in	   Alzheimer's	   disease.	   Ann	   Neurol.	  
1997;41(1):17-­‐24.	  
58.	   Hardy	   J,	   Selkoe	   DJ.	   The	   amyloid	   hypothesis	   of	   Alzheimer's	   disease:	   progress	   and	  
problems	  on	  the	  road	  to	  therapeutics.	  Science.	  2002;297(5580):353-­‐6.	  
59.	   Bennett	   DA,	   Schneider	   JA,	  Wilson	   RS,	   Bienias	   JL,	   Arnold	   SE.	   Neurofibrillary	   tangles	  
mediate	  the	  association	  of	  amyloid	  load	  with	  clinical	  Alzheimer	  disease	  and	  level	  of	  cognitive	  
function.	  Archives	  of	  neurology.	  2004;61(3):378-­‐84.	  
60.	   Roberts	   RE.	   Reliability	   of	   the	   CES-­‐D	   Scale	   in	   different	   ethnic	   contexts.	   Psychiatry	  
research.	  1980;2(2):125-­‐34.	  
61.	   McCullagh	  C,	  Craig	  D,	  McIlroy	  S,	  Passmore	  A.	  Risk	  factors	  for	  dementia.	  Advances	   in	  
Psychiatric	  Treatment.	  2001;7:8.	  
62.	   Duyckaerts	  C,	  Colle	  MA,	  Dessi	  F,	  Grignon	  Y,	  Piette	  F,	  Hauw	  JJ.	  The	  progression	  of	  the	  
lesions	   in	  Alzheimer	  disease:	   insights	   from	  a	  prospective	  clinicopathological	   study.	   J	  Neural	  
Transm	  Suppl.	  1998;53:119-­‐26.	  
63.	   Kalaria	  RN,	  Bhatti	   SU,	   Lust	  WD,	  Perry	  G.	   The	   amyloid	  precursor	  protein	   in	   ischemic	  
brain	  injury	  and	  chronic	  hypoperfusion.	  Ann	  N	  Y	  Acad	  Sci.	  1993;695:190-­‐3.	  
64.	   Jorm	  AF.	  History	  of	  depression	  as	  a	  risk	  factor	  for	  dementia:	  an	  updated	  review.	  The	  
Australian	  and	  New	  Zealand	  journal	  of	  psychiatry.	  2001;35(6):776-­‐81.	  
65.	   Speck	  CE,	  Kukull	  WA,	  Brenner	  DE,	  Bowen	  JD,	  Mccormick	  WC,	  Teri	  L,	  et	  al.	  History	  of	  
Depression	  as	  a	  Risk	  Factor	  for	  Alzheimers-­‐Disease.	  Epidemiology.	  1995;6(4):366-­‐9.	  
66.	   Stephens	  S,	  Kenny	  RA,	  Rowan	  E,	  Kalaria	  RN,	  Bradbury	  M,	  Pearce	  R,	  et	  al.	  Association	  
between	  mild	   vascular	   cognitive	   impairment	   and	   impaired	   activities	   of	   daily	   living	   in	   older	  
stroke	   survivors	   without	   dementia.	   Journal	   of	   the	   American	   Geriatrics	   Society.	  
2005;53(1):103-­‐7.	  
67.	   Zinn	  S,	  Dudley	  TK,	  Bosworth	  HB,	  Hoenig	  HM,	  Duncan	  PW,	  Horner	  RD.	  The	  effect	  of	  
poststroke	  cognitive	  impairment	  on	  rehabilitation	  process	  and	  functional	  outcome.	  Archives	  
of	  physical	  medicine	  and	  rehabilitation.	  2004;85(7):1084-­‐90.	  
68.	   Heruti	   RJ,	   Lusky	   A,	   Dankner	   R,	   Ring	   H,	   Dolgopiat	   M,	   Barell	   V,	   et	   al.	   Rehabilitation	  
outcome	  of	  elderly	  patients	  after	  a	  first	  stroke:	  effect	  of	  cognitive	  status	  at	  admission	  on	  the	  
functional	  outcome.	  Archives	  of	  Physicial	  Medical	  Rehabilitation.	  2002;83(6):742-­‐9.	  
69.	   Galski	  T,	  Bruno	  RL,	  Zorowitz	  R,	  Walker	  J.	  Predicting	  length	  of	  stay,	  functional	  outcome,	  
and	   aftercare	   in	   the	   rehabilitation	   of	   stroke	   patients.	   The	   dominant	   role	   of	   higher-­‐order	  
cognition.	  Stroke.	  1993;24(12):1794-­‐800.	  
70.	   Boyd	   JH,	   Weissman	   MM,	   Thompson	   WD,	   Myers	   JK.	   Screening	   for	   depression	   in	   a	  
community	   sample.	   Understanding	   the	   discrepancies	   between	   depression	   symptom	   and	  
diagnostic	  scales.	  Arch	  Gen	  Psychiatry.	  1982;39(10):1195-­‐200.	  
	  243	  
71.	   Yesavage	   JA,	   Brink	   TL,	   Rose	   TL,	   Lum	  O,	   Huang	   V,	   Adey	  M,	   et	   al.	   Development	   and	  
Validation	   of	   a	  Geriatric	  Depression	   Screening	   Scale	   -­‐	   a	   Preliminary-­‐Report.	   J	   Psychiat	   Res.	  
1983;17(1):37-­‐49.	  
72.	   Lesher	  EL,	  Berryhill	  JS.	  Validation	  of	  the	  Geriatric	  Depression	  Scale-­‐-­‐Short	  Form	  among	  
inpatients.	  Journal	  of	  clinical	  psychology.	  1994;50(2):256-­‐60.	  
73.	   del	  Ser	  T,	  Barba	  R,	  Morin	  MM,	  Domingo	  J,	  Cemillan	  C,	  Pondal	  M,	  et	  al.	  Evolution	  of	  
cognitive	   impairment	   after	   stroke	   and	   risk	   factors	   for	   delayed	   progression.	   Stroke.	  
2005;36(12):2670-­‐5.	  
74.	   Nys	  GM,	  van	  Zandvoort	  MJ,	  de	  Kort	  PL,	  van	  der	  Worp	  HB,	   Jansen	  BP,	  Algra	  A,	  et	  al.	  
The	   prognostic	   value	   of	   domain-­‐specific	   cognitive	   abilities	   in	   acute	   first-­‐ever	   stroke.	  
Neurology.	  2005;64(5):821-­‐7.	  
75.	   Hochstenbach	   J,	  Mulder	   T,	   van	   Limbeek	   J,	  Donders	   R,	   Schoonderwaldt	  H.	   Cognitive	  
decline	  following	  stroke:	  a	  comprehensive	  study	  of	  cognitive	  decline	  following	  stroke.	  Journal	  
of	  Clinical	  Experimental	  Neuropsychology.	  1998;20(4):503-­‐17.	  
76.	   Pendlebury	   ST,	   Wadling	   S,	   Silver	   LE,	   Mehta	   Z,	   Rothwell	   PM.	   Transient	   cognitive	  
impairment	  in	  TIA	  and	  minor	  stroke.	  Stroke.	  2011;42(11):3116-­‐21.	  
77.	   Bowler	   JV,	   Hadar	   U,	   Wade	   JP.	   Cognition	   in	   stroke.	   Acta	   neurologica	   Scandinavica.	  
1994;90(6):424-­‐9.	  
78.	   Sachdev	   PS,	   Brodaty	   H,	   Valenzuela	   MJ,	   Lorentz	   L,	   Looi	   JC,	   Wen	   W,	   et	   al.	   The	  
neuropsychological	   profile	   of	   vascular	   cognitive	   impairment	   in	   stroke	   and	   TIA	   patients.	  
Neurology.	  2004;62(6):912-­‐9.	  
79.	   Hackett	  ML,	   Yapa	  C,	  Parag	  V,	  Anderson	  CS.	   Frequency	  of	  depression	  after	   stroke:	   a	  
systematic	  review	  of	  observational	  studies.	  Stroke.	  2005;36(6):1330-­‐40.	  
80.	   Hackett	  ML,	  Anderson	  CS.	  Predictors	  of	  depression	  after	  stroke:	  a	  systematic	  review	  
of	  observational	  studies.	  Stroke.	  2005;36(10):2296-­‐301.	  
81.	   House	  A.	  Mood	  Disorders	  after	  Stroke	  -­‐	  a	  Review	  of	  the	  Evidence.	  Int	  J	  Geriatr	  Psych.	  
1987;2(4):211-­‐21.	  
82.	   House	   A,	   Dennis	  M,	  Molyneux	   A,	  Warlow	   C,	   Hawton	   K.	   Emotionalism	   after	   stroke.	  
Bmj.	  1989;298(6679):991-­‐4.	  
83.	   Astrom	   M,	   Adolfsson	   R,	   Asplund	   K.	   Major	   depression	   in	   stroke	   patients.	   A	   3-­‐year	  
longitudinal	  study.	  Stroke.	  1993;24(7):976-­‐82.	  
84.	   Williams	   LS,	  Ghose	   SS,	   Swindle	   RW.	  Depression	   and	   other	  mental	   health	   diagnoses	  
increase	   mortality	   risk	   after	   ischemic	   stroke.	   The	   American	   journal	   of	   psychiatry.	  
2004;161(6):1090-­‐5.	  
85.	   Babulal	  GM,	  Huskey	  TN,	  Roe	  CM,	  Goette	  SA,	  Connor	  LT.	  Cognitive	   impairments	  and	  
mood	  disruptions	  negatively	  impact	  instrumental	  activities	  of	  daily	  living	  performance	  in	  the	  
first	  three	  months	  after	  a	  first	  stroke.	  Top	  Stroke	  Rehabil.	  2015;22(2):144-­‐51.	  
86.	   Robinson	  RG,	   Jorge	   RE.	   Post-­‐Stroke	  Depression:	   A	   Review.	   The	  American	   journal	   of	  
psychiatry.	  2015:appiajp201515030363.	  
87.	   Petersen	  RC,	  Smith	  GE,	  Waring	  SC,	  Ivnik	  RJ,	  Kokmen	  E,	  Tangelos	  EG.	  Aging,	  memory,	  
and	  mild	  cognitive	  impairment.	  Int	  Psychogeriatr.	  1997;9	  Suppl	  1:65-­‐9.	  
88.	   Barker-­‐Collo	   SL.	   Depression	   and	   anxiety	   3	   months	   post	   stroke:	   Prevalence	   and	  
correlates.	  Arch	  Clin	  Neuropsych.	  2007;22(4):519-­‐31.	  
	  244	  
89.	   Mitchell	   AJ,	   Shiri-­‐Feshki	   M.	   Rate	   of	   progression	   of	   mild	   cognitive	   impairment	   to	  
dementia-­‐-­‐meta-­‐analysis	   of	   41	   robust	   inception	   cohort	   studies.	   Acta	   Psychiatr	   Scand.	  
2009;119(4):252-­‐65.	  
90.	   Campbell	  Burton	  CA,	  Murray	  J,	  Holmes	  J,	  Astin	  F,	  Greenwood	  D,	  Knapp	  P.	  Frequency	  
of	   anxiety	   after	   stroke:	   a	   systematic	   review	   and	   meta-­‐analysis	   of	   observational	   studies.	  
International	  Journal	  of	  Stroke.	  2013;8(7):5.	  
91.	   Elisei	   S,	   Pauselli	   L,	  Balducci	   PM,	  Moretti	   P,	  Quartesan	  R.	  Mood	  disorders	   in	   general	  
hospital	   inpatients:	   one	   year	   data	   from	   a	   psychiatric	   consultation-­‐liaison	   service.	   Psychiatr	  
Danub.	  2013;25	  Suppl	  2:S268-­‐71.	  
92.	   Mago	   R,	   Gomez	   JP,	   Gupta	   N,	   Kunhel	   EJ.	   Anxiety	   in	   medically	   ill	   patients.	   Curr	  
Psychiatry	  Rep.	  2006;8(3):228-­‐33.	  
93.	   Lerdal	   A,	   Bakken	   LN,	   Rasmussen	   EF,	   Beiermann	   C,	   Ryen	   S,	   Pynten	   S,	   et	   al.	   Physical	  
impairment,	  depressive	  symptoms	  and	  pre-­‐stroke	  fatigue	  are	  related	  to	  fatigue	  in	  the	  acute	  
phase	  after	  stroke.	  Disabil	  Rehabil.	  2011;33(4):334-­‐42.	  
94.	   Paolucci	  S.	  Epidemiology	  and	  treatment	  of	  post-­‐stroke	  depression.	  Neuropsychiatr	  Dis	  
Treat.	  2008;4(1):145-­‐54.	  
95.	   Laures-­‐Gore	   JS,	   DeFife	   LC.	   Perceived	   stress	   and	   depression	   in	   left	   and	   right	  
hemisphere	  post-­‐stroke	  patients.	  Neuropsychol	  Rehabil.	  2013;23(6):783-­‐97.	  
96.	   Thomas	  SA,	  Lincoln	  NB.	  Factors	  relating	  to	  depression	  after	  stroke.	  Br	  J	  Clin	  Psychol.	  
2006;45(Pt	  1):49-­‐61.	  
97.	   Pohjasvaara	  T,	  Leppavuori	  A,	  Siira	   I,	  Vataja	  R,	  Kaste	  M,	  Erkinjuntti	  T.	  Frequency	  and	  
clinical	  determinants	  of	  poststroke	  depression.	  Stroke.	  1998;29(11):2311-­‐7.	  
98.	   Wade	  DT,	  Legh-­‐Smith	  J,	  Hewer	  RA.	  Depressed	  mood	  after	  stroke.	  A	  community	  study	  
of	  its	  frequency.	  Br	  J	  Psychiatry.	  1987;151:200-­‐5.	  
99.	   Downhill	   JE,	   Jr.,	   Robinson	   RG.	   Longitudinal	   assessment	   of	   depression	   and	   cognitive	  
impairment	  following	  stroke.	  J	  Nerv	  Ment	  Dis.	  1994;182(8):425-­‐31.	  
100.	   De	   Ryck	   A,	   Brouns	   R,	   Fransen	   E,	   Geurden	   M,	   Van	   Gestel	   G,	   Wilssens	   I,	   et	   al.	   A	  
prospective	   study	   on	   the	   prevalence	   and	   risk	   factors	   of	   poststroke	   depression.	  
Cerebrovascular	  diseases	  extra.	  2013;3(1):1-­‐13.	  
101.	   Prince	  M,	  Bryce	  R,	  Albanese	  E,	  Wimo	  A,	  Ribeiro	  W,	  Ferri	  CP.	  The	  global	  prevalence	  of	  
dementia:	  a	  systematic	  review	  and	  metaanalysis.	  Alzheimer's	  &	  dementia	  :	  the	  journal	  of	  the	  
Alzheimer's	  Association.	  2013;9(1):63-­‐75	  e2.	  
102.	   Poeck	  K.	  Pathophysiology	  of	  emotionalb	  disorders	  associated	  with	  brain	  damage.	  In:	  
Vinken	   P,	   Bruyn	   G,	   editors.	   Handbook	   of	   clinical	   neurology.	   Holland:	   North	   Holland	  
Publishing;	  1969.	  
103.	   Kim	   JS.	   Poststroke	   emotional	   incontinence:	   is	   it	   depression?	  Current	   neurology	   and	  
neuroscience	  reports.	  2012;12(6):629-­‐30.	  
104.	   Choi-­‐Kwon	  S,	  Han	  K,	  Choi	  S,	  Suh	  M,	  Kim	  YJ,	  Song	  H,	  et	  al.	  Poststroke	  depression	  and	  
emotional	   incontinence:	   factors	   related	   to	   acute	   and	   subacute	   stages.	   Neurology.	  
2012;78(15):1130-­‐7.	  
105.	   Tang	  WK,	  Chen	  YK,	  Lu	  JY,	  Mok	  VC,	  Xiang	  YT,	  Ungvari	  GS,	  et	  al.	  Microbleeds	  and	  post-­‐
stroke	  emotional	  lability.	  J	  Neurol	  Neurosurg	  Psychiatry.	  2009;80(10):1082-­‐6.	  
106.	   Schmahmann	  JD.	  Vascular	  syndromes	  of	  the	  thalamus.	  Stroke.	  2003;34(9):2264-­‐78.	  
	  245	  
107.	   Werring	  DJ,	   Frazer	   DW,	   Coward	   LJ,	   Losseff	   NA,	  Watt	   H,	   Cipolotti	   L,	   et	   al.	   Cognitive	  
dysfunction	  in	  patients	  with	  cerebral	  microbleeds	  on	  T2*-­‐weighted	  gradient-­‐echo	  MRI.	  Brain.	  
2004;127(Pt	  10):2265-­‐75.	  
108.	   Broomfield	   NM,	   Scoular	   A,	   Welsh	   P,	   Walters	   M,	   Evans	   JJ.	   Poststroke	   anxiety	   is	  
prevalent	   at	   the	   population	   level,	   especially	   among	   socially	   deprived	   and	   younger	   age	  
community	   stroke	   survivors.	   International	   journal	   of	   stroke	   :	   official	   journal	   of	   the	  
International	  Stroke	  Society.	  2013.	  
109.	   Ahlsio	  B,	  Britton	  M,	  Murray	  V,	  Theorell	  T.	  Disablement	  and	  quality	  of	  life	  after	  stroke.	  
Stroke.	  1984;15(5):886-­‐90.	  
110.	   Thompson	  S.	  Rehabilitation	  of	  cognitive	  and	  emotional	  problems	  following	  stroke	  In:	  
Fawcus	  R,	  editor.	  Stroke	  rehabilitation:	  A	  collaborative	  approach.	  Oxford	  Blackwell;	  2000.	  p.	  
13.	  
111.	   Reid	  A,	  Chesson	  R.	  Goal	  Attainment	  Scaling:	  Is	   it	  appropriate	  for	  stroke	  patients	  and	  
their	  physiotherapists?	  Physiotherapy.	  1998;84(3):9.	  
112.	   Schmid	   AA,	   Acuff	   M,	   Doster	   K,	   Gwaltney-­‐Duiser	   A,	   Whitaker	   A,	   Damush	   T,	   et	   al.	  
Poststroke	  fear	  of	  falling	  in	  the	  hospital	  setting.	  Top	  Stroke	  Rehabil.	  2009;16(5):357-­‐66.	  
113.	   Townend	   E,	   Tinson	   D,	   Kwan	   J,	   Sharpe	   M.	   Fear	   of	   recurrence	   and	   beliefs	   about	  
preventing	   recurrence	   in	   persons	   who	   have	   suffered	   a	   stroke.	   J	   Psychosom	   Res.	  
2006;61(6):747-­‐55.	  
114.	   Castillo	   CS,	   Starkstein	   SE,	   Fedoroff	   JP,	   Price	   TR,	   Robinson	   RG.	   Generalized	   anxiety	  
disorder	  after	  stroke.	  J	  Nerv	  Ment	  Dis.	  1993;181(2):100-­‐6.	  
115.	   Astrom	   M.	   Generalized	   anxiety	   disorder	   in	   stroke	   patients	   -­‐	   A	   3-­‐year	   longitudinal	  
study.	  Stroke.	  1996;27(2):270-­‐5.	  
116.	   Starkstein	  SE,	  Cohen	  BS,	  Fedoroff	  P,	  Parikh	  RM,	  Price	  TR,	  Robinson	  RG.	  Relationship	  
between	  Anxiety	  Disorders	  and	  Depressive-­‐Disorders	  in	  Patients	  with	  Cerebrovascular	  Injury.	  
Arch	  Gen	  Psychiat.	  1990;47(3):246-­‐51.	  
117.	   Tang	  WK,	   Chen	   Y,	   Lu	   J,	   Liang	   H,	   Chu	  WC,	   Tong	  Mok	   VC,	   et	   al.	   Frontal	   infarcts	   and	  
anxiety	  in	  stroke.	  Stroke.	  2012;43(5):1426-­‐8.	  
118.	   Bhogal	   SK,	   Teasell	   R,	   Foley	   N,	   Speechley	   M.	   Lesion	   location	   and	   poststroke	  
depression:	   systematic	   review	   of	   the	   methodological	   limitations	   in	   the	   literature.	   Stroke.	  
2004;35(3):794-­‐802.	  
119.	   Taylor	  GH,	  Todman	  J,	  Broomfield	  NM.	  Post-­‐stroke	  emotional	  adjustment:	  a	  modified	  
Social	  Cognitive	  Transition	  model.	  Neuropsychol	  Rehabil.	  2011;21(6):808-­‐24.	  
120.	   Brennan	   J.	   Adjustment	   to	   cancer	   -­‐	   coping	   or	   personal	   transition?	   Psycho-­‐oncology.	  
2001;10(1):1-­‐18.	  
121.	   American	  Psychiatric	  Association,	  editor.	  Diagnostic	  and	  statistical	  manual	  of	  mental	  
disorders.	   Fourth	   Edition,	   Text	   Revision	   ed.	   Washington,	   DC:	   American	   Psychiatric	  
Association;	  2000.	  
122.	   Carta	  MG,	  Balestrieri	  M,	  Murru	  A,	  Hardoy	  MC.	  Adjustment	  Disorder:	   epidemiology,	  
diagnosis	   and	   treatment.	   Clinical	   practice	   and	   epidemiology	   in	  mental	   health	   :	   CP	  &	   EMH.	  
2009;5:15.	  
123.	   Despland	  JN,	  Monod	  L,	  Ferrero	  F.	  Clinical	  relevance	  of	  adjustment	  disorder	  in	  DSM-­‐III-­‐
4	  and	  DSM-­‐IV.	  Comprehensive	  psychiatry.	  1995;36(6):454-­‐60.	  
	  246	  
124.	   Sarre	   S,	   Redlich	   C,	   Tinker	   A,	   Sadler	   E,	   Bhalla	   A,	  McKevitt	   C.	   A	   systematic	   review	   of	  
qualitative	   studies	   on	   adjusting	   after	   stroke:	   lessons	   for	   the	   study	   of	   resilience.	   Disabil	  
Rehabil.	  2014;36(9):716-­‐26.	  
125.	   Mumby	   K,	   Whitworth	   A.	   Adjustment	   processes	   in	   chronic	   aphasia	   after	   stroke:	  
Exploring	   multiple	   perspectives	   in	   the	   context	   of	   a	   community-­‐based	   intervention.	  
Aphasiology.	  2013;27(4):462-­‐89.	  
126.	   Anson	   K,	   Ponsford	   J.	   Coping	   and	   emotional	   adjustment	   following	   traumatic	   brain	  
injury.	  The	  Journal	  of	  head	  trauma	  rehabilitation.	  2006;21(3):248-­‐59.	  
127.	   Bossuyt	  P,	  Davenport	  C,	  Deeks	  J,	  Hyde	  C,	  Leeflang	  M,	  Scholten	  R.	  Interpreting	  results	  
and	  drawing	  conclusions.	  2013.	  In:	  Cochrane	  handbook	  for	  systematic	  reviews	  of	  diagnostic	  
test	  accuracy	  [Internet].	  The	  Cochrane	  Collaboration;	  [31].	  
128.	   Hofer	   H,	   Holtforth	   MG,	   Frischknecht	   E,	   Znoj	   HJ.	   Fostering	   adjustment	   to	   acquired	  
brain	   injury	   by	   psychotherapeutic	   interventions:	   a	   preliminary	   study.	   Applied	  
neuropsychology.	  2010;17(1):18-­‐26.	  
129.	   Staub	   F,	   Bogousslavsky	   J.	   Fatigue	   after	   stroke:	   a	   major	   but	   neglected	   issue.	  
Cerebrovasc	  Dis.	  2001;12(2):75-­‐81.	  
130.	   Carlsson	   GE,	  Moller	   A,	   Blomstrand	   C.	   Consequences	   of	   mild	   stroke	   in	   persons	   <75	  
years	  -­‐-­‐	  a	  1-­‐year	  follow-­‐up.	  Cerebrovasc	  Dis.	  2003;16(4):383-­‐8.	  
131.	   Glader	   EL,	   Stegmayr	   B,	   Asplund	   K.	   Poststroke	   fatigue:	   a	   2-­‐year	   follow-­‐up	   study	   of	  
stroke	  patients	  in	  Sweden.	  Stroke.	  2002;33(5):1327-­‐33.	  
132.	   Ingles	  JL,	  Eskes	  GA,	  Phillips	  SJ.	  Fatigue	  after	  stroke.	  Archives	  of	  physical	  medicine	  and	  
rehabilitation.	  1999;80(2):173-­‐8.	  
133.	   van	  der	  Werf	  SP,	  van	  den	  Broek	  HL,	  Anten	  HW,	  Bleijenberg	  G.	  Experience	  of	  severe	  
fatigue	  long	  after	  stroke	  and	  its	  relation	  to	  depressive	  symptoms	  and	  disease	  characteristics.	  
European	  neurology.	  2001;45(1):28-­‐33.	  
134.	   Radman	   N,	   Staub	   F,	   Aboulafia-­‐Brakha	   T,	   Berney	   A,	   Bogousslavsky	   J,	   Annoni	   JM.	  
Poststroke	   fatigue	   following	   minor	   infarcts:	   a	   prospective	   study.	   Neurology.	  
2012;79(14):1422-­‐7.	  
135.	   Wu	   S,	   Barugh	   A,	   Macleod	   M,	   Mead	   G.	   Psychological	   Associations	   of	   Poststroke	  
Fatigue:	  A	  Systematic	  Review	  and	  Meta-­‐Analysis.	  Stroke.	  2014.	  
136.	   Hackett	   ML,	   Pickles	   K.	   Part	   I:	   frequency	   of	   depression	   after	   stroke:	   an	   updated	  
systematic	  review	  and	  meta-­‐analysis	  of	  observational	  studies.	  International	  Journal	  of	  Stroke.	  
2014.	  
137.	   Morris	   PLP,	   Robinson	   RG,	   Andrzejewski	   P,	   Samuels	   J,	   Price	   TR.	   Association	   of	  
Depression	   with	   10-­‐Year	   Poststroke	   Mortality.	   American	   Journal	   of	   Psychiatry.	  
1993;150(1):124-­‐9.	  
138.	   House	  A,	  Dennis	  M,	  Mogridge	  L,	  Warlow	  C,	  Hawton	  K,	  Jones	  L.	  Mood	  disorders	  in	  the	  
year	  after	  first	  stroke.	  Br	  J	  Psychiatry.	  1991;158:83-­‐92.	  
139.	   House	  A,	  Knapp	  P,	  Bamford	  J,	  Vail	  A.	  Mortality	  at	  12	  and	  24	  months	  after	  stroke	  may	  
be	  associated	  with	  depressive	  symptoms	  at	  1	  month.	  Stroke.	  2001;32(3):696-­‐701.	  
140.	   Morris	  JH,	  van	  Wijck	  F,	  Joice	  S,	  Donaghy	  M.	  Predicting	  health	  related	  quality	  of	  life	  6	  
months	   after	   stroke:	   the	   role	   of	   anxiety	   and	   upper	   limb	   dysfunction.	   Disabil	   Rehabil.	  
2013;35(4):291-­‐9.	  
	  247	  
141.	   Kauhanen	   ML,	   Korpelainen	   JT,	   Hiltunen	   P,	   Nieminen	   P,	   Sotaniemi	   KA,	   Myllyla	   VV.	  
Domains	  and	  determinants	  of	  quality	  of	  life	  after	  stroke	  caused	  by	  brain	  infarction.	  Archives	  
of	  physical	  medicine	  and	  rehabilitation.	  2000;81(12):1541-­‐6.	  
142.	   Choi	  DH,	   Jeong	  BO,	  Kang	  HJ,	  Kim	  SW,	  Kim	  JM,	  Shin	   IS,	  et	  al.	  Psychiatric	  comorbidity	  
and	   quality	   of	   life	   in	   patients	   with	   post-­‐stroke	   emotional	   incontinence.	   Psychiatry	  
investigation.	  2013;10(4):382-­‐7.	  
143.	   Chemerinski	  E,	  Robinson	  RG,	  Kosier	  JT.	   Improved	  recovery	   in	  activities	  of	  daily	   living	  
associated	  with	  remission	  of	  poststroke	  depression.	  Stroke.	  2001;32(1):113-­‐7.	  
144.	   Parikh	  RM,	  Robinson	  RG,	  Lipsey	  JR,	  Starkstein	  SE,	  Fedoroff	  JP,	  Price	  TR.	  The	  Impact	  of	  
Poststroke	   Depression	   on	   Recovery	   in	   Activities	   of	   Daily	   Living	   over	   a	   2-­‐Year	   Follow-­‐Up.	  
Archives	  of	  neurology.	  1990;47(7):785-­‐9.	  
145.	   Pohjasvaara	   T,	   Vataja	   R,	   Leppavuori	   A,	   Kaste	   M,	   Erkinjuntti	   T.	   Depression	   is	   an	  
independent	  predictor	  of	  poor	  long-­‐term	  functional	  outcome	  post-­‐stroke.	  European	  Journal	  
of	  Neurology.	  2001;8(4):315-­‐9.	  
146.	   Sinyor	   D,	   Amato	   P,	   Kaloupek	   DG,	   Becker	   R,	   Goldenberg	   M,	   Coopersmith	   H.	   Post-­‐
stroke	   depression:	   relationships	   to	   functional	   impairment,	   coping	   strategies,	   and	  
rehabilitation	  outcome.	  Stroke.	  1986;17(6):1102-­‐7.	  
147.	   St	   George	   B,	   Pollock	   A,	   Firkins	   L.	   Research	   priorities	   related	   to	   stroke:	   results	   of	   a	  
James	   Lind	   Alliance	   priority	   setting	   project.	   International	   Journal	   of	   Stroke.	   2011;6	   (suppl	  
2):2.	  
148.	   Hachinski	   V.	   The	   2005	   Thomas	   Willis	   Lecture:	   stroke	   and	   vascular	   cognitive	  
impairment:	   a	   transdisciplinary,	   translational	   and	   transactional	   approach.	   Stroke.	  
2007;38(4):1396.	  
149.	   Miller	  EL,	  Murray	  L,	  Richards	  L,	  Zorowitz	  RD,	  Bakas	  T,	  Clark	  P,	  et	  al.	  Comprehensive	  
overview	  of	  nursing	  and	  interdisciplinary	  rehabilitation	  care	  of	  the	  stroke	  patient:	  a	  scientific	  
statement	  from	  the	  American	  Heart	  Association.	  Stroke.	  2010;41(10):2402-­‐48.	  
150.	   Scottish	   Intercollegiate	   Guidelines	   Network	   (SIGN).	   Management	   of	   patients	   with	  
stroke.	  Rehabilitation,	  prevention	  and	  management	  of	  complications	  and	  discharge	  planning	  
In:	  Network	  SIG,	  editor.:	  SIGN	  publication	  Guideline	  2010.	  
151.	   Brunet	  MD,	  McCartney	  M,	  Heath	   I,	  Tomlinson	  J,	  Cosgrove	   J,	  Deveson	  P,	  et	  al.	  Open	  
letter	  to	  the	  prime	  minister	  and	  chief	  medical	  officer	  for	  England.	  There	  is	  no	  evidence	  base	  
for	  proposed	  dementia	  screening.	  Bmj.	  2012;345(e8588).	  
152.	   Le	   Couteur	   DG,	   Doust	   J,	   Creasey	   H,	   Brayne	   C.	   Political	   drive	   to	   screen	   for	   pre-­‐
dementia:	  not	  evidence	  based	  and	  ignores	  the	  harms	  of	  diagnosis.	  Bmj.	  2013;347:f5125.	  
153.	   Quinn	   TJ,	   Dawson	   J,	   Walters	   MR,	   Lees	   KR.	   Functional	   outcome	   measures	   in	  
contemporary	   stroke	   trials.	   International	   journal	   of	   stroke	   :	   official	   journal	   of	   the	  
International	  Stroke	  Society.	  2009;4(3):200-­‐5.	  
154.	   The	   Internet	   Stroke	   Centre.	   Stroke	   Assessment	   Scales	  
http://www.strokecenter.org1997-­‐2014	   [cited	   2014	   23/07/2014].	   Available	   from:	  
http://www.strokecenter.org/professionals/stroke-­‐diagnosis/stroke-­‐assessment-­‐scales/.	  
155.	   Lima-­‐Silva	  TB,	  Bahia	  VS,	  Carvalho	  VA,	  Guimaraes	  HC,	  Caramelli	  P,	  Balthazar	  ML,	  et	  al.	  
Direct	   and	   Indirect	   Assessments	   of	   Activities	   of	   Daily	   Living	   in	   Behavioral	   Variant	  
Frontotemporal	   Dementia	   and	   Alzheimer	   Disease.	   Journal	   of	   geriatric	   psychiatry	   and	  
neurology.	  2014.	  
	  248	  
156.	   Pickard	   AS,	   Johnson	   JA,	   Feeny	   DH,	   Shuaib	   A,	   Carriere	   KC,	   Nasser	   AM.	   Agreement	  
between	  patient	  and	  proxy	  assessments	  of	  health-­‐related	  quality	  of	  life	  after	  stroke	  using	  the	  
EQ-­‐5D	  and	  Health	  Utilities	  Index.	  Stroke.	  2004;35(2):607-­‐12.	  
157.	   Voepel-­‐Lewis	   T,	  Malviya	   S,	   Tait	   AR.	   Validity	   of	   parent	   ratings	   as	   proxy	  measures	   of	  
pain	  in	  children	  with	  cognitive	  impairment.	  Pain	  management	  nursing	  :	  official	  journal	  of	  the	  
American	  Society	  of	  Pain	  Management	  Nurses.	  2005;6(4):168-­‐74.	  
158.	   Folstein	   MF,	   Folstein	   SE,	   McHugh	   PR.	   "Mini-­‐mental	   state".	   A	   practical	   method	   for	  
grading	  the	  cognitive	  state	  of	  patients	  for	  the	  clinician.	  J	  Psychiat	  Res.	  1975;12(3):189-­‐98.	  
159.	   Juby	  A,	  Tench	  S,	  Baker	  V.	  The	  value	  of	  clock	  drawing	  in	  identifying	  executive	  cognitive	  
dysfunction	   in	   people	   with	   a	   normal	   Mini-­‐Mental	   State	   Examination	   score.	   CMAJ.	  
2002;167(8):859-­‐64.	  
160.	   Mitchell	  AJ.	  A	  meta-­‐analysis	  of	  the	  accuracy	  of	  the	  mini-­‐mental	  state	  examination	  in	  
the	  detection	  of	  dementia	  and	  mild	  cognitive	  impairment.	  J	  Psychiatr	  Res.	  2009;43(4):411-­‐31.	  
161.	   Nasreddine	  ZS,	   Phillips	  NA,	  Bedirian	  V,	  Charbonneau	  S,	  Whitehead	  V,	  Collin	   I,	   et	   al.	  
The	   Montreal	   Cognitive	   Assessment,	   MoCA:	   a	   brief	   screening	   tool	   for	   mild	   cognitive	  
impairment.	  Journal	  of	  the	  American	  Geriatrics	  Society.	  2005;53(4):695-­‐9.	  
162.	   Luis	  CA,	  Keegan	  AP,	  Mullan	  M.	  Cross	  validation	  of	  the	  Montreal	  Cognitive	  Assessment	  
in	  community	  dwelling	  older	  adults	  residing	  in	  the	  Southeastern	  US.	  Int	  J	  Geriatr	  Psychiatry.	  
2009;24(2):197-­‐201.	  
163.	   Blackburn	  DJ,	   Bafadhel	   L,	   Randall	  M,	  Harkness	   KA.	   Cognitive	   screening	   in	   the	   acute	  
stroke	  setting.	  Age	  and	  ageing.	  2013;42(1):113-­‐6.	  
164.	   Cumming	  TB,	  Churilov	  L,	   Linden	  T,	  Bernhardt	   J.	  Montreal	  Cognitive	  Assessment	  and	  
Mini-­‐Mental	   State	   Examination	   are	   both	   valid	   cognitive	   tools	   in	   stroke.	   Acta	   neurologica	  
Scandinavica.	  2013;128(2):122-­‐9.	  
165.	   Godefroy	   O,	   Fickl	   A,	   Roussel	   M,	   Auribault	   C,	   Bugnicourt	   JM,	   Lamy	   C,	   et	   al.	   Is	   the	  
Montreal	   Cognitive	   Assessment	   Superior	   to	   the	   Mini-­‐Mental	   State	   Examination	   to	   Detect	  
Poststroke	   Cognitive	   Impairment?	   A	   Study	   With	   Neuropsychological	   Evaluation.	   Stroke.	  
2011;42(6):1712-­‐6.	  
166.	   Pendlebury	   ST,	   Mariz	   J,	   Bull	   L,	   Mehta	   Z,	   Rothwell	   PM.	   MoCA,	   ACE-­‐R,	   and	   MMSE	  
Versus	  the	  National	  Institute	  of	  Neurological	  Disorders	  and	  Stroke-­‐Canadian	  Stroke	  Network	  
Vascular	   Cognitive	   Impairment	   Harmonization	   Standards	   Neuropsychological	   Battery	   After	  
TIA	  and	  Stroke.	  Stroke.	  2012;43(2):464-­‐9.	  
167.	   Mathuranath	  PS,	  Nestor	  PJ,	  Berrios	  GE,	  Rakowicz	  W,	  Hodges	  JR.	  A	  brief	  cognitive	  test	  
battery	   to	   differentiate	   Alzheimer's	   disease	   and	   frontotemporal	   dementia.	   Neurology.	  
2000;55(11):1613-­‐20.	  
168.	   Gaber	   TA,	   Parsons	   F,	   Gautam	   V.	   Validation	   of	   the	   language	   component	   of	   the	  
Addenbrooke's	   Cognitive	   Examination-­‐-­‐Revised	   (ACE-­‐R)	   as	   a	   screening	   tool	   for	   aphasia	   in	  
stroke	  patients.	  Australasian	  Journal	  of	  Ageing.	  2011;30(3):156-­‐8.	  
169.	   Morris	   K,	   Hacker	   V,	   Lincoln	   NB.	   The	   validity	   of	   the	   Addenbrooke's	   Cognitive	  
Examination-­‐Revised	  (ACE-­‐R)	  in	  acute	  stroke.	  Disabil	  Rehabil.	  2012;34(3):189-­‐95.	  
170.	   Mioshi	   E,	   Dawson	   K,	  Mitchell	   J,	   Arnold	   R,	   Hodges	   JR.	   The	   Addenbrooke's	   Cognitive	  
Examination	   Revised	   (ACE-­‐R):	   a	   brief	   cognitive	   test	   battery	   for	   dementia	   screening.	   Int	   J	  
Geriatr	  Psychiatry.	  2006;21(11):1078-­‐85.	  
	  249	  
171.	   Torralva	  T,	  Roca	  M,	  Gleichgerrcht	  E,	  Bonifacio	  A,	  Raimondi	  C,	  Manes	  F.	  Validation	  of	  
the	   Spanish	   Version	   of	   the	   Addenbrooke's	   Cognitive	   Examination-­‐Revised	   (ACE-­‐R).	  
Neurologia.	  2011;26(6):351-­‐6.	  
172.	   Velayudhan	  L,	  Ryu	  SH,	  Raczek	  M,	  Philpot	  M,	  Lindesay	  J,	  Critchfield	  M,	  et	  al.	  Review	  of	  
brief	   cognitive	   tests	   for	   patients	   with	   suspected	   dementia.	   Int	   Psychogeriatr.	  
2014;26(8):1247-­‐62.	  
173.	   Hodkinson	  H.	  Evaluation	  of	  a	  mental	  test	  score	  for	  assessment	  of	  mental	  impairment	  
in	  the	  elderly.	  Age	  and	  ageing.	  1972;1:6.	  
174.	   Schofield	  I,	  Monaghan	  J,	  McFadyen	  A,	  Scott	  D,	  Tolson	  D,	  Nelson	  D.	  The	  validity	  of	  the	  
4-­‐item	   Abbreviated	   Mental	   Test	   for	   older	   people	   in	   Accident	   and	   Emergency.	   European	  
Journal	  of	  Emergency	  Medicine.	  2010.	  
175.	   Schofield	   I,	   Stott	   DJ,	   Tolson	   D,	   McFadyen	   A,	   Monaghan	   J,	   Nelson	   D.	   Screening	   for	  
cognitive	   impairment	   in	   older	   people	   attending	   accident	   and	   emergency	   using	   the	   4-­‐item	  
Abbreviated	  Mental	   Test.	   European	   journal	   of	   emergency	  medicine	   :	   official	   journal	   of	   the	  
European	  Society	  for	  Emergency	  Medicine.	  2010;17(6):340-­‐2.	  
176.	   Bonaiuto	  S,	  Rocca	  WA,	  Lippi	  A,	  Luciani	  P,	  Giannandrea	  E,	  Cavarzeran	  F,	  et	  al.	  Study	  on	  
the	  validity	  of	  the	  Hodkinson	  Abbreviated	  Mental	  Test	  Score	  (AMTS)	  in	  detecting	  dementia	  of	  
elderly	   subjects	   in	   appignano	   (Macerata	   province),	   Italy.	   Arch	   Gerontol	   Geriatr.	   1992;15	  
Suppl	  1:75-­‐85.	  
177.	   Antonelli	   Incalzi	  R,	  Cesari	  M,	  Pedone	  C,	  Carosella	  L,	  Carbonin	  P.	  Construct	  validity	  of	  
the	   abbreviated	  mental	   test	   in	   older	   medical	   inpatients.	   Dementia	   and	   geriatric	   cognitive	  
disorders.	  2003;15(4):8.	  
178.	   Chu	   L,	   Pei	   C,	  Ho	  M,	  Chan	  P.	  Validation	  of	   the	  Abbreviated	  mental	   Test	   (Hong	  Kong	  
version)	  in	  the	  elderly	  medical	  patient.	  Hong	  Kong	  Medical	  Journal	  1995;1(3):5.	  
179.	   Jitapunkul	  S,	  Pillay	  I,	  Ebrahim	  S.	  The	  abbreviated	  mental	  test:	  its	  use	  and	  validity.	  Age	  
and	  ageing.	  1991;20(5):332-­‐6.	  
180.	   Harwood	  DM,	  Hope	   T,	   Jacoby	   R.	   Cognitive	   impairment	   in	  medical	   inpatients.	   II:	   Do	  
physicians	  miss	  cognitive	  impairment?	  Age	  and	  ageing.	  1997;26(1):37-­‐9.	  
181.	   Wei	  LA,	  Fearing	  MA,	  Sternberg	  EJ,	   Inouye	  SK.	  The	  Confusion	  Assessment	  Method:	  a	  
systematic	   review	   of	   current	   usage.	   Journal	   of	   the	   American	   Geriatrics	   Society.	  
2008;56(5):823-­‐30.	  
182.	   Inouye	  SK,	  van	  Dyck	  CH,	  Alessi	  CA,	  Balkin	  S,	  Siegal	  AP,	  Horwitz	  RI.	  Clarifying	  confusion:	  
the	  confusion	  assessment	  method.	  A	  new	  method	  for	  detection	  of	  delirium.	  Ann	  Intern	  Med.	  
1990;113(12):941-­‐8.	  
183.	   Linn	   S.	   A	   new	   conceptual	   approach	   to	   teaching	   the	   interpretation	   of	   clinical	   tests.	  
Journal	  of	  Statistics	  Education.	  2004;12(3).	  
184.	   Jorm	  AF,	  Jacomb	  PA.	  The	  Informant	  Questionnaire	  on	  Cognitive	  Decline	  in	  the	  Elderly	  
(Iqcode)	  -­‐	  Socio-­‐Demographic	  Correlates,	  Reliability,	  Validity	  and	  Some	  Norms.	  Psychological	  
medicine.	  1989;19(4):1015-­‐22.	  
185.	   McArthur	   K,	   Beagan	  ML,	   Degnan	   A,	   Howarth	   RC,	  Mitchell	   KA,	  McQuaige	   FB,	   et	   al.	  
Properties	  of	  proxy-­‐derived	  modified	  Rankin	  Scale	  assessment.	  International	  journal	  of	  stroke	  
:	  official	  journal	  of	  the	  International	  Stroke	  Society.	  2013;8(6):403-­‐7.	  
186.	   Burton	   L,	   Tyson	   SF.	   Screening	   for	   cognitive	   impairment	   after	   stroke:	   a	   systematic	  
review	   of	   psychometric	   properties	   and	   clinical	   utility.	   Journal	   of	   rehabilitation	   medicine.	  
2015;47(3):193-­‐203.	  
	  250	  
187.	   Srikanth	  V,	  Thrift	  AG,	  Fryer	  JL,	  Saling	  MM,	  Dewey	  HM,	  Sturm	  JW,	  et	  al.	  The	  validity	  of	  
brief	  screening	  cognitive	  instruments	  in	  the	  diagnosis	  of	  cognitive	  impairment	  and	  dementia	  
after	  first-­‐ever	  stroke.	  Int	  Psychogeriatr.	  2006;18(2):295-­‐305.	  
188.	   Schellinger	  PD,	  Bath	  PM,	  Lees	  KR,	  Bornstein	  NM,	  Uriel	  E,	  Eisert	  W,	  et	  al.	  Assessment	  
of	  additional	  endpoints	  for	  trials	  in	  acute	  stroke	  -­‐	  what,	  when,	  where,	  in	  who?	  International	  
Journal	  of	  Stroke.	  2012;7(3):227-­‐30.	  
189.	   Yu	  KH,	  Cho	  SJ,	  Oh	  MS,	  Jung	  S,	  Lee	  JH,	  Shin	  JH,	  et	  al.	  Cognitive	  impairment	  evaluated	  
with	   Vascular	   Cognitive	   Impairment	   Harmonization	   Standards	   in	   a	  multicenter	   prospective	  
stroke	  cohort	  in	  Korea.	  Stroke.	  2013;44(3):786-­‐8.	  
190.	   Morales	   JM,	   Gonzalez-­‐Montalvo	   JI,	   Bermejo	   F,	   Del-­‐Ser	   T.	   The	   screening	   of	   mild	  
dementia	   with	   a	   shortened	   Spanish	   version	   of	   the	   "Informant	   Questionnaire	   on	   Cognitive	  
Decline	  in	  the	  Elderly".	  Alzheimer	  disease	  and	  associated	  disorders.	  1995;9(2):105-­‐11.	  
191.	   Radloff	  L.	  The	  CES-­‐D	  Scale:	  A	  self-­‐report	  depression	  scale	  for	  research	  in	  the	  general	  
population.	  Applied	  Psychological	  Measurement.	  1977;1:385-­‐401.	  
192.	   Roberts	   RE,	   Vernon	   SW.	   The	   Center	   for	   Epidemiologic	   Studies	  Depression	   Scale:	   its	  
use	  in	  a	  community	  sample.	  The	  American	  journal	  of	  psychiatry.	  1983;140(1):41-­‐6.	  
193.	   Agrell	   B,	   Dehlin	   O.	   Comparison	   of	   six	   depression	   rating	   scales	   in	   geriatric	   stroke	  
patients.	  Stroke.	  1989;20(9):1190-­‐4.	  
194.	   Parikh	   R,	   Mathai	   A,	   Parikh	   S,	   Sekhar	   GC,	   Thomas	   R.	   Understanding	   and	   using	  
sensitivity,	  specificity	  and	  predictive	  values	  -­‐	  Reply.	  Indian	  J	  Ophthalmol.	  2008;56(4):341-­‐.	  
195.	   Buist	  A,	  Condon	   J,	  Brooks	   J,	   Speelman	  C,	  Milgrom	   J,	  Hayes	  B,	  et	  al.	  Acceptability	  of	  
routine	  screening	  for	  perinatal	  depression.	  J	  Affect	  Disord.	  2006;93(1-­‐3):233-­‐7.	  
196.	   Johnston	  O,	  Fornai	  G,	  Cabrini	  S,	  Kendrick	  T.	  Feasibility	  and	  acceptability	  of	  screening	  
for	  eating	  disorders	  in	  primary	  care.	  Family	  practice.	  2007;24(5):511-­‐7.	  
197.	   Zigmond	   AS,	   Snaith	   RP.	   The	   Hospital	   Anxiety	   and	   Depression	   Scale.	   Acta	   Psychiatr	  
Scand.	  1983;67(6):361-­‐70.	  
198.	   Bjellanda	  I,	  Dahlb	  A,	  Haugc	  T,	  Neckelmannd	  D.	  The	  validity	  of	  the	  Hospital	  Anxiety	  and	  
Depression	   Scale:	   An	   updated	   literature	   review.	   Journal	   of	   Psychosomatic	   research.	  
2002;52:9.	  
199.	   Aben	   I,	   Verhey	   F,	   Lousberg	   R,	   Lodder	   J,	   Honig	   A.	   Validity	   of	   the	   beck	   depression	  
inventory,	   hospital	   anxiety	   and	   depression	   scale,	   SCL-­‐90,	   and	   hamilton	   depression	   rating	  
scale	   as	   screening	   instruments	   for	   depression	   in	   stroke	   patients.	   Psychosomatics.	  
2002;43(5):386-­‐93.	  
200.	   Mitchell	   AJ,	   Kaar	   S,	   Coggan	   C,	   Herdman	   J.	   Acceptability	   of	   common	   screening	  
methods	   used	   to	   detect	   distress	   and	   related	   mood	   disorders-­‐preferences	   of	   cancer	  
specialists	  and	  non-­‐specialists.	  Psycho-­‐oncology.	  2008;17(3):226-­‐36.	  
201.	   Johnson	   G,	   Burvill	   PW,	   Anderson	   CS,	   Jamrozik	   K,	   Stewart-­‐Wynne	   EG,	   Chakera	   TM.	  
Screening	   instruments	   for	  depression	  and	  anxiety	   following	  stroke:	  experience	   in	   the	  Perth	  
community	  stroke	  study.	  Acta	  Psychiatr	  Scand.	  1995;91(4):252-­‐7.	  
202.	   Scotland	  NNS.	  2012	  National	  Report	   :	   Stroke	  Services	   in	   Scottish	  Hospitals.	   In:	   (ISD)	  
ISD,	  editor.	  2012.	  
203.	   O'Rourke	  S,	  MacHale	  S,	  Signorini	  D,	  Dennis	  M.	  Detecting	  psychiatric	  morbidity	  after	  
stroke:	  comparison	  of	  the	  GHQ	  and	  the	  HAD	  Scale.	  Stroke.	  1998;29(5):980-­‐5.	  
	  251	  
204.	   Sagen	  U,	  Vik	  TG,	  Moum	  T,	  Morland	  T,	  Finset	  A,	  Dammen	  T.	  Screening	  for	  anxiety	  and	  
depression	   after	   stroke:	   comparison	   of	   the	   hospital	   anxiety	   and	   depression	   scale	   and	   the	  
Montgomery	  and	  Asberg	  depression	  rating	  scale.	  J	  Psychosom	  Res.	  2009;67(4):325-­‐32.	  
205.	   Tang	  WK,	  Chan	  SSM,	  Chin	  HFK,	  Wong	  KS,	  Kwok	  TCY,	  Mok	  V,	  et	  al.	  Can	   the	  geriatric	  
depression	   scale	   detect	   poststroke	   depression	   in	   Chinese	   elderly?	   J	   Affect	   Disorders.	  
2004;81(2):153-­‐6.	  
206.	   Ferraro	   FR,	   Chelminski	   I.	   Preliminary	   normative	   data	   on	   the	   Geriatric	   Depression	  
Scale-­‐Short	   Form	   (GDS-­‐SF)	   in	   a	   young	   adult	   sample.	   Journal	   of	   clinical	   psychology.	  
1996;52(4):443-­‐7.	  
207.	   Brink	   TL,	   Yesavage	   JA,	   Lum	  O,	   Heersema	   PH,	   Adey	  M,	   Rose	   TL.	   Screening	   tests	   for	  
geriatric	  depression.	  Clinical	  Gerontologist.	  1982;1(1):6.	  
208.	   Watkins	  CL,	  Lightbody	  CE,	  Sutton	  CJ,	  Holcroft	  L,	  Jack	  CI,	  Dickinson	  HA,	  et	  al.	  Evaluation	  
of	   a	   single-­‐item	   screening	   tool	   for	   depression	   after	   stroke:	   a	   cohort	   study.	   Clinical	  
rehabilitation.	  2007;21(9):846-­‐52.	  
209.	   Temple	   RO,	   Stern	   RA,	   Latham	   J,	   Ruffolo	   JS,	   Arruda	   JE,	   Tremont	   G.	   Assessment	   of	  
mood	   state	   in	   dementia	   by	   use	   of	   the	   visual	   analog	   mood	   scales	   (VAMS).	   Am	   J	   Geriatr	  
Psychiatry.	  2004;12(5):527-­‐30.	  
210.	   Mulley	  AG,	  Jr.	  Assessing	  patients'	  utilities.	  Can	  the	  ends	  justify	  the	  means?	  Med	  Care.	  
1989;27(3	  Suppl):S269-­‐81.	  
211.	   Macaskill	  P,	  Gatsonis	  C,	  Deeks	  J,	  Harbord	  R,	  Takwoingi	  Y.	  Chapter	  10:	  Analysing	  and	  
Presenting	  Results	  2010.	   In:	  Cochrane	  Handbook	   for	   systematic	  Reviews	  of	  Diagnostic	  Test	  
Accuracy	  [Internet].	  The	  Cochrane	  Collaboration;	  [61].	  
212.	   Zhu	   W,	   Zeng	   N,	   Wang	   N.	   Sensitivity,	   specificity,	   accuracy,	   associated	   confidence	  
interval	   and	   ROC	   analysis	   with	   practical	   SAS	   implementations.	   NESUG	   Proceedings.	  
2010;Health	  Care	  and	  Life	  Sciences(November	  14-­‐17):9.	  
213.	   Berthier	   ML.	   Poststroke	   aphasia	   :	   epidemiology,	   pathophysiology	   and	   treatment.	  
Drugs	  Aging.	  2005;22(2):163-­‐82.	  
214.	   Laska	  AC,	  Martensson	  B,	  Kahan	  T,	  von	  Arbin	  M,	  Murray	  V.	  Recognition	  of	  depression	  
in	  aphasic	  stroke	  patients.	  Cerebrovasc	  Dis.	  2007;24(1):74-­‐9.	  
215.	   Laska	  AC.	  Aphasia	  in	  acute	  stroke.	  Stockholm2007.	  
216.	   Berg	  A,	  Palomaki	  H,	  Lehtihalmes	  M,	  Lonnqvist	  J,	  Kaste	  M.	  Poststroke	  depression:	  an	  
18-­‐month	  follow-­‐up.	  Stroke.	  2003;34(1):138-­‐43.	  
217.	   Schmid	  AA,	  Kroenke	  K,	  Hendrie	  HC,	  Bakas	  T,	  Sutherland	   JM,	  Williams	  LS.	  Poststroke	  
depression	  and	  treatment	  effects	  on	  functional	  outcomes.	  Neurology.	  2011;76(11):1000-­‐5.	  
218.	   Dennis	   M,	   O'Rourke	   S,	   Lewis	   S,	   Sharpe	   M,	   Warlow	   C.	   Emotional	   outcomes	   after	  
stroke:	  factors	  associated	  with	  poor	  outcome.	  J	  Neurol	  Neurosurg	  Psychiatry.	  2000;68(1):47-­‐
52.	  
219.	   Whiting	   P,	   Rutjes	   AW,	   Reitsma	   JB,	   Bossuyt	   PM,	   Kleijnen	   J.	   The	   development	   of	  
QUADAS:	   a	   tool	   for	   the	   quality	   assessment	   of	   studies	   of	   diagnostic	   accuracy	   included	   in	  
systematic	  reviews.	  BMC	  medical	  research	  methodology.	  2003;3:25.	  
220.	   de	  Rooij	  SE,	  Schuurmans	  MJ,	  van	  der	  Mast	  RC,	  Levi	  M.	  Clinical	   subtypes	  of	  delirium	  
and	   their	   relevance	   for	   daily	   clinical	   practice:	   a	   systematic	   review.	   International	   Journal	  
Geriatric	  Psychiatry.	  2005;20(7):609-­‐15.	  
	  252	  
221.	   McDowd	   JM,	   Filion	   DL,	   Pohl	   PS,	   Richards	   LG,	   Stiers	   W.	   Attentional	   abilities	   and	  
functional	  outcomes	  following	  stroke.	  Journal	  of	  Gerontology	  Series	  B,	  Psychological	  Sciences	  
and	  Social	  Sciences.	  2003;58(1):P45-­‐53.	  
222.	   Kirkwood	   BR,	   J.A.C	   S.	   Essential	   Medical	   Statistics.	   USA:	   Massachusetts:	   Blackwell	  
Science;	  2003.	  
223.	   Malik	  A,	  Turner	  M,	  Sohail	  M,	  Potter	  P,	  Sadler	  C,	  Salcido	  R,	  et	  al.	  Neuropsychological	  
Evaluation2013	   15/04/2014.	   Available	   from:	  
http://emedicine.medscape.com/article/317596-­‐overview.	  
224.	   Holmes	   J,	   Gilbody	   S.	   Differences	   in	   use	   of	   abbreviated	   mental	   test	   score	   by	  
geriatricians	  and	  psychiatrists.	  Brit	  Med	  J.	  1996;313(7055):465-­‐.	  
225.	   McKeith	   IG,	  Fairbairn	  AF,	  Bothwell	  RA,	  Moore	  PB,	  Ferrier	   IN,	  Thompson	  P,	  et	  al.	  An	  
evaluation	  of	  the	  predictive	  validity	  and	  inter-­‐rater	  reliability	  of	  clinical	  diagnostic	  criteria	  for	  
senile	  dementia	  of	  Lewy	  body	  type.	  Neurology.	  1994;44(5):872-­‐7.	  
226.	   Ghiselli	  EE.	  The	  Prediction	  of	  Predictability.	  Educ	  Psychol	  Meas.	  1960;20(1):3-­‐8.	  
227.	   Craig	  P,	  Dieppe	  P,	  Macintyre	  S,	  Michie	  S,	  Nazareth	   I,	  Petticrew	  M,	  et	  al.	  Developing	  
and	   evaluating	   complex	   interventions:	   the	   new	   Medical	   Research	   Council	   guidance.	   Bmj.	  
2008;337:a1655.	  
228.	   Royal	   College	   of	   Physicians.	   National	   Clinical	   Guidelines	   for	   Stroke	   In:	   Clincial	  
Effectiveness	   and	   evaluation	   Unit	   RCoP,	   editor.	   3	   ed.	   London	   Royal	   College	   of	   Physicians	  
2008.	  
229.	   Hart	   S,	   Morris	   R.	   Screening	   for	   depression	   after	   stroke:	   an	   exploration	   of	  
professionals'	  compliance	  with	  guidelines.	  Clinical	  rehabilitation.	  2008;22(1):60-­‐70.	  
230.	   Toniolo	   S.	   Neuropsychological	   interventions	   in	   stroke	   survivors:	   implications	   for	  
evidence	  based	  psychological	  practice.	  Giornale	  italiano	  di	  medicina	  del	  lavoro	  ed	  ergonomia.	  
2011;33(1	  Suppl	  A):A29-­‐36.	  
231.	   Bunn	  F,	  Goodman	  C,	  Sworn	  K,	  Rait	  G,	  Brayne	  C,	  Robinson	  L,	  et	  al.	  Psychosocial	  factors	  
that	  shape	  patient	  and	  carer	  experiences	  of	  dementia	  diagnosis	  and	  treatment:	  a	  systematic	  
review	  of	  qualitative	  studies.	  PLoS	  medicine.	  2012;9(10):e1001331.	  
232.	   Draper	  B,	  Peisah	  C,	  Snowdon	   J,	  Brodaty	  H.	  Early	  dementia	  diagnosis	  and	   the	   risk	  of	  
suicide	  and	  euthanasia.	  Alzheimer's	  &	  dementia	  :	  the	  journal	  of	  the	  Alzheimer's	  Association.	  
2010;6(1):75-­‐82.	  
233.	   Broderick	   JE,	   Vikingstad	   G.	   Frequent	   assessment	   of	   negative	   symptoms	   does	   not	  
induce	  depressed	  mood.	   Journal	  of	   clinical	   psychology	   in	  medical	   settings.	   2008;15(4):296-­‐
300.	  
234.	   Fox	   C,	   Lafortune	   L,	   Boustani	  M,	   Brayne	   C.	   The	   pros	   and	   cons	   of	   early	   diagnosis	   in	  
dementia.	  The	  British	  journal	  of	  general	  practice	  :	  the	  journal	  of	  the	  Royal	  College	  of	  General	  
Practitioners.	  2013;63(612):e510-­‐2.	  
235.	   Turner	  S,	  Iliffe	  S,	  Downs	  M,	  Wilcock	  J,	  Bryans	  M,	  Levin	  E,	  et	  al.	  General	  practitioners'	  
knowledge,	  confidence	  and	  attitudes	  in	  the	  diagnosis	  and	  management	  of	  dementia.	  Age	  and	  
ageing.	  2004;33(5):461-­‐7.	  
236.	   Hobson	  JP,	  Leeds	  L,	  Meara	  RJ.	  The	   feasibility	  of	  cognitive	  screening	  of	  patients	  with	  
ischaemic	   stroke	   using	   the	   preliminary	   neuropsychological	   battery.	   Psychol	   Health.	  
2003;18(5):655-­‐65.	  
237.	   Duncan	  PW,	  Zorowitz	  R,	  Bates	  B,	  Choi	  JY,	  Glasberg	  JJ,	  Graham	  GD,	  et	  al.	  Management	  
of	  Adult	  Stroke	  Rehabilitation	  Care:	  a	  clinical	  practice	  guideline.	  Stroke.	  2005;36(9):e100-­‐43.	  
	  253	  
238.	   Kneebone,	   II,	   Neffgen	   LM,	   Pettyfer	   SL.	   Screening	   for	   depression	   and	   anxiety	   after	  
stroke:	  developing	  protocols	  for	  use	  in	  the	  community.	  Disabil	  Rehabil.	  2012;34(13):1114-­‐20.	  
239.	   Blake	   H,	   McKinney	   M,	   Treece	   K,	   Lee	   E,	   Lincoln	   NB.	   An	   evaluation	   of	   screening	  
measures	  for	  cognitive	  impairment	  after	  stroke.	  Age	  and	  ageing.	  2002;31(6):451-­‐6.	  
240.	   Burns	  KE,	  Duffett	  M,	  Kho	  ME,	  Meade	  MO,	  Adhikari	  NK,	  Sinuff	  T,	  et	  al.	  A	  guide	  for	  the	  
design	  and	  conduct	  of	  self-­‐administered	  surveys	  of	  clinicians.	  CMAJ.	  2008;179(3):245-­‐52.	  
241.	   Eysenbach	   G.	   Improving	   the	   quality	   of	   Web	   surveys:	   the	   Checklist	   for	   Reporting	  
Results	  of	  Internet	  E-­‐Surveys	  (CHERRIES).	  J	  Med	  Internet	  Res.	  2004;6(3):e34.	  
242.	   Kelley	   K,	   Clark	   B,	   Brown	   V,	   Sitzia	   J.	   Good	   practice	   in	   the	   conduct	   and	   reporting	   of	  
survey	  research.	  Int	  J	  Qual	  Health	  Care.	  2003;15(3):261-­‐6.	  
243.	   NHS	   National	   Services	   Scotland.	   Scottish	   Stroke	   Care	   Audit	   Stroke	   Care	   Audit	  
Homepage:	  ISD	  Scotland;	  2012	  [April].	  Available	  from:	  http://www.strokeaudit.scot.nhs.uk.	  
244.	   Patel	  M,	  Coshall	  C,	  Rudd	  AG,	  Wolfe	  CD.	  Natural	  history	  of	  cognitive	  impairment	  after	  
stroke	  and	  factors	  associated	  with	  its	  recovery.	  Clinical	  rehabilitation.	  2003;17(2):158-­‐66.	  
245.	   Gorelick	  PB,	  Scuteri	  A,	  Black	  SE,	  Decarli	  C,	  Greenberg	  SM,	   Iadecola	  C,	  et	  al.	  Vascular	  
contributions	   to	   cognitive	   impairment	   and	   dementia:	   a	   statement	   for	   healthcare	  
professionals	   from	   the	   american	   heart	   association/american	   stroke	   association.	   Stroke.	  
2011;42(9):2672-­‐713.	  
246.	   Agrell	  B,	  Dehlin	  O.	  Mini	  mental	  state	  examination	  in	  geriatric	  stroke	  patients.	  Validity,	  
differences	   between	   subgroups	   of	   patients,	   and	   relationships	   to	   somatic	   and	   mental	  
variables.	  Aging	  (Milano).	  2000;12(6):439-­‐44.	  
247.	   Nys	   GM,	   van	   Zandvoort	   MJ,	   de	   Kort	   PL,	   Jansen	   BP,	   Kappelle	   LJ,	   de	   Haan	   EH.	  
Restrictions	   of	   the	   Mini-­‐Mental	   State	   Examination	   in	   acute	   stroke.	   Archives	   of	   clinical	  
neuropsychology	   :	   the	   official	   journal	   of	   the	   National	   Academy	   of	   Neuropsychologists.	  
2005;20(5):623-­‐9.	  
248.	   Townend	  B,	  Whyte	  S,	  Desborough	  T,	  Crimmins	  D,	  Markus	  R,	  Levi	  C,	  et	  al.	  Longitudinal	  
prevalence	   and	   determinants	   of	   early	   mood	   disorder	   post-­‐stroke.	   Journal	   of	   Clinical	  
Neuroscience	  2006;14:6.	  
249.	   Tang	   WK,	   Ungvari	   GS,	   Chiu	   HF,	   Sze	   KH,	   Yu	   AC,	   Leung	   TL.	   Screening	   post-­‐stroke	  
depression	   in	   Chinese	   older	   adults	   using	   the	   hospital	   anxiety	   and	   depression	   scale.	   Aging	  
Ment	  Health.	  2004;8(5):397-­‐9.	  
250.	   Thomas	   SA,	  Walker	  MF,	  Macniven	   JA,	   Haworth	   H,	   Lincoln	   NB.	   Communication	   and	  
Low	  Mood	  (CALM):	  a	  randomized	  controlled	  trial	  of	  behavioural	  therapy	  for	  stroke	  patients	  
with	  aphasia.	  Clinical	  rehabilitation.	  2013.	  
251.	   Saver	  JL,	  Kidwell	  CS,	  Liebeskind	  DS,	  Starkman	  S.	  Acute	   ischemic	  stroke	  trials.	  Stroke.	  
2001;32(1):275-­‐8.	  
252.	   Jadad	   AR,	   To	   MJ,	   Emara	   M,	   Jones	   J.	   Consideration	   of	   multiple	   chronic	   diseases	   in	  
randomized	  controlled	  trials.	  JAMA.	  2011;306(24):2670-­‐2.	  
253.	   Lees	   R,	   Fearon	   P,	   Harrison	   JK,	   Broomfield	   NM,	   Quinn	   TJ.	   Cognitive	   and	   mood	  
assessment	   in	   stroke	   research:	   focused	   review	   of	   contemporary	   studies.	   Stroke.	  
2012;43(6):1678-­‐80.	  
254.	   Chodosh	   J,	   Petitti	   DB,	   Elliott	   M,	   Hays	   RD,	   Crooks	   VC,	   Reuben	   DB,	   et	   al.	   Physician	  
recognition	   of	   cognitive	   impairment:	   evaluating	   the	   need	   for	   improvement.	   Journal	   of	   the	  
American	  Geriatrics	  Society.	  2004;52(7):1051-­‐9.	  
	  254	  
255.	   Royal	  College	  of	  Physicians	  R.	  National	  Clinical	  Guidelines	  for	  Stroke	  -­‐	  Forth	  Edition	  In:	  
The	  Clinical	  Effectiveness	  and	  Evaluation	  Unit	  C,	  editor.	  Forth	  Edition	  ed.	  London:	  The	  Royal	  
College	  of	  Physicians;	  2012.	  p.	  232.	  
256.	   Higgins	   J,	   Green	   S,	   editors.	   Cochrane	   Handbook	   for	   Systematic	   Reviews	   of	  
Interventions	  Version	  5.0.2.	  ed:	  The	  Cochrane	  Collaboration;	  2009.	  
257.	   Liberati	   A,	   Altman	   DG,	   Tetzlaff	   J,	   Mulrow	   C,	   Gotzsche	   PC,	   Ioannidis	   JP,	   et	   al.	   The	  
PRISMA	   statement	   for	   reporting	   systematic	   reviews	   and	   meta-­‐analyses	   of	   studies	   that	  
evaluate	   health	   care	   interventions:	   explanation	   and	   elaboration.	   Ann	   Intern	   Med.	  
2009;151(4):W65-­‐94.	  
258.	   Stroup	  DF,	  Berlin	  JA,	  Morton	  SC,	  Olkin	  I,	  Williamson	  GD,	  Rennie	  D,	  et	  al.	  Meta-­‐analysis	  
of	   observational	   studies	   in	   epidemiology:	   a	   proposal	   for	   reporting.	   Meta-­‐analysis	   Of	  
Observational	  Studies	  in	  Epidemiology	  (MOOSE)	  group.	  JAMA.	  2000;283(15):2008-­‐12.	  
259.	   Pendlebury	  ST,	  Mariz	  J,	  Bull	  L,	  Mehta	  Z,	  Rothwell	  PM.	  Impact	  of	  different	  operational	  
definitions	  on	  mild	  cognitive	  impairment	  rate	  and	  MMSE	  and	  MoCA	  performance	  in	  transient	  
ischaemic	  attack	  and	  stroke.	  Cerebrovasc	  Dis.	  2013;36(5-­‐6):355-­‐62.	  
260.	   Davis	  DHJ,	  Creavin	  ST,	  Noel-­‐Storr	  A,	  Quinn	  TJ,	  Smailagic	  N,	  Hyde	  C,	  et	  al.	  Cochrane	  Db	  
Syst	  Rev	  [Internet].	  Group	  CDaCI,	  editor.	  The	  Cochrane	  Library:	  The	  Cochrane	  Collaboration.	  
2013.	  [cited	  2013].	  
261.	   F-­‐FDG	   PET	   for	   the	   early	   diagnosis	   of	   Alzheimer’s	   disease	   dementia	   and	   other	  
dementias	   in	   people	   with	   mild	   cognitive	   impairment	   (MCI)	   (Protocol)	   [Internet].	   The	  
Cochrane	  Collaboration.	  2013.	  
262.	   Whiting	  PF,	  Rutjes	  AW,	  Westwood	  ME,	  Mallett	  S,	  Deeks	  JJ,	  Reitsma	  JB,	  et	  al.	  QUADAS-­‐
2:	  a	  revised	  tool	  for	  the	  quality	  assessment	  of	  diagnostic	  accuracy	  studies.	  Ann	  Intern	  Med.	  
2011;155(8):529-­‐36.	  
263.	   Fong	  TG,	  Tulebaev	  SR,	  Inouye	  SK.	  Delirium	  in	  elderly	  adults:	  diagnosis,	  prevention	  and	  
treatment.	  Nature	  Reviews	  Neurology.	  2009;5(4):210-­‐20.	  
264.	   Takwoingi	  Y,	  Deeks	  JJ.	  MetaDAS:	  A	  SAS	  macro	  for	  meta-­‐analysis	  of	  diagnostic	  accuracy	  
studies.	  Quick	   reference	  and	  worked	  example.	  User	  Guide	  Version	  13	   [Internet].	   2010	   July	  
Available	  from:	  http://srdta.cochrane.org/.	  
265.	   Mitchell	  AJ.	  Sensitivity	  x	  PPV	  is	  a	  recognized	  test	  called	  the	  clinical	  utility	  index	  (CUI+).	  
Eur	  J	  Epidemiol.	  2011;26(3):251-­‐2.	  
266.	   Baum	  CM,	  Connor	   LT,	  Morrison	  T,	  Hahn	  M,	  Dromerick	  AW,	  Edwards	  DF.	  Reliability,	  
validity,	   and	   clinical	   utility	   of	   the	   Executive	   Function	   Performance	   Test:	   a	   measure	   of	  
executive	  function	  in	  a	  sample	  of	  people	  with	  stroke.	  The	  American	  journal	  of	  occupational	  
therapy	   :	   official	   publication	   of	   the	   American	   Occupational	   Therapy	   Association.	  
2008;62(4):446-­‐55.	  
267.	   Cumming	  TB,	  Blomstrand	  C,	  Bernhardt	  J,	  Linden	  T.	  The	  NIH	  stroke	  scale	  can	  establish	  
cognitive	  function	  after	  stroke.	  Cerebrovasc	  Dis.	  2010;30(1):7-­‐14.	  
268.	   Green	   S,	   Sinclair	   E,	   Rodgers	   E,	   Birks	   E,	   Lincoln	   N.	   The	   Repeatable	   Battery	   for	   the	  
Assessment	   of	   Neuropsychological	   Status	   (RBANS)	   for	   post	   stroke	   cognitive	   impairment	  
screening.	  International	  Journal	  of	  Therapy	  and	  Rehabilitation.	  2013;20(11):7.	  
269.	   Salvadori	  E,	  Pasi	  M,	  Poggesi	  A,	  Chiti	  G,	  Inzitari	  D,	  Pantoni	  L.	  Predictive	  value	  of	  MoCA	  
in	   the	   acute	  phase	  of	   stroke	  on	   the	  diagnosis	   of	  mid-­‐term	   cognitive	   impairment.	   J	  Neurol.	  
2013;260(9):2220-­‐7.	  
	  255	  
270.	   Wolf	  TJ,	  Stift	  S,	  Connor	  LT,	  Baum	  C,	  Cognitive	  Rehabilitation	  Research	  G.	  Feasibility	  of	  
using	   the	   EFPT	   to	   detect	   executive	   function	   deficits	   at	   the	   acute	   stage	   of	   stroke.	   Work.	  
2010;36(4):405-­‐12.	  
271.	   Bour	  A,	  Rasquin	  S,	  Boreas	  A,	  Limburg	  M,	  Verhey	  F.	  How	  predictive	   is	   the	  MMSE	  for	  
cognitive	  performance	  after	  stroke?	  Journal	  of	  Neurology.	  2010;257(4):630-­‐7.	  
272.	   Desmond	  DW,	  Tatemichi	  TK,	  Hanzawa	  L.	  The	  Telephone	  Interview	  for	  Cognitive	  Status	  
(Tics)	  -­‐	  Reliability	  and	  Validity	  in	  a	  Stroke	  Sample.	  Int	  J	  Geriatr	  Psych.	  1994;9(10):803-­‐7.	  
273.	   Larson	  E,	   Kirschner	  K,	   Bode	  R,	  Heinemann	  A,	  Goodman	  R.	   Construct	   and	  predictive	  
validity	   of	   the	   repeatable	   battery	   for	   the	   assessment	   of	   neuropsychological	   status	   in	   the	  
evaluation	  of	  stroke	  patients.	  J	  Clin	  Exp	  Neuropsychol.	  2005;27(1):16-­‐32.	  
274.	   Pendlebury	  ST,	  Welch	  SJ,	  Cuthbertson	  FC,	  Mariz	  J,	  Mehta	  Z,	  Rothwell	  PM.	  Telephone	  
Assessment	   of	   Cognition	   After	   Transient	   Ischemic	   Attack	   and	   Stroke:	   Modified	   Telephone	  
Interview	  of	  Cognitive	  Status	  and	  Telephone	  Montreal	  Cognitive	  Assessment	  Versus	  Face-­‐to-­‐
Face	   Montreal	   Cognitive	   Assessment	   and	   Neuropsychological	   Battery.	   Stroke.	  
2013;44(1):227-­‐9.	  
275.	   Brookes	  RL,	  Hannesdottir	   K,	   Lawrence	  R,	  Morris	   RG,	  Markus	  HS.	   Brief	  Memory	   and	  
Executive	   Test:	   evaluation	   of	   a	   new	   screening	   test	   for	   cognitive	   impairment	   due	   to	   small	  
vessel	  disease.	  Age	  and	  ageing.	  2012;41(2):212-­‐8.	  
276.	   Cartoni	   A,	   Lincoln	   NB.	   The	   sensitivity	   and	   specificity	   of	   the	   Middlesex	   Elderly	  
Assessment	   of	   Mental	   State	   (MEAMS)	   for	   detecting	   cognitive	   impairment	   after	   stroke.	  
Neuropsychol	  Rehabil.	  2005;15(1):55-­‐67.	  
277.	   de	  Koning	  I,	  Dippel	  DW,	  van	  Kooten	  F,	  Koudstaal	  PJ.	  A	  short	  screening	  instrument	  for	  
poststroke	  dementia	  :	  the	  R-­‐CAMCOG.	  Stroke.	  2000;31(7):1502-­‐8.	  
278.	   de	   Koning	   I,	   van	   Kooten	   F,	   Koudstaal	   PJ,	   Dippel	   DW.	   Diagnostic	   value	   of	   the	  
Rotterdam-­‐CAMCOG	   in	   post-­‐stroke	   dementia.	   J	   Neurol	   Neurosurg	   Psychiatry.	  
2005;76(2):263-­‐5.	  
279.	   Dong	  Y,	  Venketasubramanian	  N,	  Chan	  BP,	  Sharma	  VK,	  Slavin	  MJ,	  Collinson	  SL,	  et	  al.	  
Brief	   screening	   tests	   during	   acute	   admission	   in	   patients	  with	  mild	   stroke	   are	   predictive	   of	  
vascular	   cognitive	   impairment	   3-­‐6	   months	   after	   stroke.	   J	   Neurol	   Neurosurg	   Psychiatry.	  
2012;83(6):580-­‐5.	  
280.	   Dong	  YH,	  Sharma	  VK,	  Chan	  BPL,	  Venketasubramanian	  N,	  Teoh	  HL,	  Seet	  RCS,	  et	  al.	  The	  
Montreal	   Cognitive	   Assessment	   (MoCA)	   is	   superior	   to	   the	  Mini-­‐Mental	   State	   Examination	  
(MMSE)	  for	  the	  detection	  of	  vascular	  cognitive	  impairment	  after	  acute	  stroke.	  Journal	  of	  the	  
neurological	  sciences.	  2010;299(1-­‐2):15-­‐8.	  
281.	   Grace	  J,	  Nadler	  JD,	  White	  DA,	  Guilmette	  TJ,	  Giuliano	  AJ,	  Monsch	  AU,	  et	  al.	  Folstein	  vs	  
modified	  Mini-­‐Mental	  State	  Examination	  in	  geriatric	  stroke.	  Stability,	  validity,	  and	  screening	  
utility.	  Archives	  of	  neurology.	  1995;52(5):477-­‐84.	  
282.	   Hershey	  LA,	   Jaffe	  DF,	  Greenough	  PG,	  Yang	  SL.	  Validation	  of	  cognitive	  and	  functional	  
assessment	  instruments	  in	  vascular	  dementia.	  International	  journal	  of	  psychiatry	  in	  medicine.	  
1987;17(2):183-­‐92.	  
283.	   Jodzio	   K,	   Biechowska	   D.	   Wisconsin	   card	   sorting	   test	   as	   a	   measure	   of	   executive	  
function	  impairments	  in	  stroke	  patients.	  Applied	  neuropsychology.	  2010;17(4):267-­‐77.	  
284.	   Tang	  WK,	  Mok	  V,	  Chan	  SS,	  Chiu	  HF,	  Wong	  KS,	  Kwok	  TC,	  et	  al.	  Screening	  of	  dementia	  in	  
stroke	  patients	  with	  lacunar	  infarcts:	  comparison	  of	  the	  mattis	  dementia	  rating	  scale	  and	  the	  
mini-­‐mental	  state	  examination.	  Journal	  of	  geriatric	  psychiatry	  and	  neurology.	  2005;18(1):3-­‐7.	  
	  256	  
285.	   Wong	  A,	  Xiong	  YY,	  Kwan	  PW,	  Chan	  AY,	  Lam	  WW,	  Wang	  K,	  et	  al.	  The	  validity,	  reliability	  
and	  clinical	  utility	  of	   the	  Hong	  Kong	  Montreal	  Cognitive	  Assessment	   (HK-­‐MoCA)	   in	  patients	  
with	  cerebral	  small	  vessel	  disease.	  Dementia	  and	  geriatric	  cognitive	  disorders.	  2009;28(1):81-­‐
7.	  
286.	   Wu	  Y,	  Wang	  M,	   Ren	  M,	   Xu	  W.	   The	   effects	   of	   educational	   background	  on	  Montreal	  
Cognitive	  Assessment	  screening	   for	  vascular	  cognitive	   impairment,	  no	  dementia,	  caused	  by	  
ischemic	  stroke.	  Journal	  of	  clinical	  neuroscience	  :	  official	  journal	  of	  the	  Neurosurgical	  Society	  
of	  Australasia.	  2013;20(10):1406-­‐10.	  
287.	   Nokleby	  K,	  Boland	  E,	  Bergersen	  H,	  Schanke	  AK,	  Farner	  L,	  Wagle	  J,	  et	  al.	  Screening	  for	  
cognitive	  deficits	  after	  stroke:	  a	  comparison	  of	  three	  screening	  tools.	  Clinical	  rehabilitation.	  
2008;22(12):1095-­‐104.	  
288.	   de	  Koning	  I,	  van	  Kooten	  F,	  Dippel	  DW,	  van	  Harskamp	  F,	  Grobbee	  DE,	  Kluft	  C,	  et	  al.	  The	  
CAMCOG:	   a	   useful	   screening	   instrument	   for	   dementia	   in	   stroke	   patients.	   Stroke.	  
1998;29(10):2080-­‐6.	  
289.	   Johnson-­‐Greene	   D,	   Touradji	   P,	   Emmerson	   LC.	   The	   Three	   Cities	   Test:	   Preliminary	  
Validation	   of	   a	   Short	   Bedside	  Memory	   Test	   in	   Persons	  with	  Acute	   Stroke.	   Topics	   in	   Stroke	  
Rehabilitation.	  2009;16(5):321-­‐9.	  
290.	   Lees	   R,	   Corbet	   S,	   Johnston	   C,	   Moffitt	   E,	   Shaw	   G,	   Quinn	   TJ.	   Test	   accuracy	   of	   short	  
screening	   tests	   for	   diagnosis	   of	   delirium	   or	   cognitive	   impairment	   in	   an	   acute	   stroke	   unit	  
setting.	  Stroke.	  2013;44(11):3078-­‐83.	  
291.	   Pendlebury	  ST,	  Cuthbertson	  FC,	  Welch	  SJ,	  Mehta	  Z,	  Rothwell	  PM.	  Underestimation	  of	  
cognitive	   impairment	   by	   Mini-­‐Mental	   State	   Examination	   versus	   the	   Montreal	   Cognitive	  
Assessment	  in	  patients	  with	  transient	  ischemic	  attack	  and	  stroke:	  a	  population-­‐based	  study.	  
Stroke.	  2010;41(6):1290-­‐3.	  
292.	   Wong	  A,	  Mok	  VC,	  Yim	  P,	  Fu	  M,	  Lam	  WW,	  Yau	  C,	  et	  al.	  The	  executive	  clock	  drawing	  
task	  (CLOX)	  is	  a	  poor	  screening	  test	  for	  executive	  dysfunction	  in	  Chinese	  elderly	  patients	  with	  
subcortical	  ischemic	  vascular	  disease.	  Journal	  of	  clinical	  neuroscience	  :	  official	  journal	  of	  the	  
Neurosurgical	  Society	  of	  Australasia.	  2004;11(5):493-­‐7.	  
293.	   Bossuyt	  PM,	  Reitsma	  JB,	  Bruns	  DE,	  Gatsonis	  CA,	  Glasziou	  PP,	  Irwig	  LM,	  et	  al.	  Towards	  
complete	  and,accurate	  reporting	  of	  studies	  of	  diagnostic	  accuracy:	  the	  STARD	  initiative.	  Brit	  
Med	  J.	  2003;326(7379):41-­‐4.	  
294.	   Kutlubaev	   MA.	   [Detection	   of	   cognitive	   deficit	   in	   a	   therapist's	   practice:	   review	   of	  
screening	  scales].	  Ter	  Arkh.	  2014;86(11):135-­‐8.	  
295.	   Schuetz	   GM,	   Schlattmann	   P,	   Dewey	   M.	   Use	   of	   3x2	   tables	   with	   an	   intention	   to	  
diagnose	   approach	   to	   assess	   clinical	   performance	   of	   diagnostic	   tests:	   meta-­‐analytical	  
evaluation	  of	  coronary	  CT	  angiography	  studies.	  Brit	  Med	  J.	  2012;345.	  
296.	   Cullen	   B,	   O'Neill	   B,	   Evans	   JJ,	   Coen	   RF,	   Lawlor	   BA.	   A	   review	   of	   screening	   tests	   for	  
cognitive	  impairment.	  J	  Neurol	  Neurosurg	  Psychiatry.	  2007;78(8):790-­‐9.	  
297.	   Barber	  M,	  Stott	  DJ.	  Validity	  of	  the	  Telephone	  Interview	  for	  Cognitive	  Status	  (TICS)	   in	  
post-­‐stroke	  subjects.	  Int	  J	  Geriatr	  Psychiatry.	  2004;19(1):75-­‐9.	  
298.	   Mayo	  NE,	  Korner-­‐Bitensky	  NA,	  Becker	  R.	  Recovery	  time	  of	  independent	  function	  post-­‐
stroke.	  American	  Journal	  of	  Physical	  Medicine	  and	  Rehabilitation	  1991;70(1):5-­‐12.	  
299.	   Farrell	   TW,	   Dosa	   D.	   The	   assessment	   and	   management	   of	   hypoactive	   delirium.	  
Medicine	  and	  health,	  Rhode	  Island.	  2007;90(12):393-­‐5.	  
	  257	  
300.	   Association	   TS.	   Feeling	   overwhelmed:	   The	   emotional	   impact	   of	   stroke.	  
http://www.stroke.org.uk:	  2013.	  
301.	   Singh	  A,	  Black	  SE,	  Herrmann	  N,	  Leibovitch	  FS,	  Ebert	  PL,	  Lawrence	  J,	  et	  al.	  Functional	  
and	   neuroanatomic	   correlations	   in	   poststroke	   depression:	   the	   Sunnybrook	   Stroke	   Study.	  
Stroke.	  2000;31(3):637-­‐44.	  
302.	   Whyte	  EM,	  Mulsant	  BH.	  Post	  stroke	  depression:	  epidemiology,	  pathophysiology,	  and	  
biological	  treatment.	  Biol	  Psychiatry.	  2002;52(3):253-­‐64.	  
303.	   King	  RB,	   Shade-­‐Zeldow	  Y,	   Carlson	  CE,	   Feldman	   JL,	   Philip	  M.	  Adaptation	   to	   stroke:	   a	  
longitudinal	  study	  of	  depressive	  symptoms,	  physical	  health,	  and	  coping	  process.	  Top	  Stroke	  
Rehabil.	  2002;9(1):46-­‐66.	  
304.	   Sibolt	  G,	  Curtze	  S,	  Melkas	  S,	  Pohjasvaara	  T,	  Kaste	  M,	  Karhunen	  PJ,	  et	  al.	  Post-­‐stroke	  
depression	  and	  depression-­‐executive	  dysfunction	  syndrome	  are	  associated	  with	   recurrence	  
of	  ischaemic	  stroke.	  Cerebrovasc	  Dis.	  2013;36(5-­‐6):336-­‐43.	  
305.	   Lincoln	   NB,	   Jackson	   JM,	   Edmans	   JA,	  Walker	  MF,	   Farrow	   VM,	   Latham	   A,	   et	   al.	   The	  
accuracy	   of	   predictions	   about	   progress	   of	   patients	   on	   a	   stroke	   unit.	   J	   Neurol	   Neurosurg	  
Psychiatry.	  1990;53(11):972-­‐5.	  
306.	   Caeiro	  L,	  Ferro	   JM,	  Santos	  CO,	  Figueira	  ML.	  Depression	   in	  acute	  stroke.	   J	  Psychiatry	  
Neurosci.	  2006;31(6):377-­‐83.	  
307.	   Sibon	  I,	  Lassalle-­‐Lagadec	  S,	  Renou	  P,	  Swendsen	  J.	  Evolution	  of	  depression	  symptoms	  
following	   stroke:	   a	   prospective	   study	   using	   computerized	   ambulatory	   monitoring.	  
Cerebrovasc	  Dis.	  2012;33(3):280-­‐5.	  
308.	   Turner-­‐Stokes	  L,	  Kalmus	  M,	  Hirani	  D,	  Clegg	  F.	  The	  Depression	   Intensity	  Scale	  Circles	  
(DISCs):	  a	  first	  evaluation	  of	  a	  simple	  assessment	  tool	  for	  depression	  in	  the	  context	  of	  brain	  
injury.	  J	  Neurol	  Neurosurg	  Psychiatry.	  2005;76(9):1273-­‐8.	  
309.	   Dawkins	   N,	   Cloherty	   ME,	   Gracey	   F,	   Evans	   JJ.	   The	   factor	   structure	   of	   the	   Hospital	  
Anxiety	  and	  Depression	  Scale	  in	  acquired	  brain	  injury.	  Brain	  Inj.	  2006;20(12):1235-­‐9.	  
310.	   Sheehan	  DV,	  Lecrubier	  Y,	  Sheehan	  KH,	  Amorim	  P,	  Janavs	  J,	  Weiller	  E,	  et	  al.	  The	  Mini-­‐
International	   Neuropsychiatric	   Interview	   (M.I.N.I.):	   the	   development	   and	   validation	   of	   a	  
structured	  diagnostic	  psychiatric	  interview	  for	  DSM-­‐IV	  and	  ICD-­‐10.	  J	  Clin	  Psychiatry.	  1998;59	  
Suppl	  20:22-­‐33;quiz	  4-­‐57.	  
311.	   World	   Health	   Organisation	   (WHO).	   The	   ICD-­‐10	   classification	   of	   mental	   and	  
behavioural	  disorders.	  Diagnostic	  criteria	  for	  research.	  Geneva1993.	  
312.	   Duburcq	   A,	   Blin	   P,	   Charpak	   Y,	   Blachier	   C,	   Allicar	  MP,	   Bouhassira	  M,	   et	   al.	   Use	   of	   a	  
structured	  diagnostic	   interview	  to	   identify	  depressive	  episodes	   in	  an	  epidemiologic	  study:	  a	  
posteriori	  internal	  validation.	  Rev	  Epidemiol	  Sante.	  1999;47(5):455-­‐63.	  
313.	   Diggle	   PJ,	   Heagerty	   P,	   Liang	   K-­‐Y,	   Zeger	   SL.	   Analysis	   of	   Longitudinal	   Data.	   Second	  
Edition	  ed.	  Oxford,	  UK:	  Oxford	  University	  Press;	  2002.	  
314.	   Information	   Services	   Devision	   of	   National	   Services	   Scotland.	   Scottish	   Stroke	   care	  
audit:	  about	  the	  audit	  http://www.strokeaudit.scot.nhs.uk/2014	  [updated	  06/02/2015;	  cited	  
2015	  26/02/2015].	  
315.	   Broomfield	  N,	  Scoular	  A,	  Welsh	  P,	  Walters	  M,	  Evans	  J.	  Poststroke	  anxiety	  is	  prevalent	  
at	   the	   population	   level,	   especially	   among	   socially	   deprived	   and	   younger	   age	   community	  
stroke	  survivors.	  International	  Journal	  of	  Stroke.	  2015;10(6):6.	  
316.	   Kneebone	   I,	  Walker-­‐Samuel	  N,	   Swanston	   J,	  Otto	   E.	   Relaxation	   training	   after	   stroke:	  
potential	  to	  reduce	  anxiety.	  Disabil	  Rehabil.	  2013.	  
	  258	  
317.	   Williams	  LS,	  Brizendine	  EJ,	  Plue	  L,	  Bakas	  T,	  Tu	  W,	  Hendrie	  H,	  et	  al.	  Performance	  of	  the	  
PHQ-­‐9	  as	  a	  screening	  tool	  for	  depression	  after	  stroke.	  Stroke.	  2005;36(3):635-­‐8.	  
318.	   Quaranta	  D,	  Marra	  C,	  Gainotti	  G.	  Mood	  disorders	  after	  stroke:	  diagnostic	  validation	  of	  
the	  poststroke	  depression	  rating	  scale.	  Cerebrovasc	  Dis.	  2008;26(3):237-­‐43.	  
319.	   Brott	  T,	  Adams	  HP,	  Jr.,	  Olinger	  CP,	  Marler	  JR,	  Barsan	  WG,	  Biller	  J,	  et	  al.	  Measurements	  
of	  acute	  cerebral	  infarction:	  a	  clinical	  examination	  scale.	  Stroke.	  1989;20(7):864-­‐70.	  
320.	   Ankolekar	  S,	  Renton	  C,	  Sprigg	  N,	  Bath	  PM.	  The	  cog-­‐4	  subset	  of	  the	  national	  institutes	  
of	   health	   stroke	   scale	   as	   a	   measure	   of	   cognition:	   relationship	   with	   baseline	   factors	   and	  
functional	  outcome	  after	  stroke	  using	  data	  from	  the	  virtual	  international	  stroke	  trials	  archive.	  
Stroke	  Res	  Treat.	  2013;2013:562506.	  
321.	   Hajjar	   K,	   Fulton	   RL,	   Diener	  HC,	   Lees	   KR,	   the	   VC.	   Does	   the	   cognitive	  measure	   Cog-­‐4	  
show	   improvement	   among	   patients	   treated	   with	   thrombolysis	   after	   acute	   stroke?	  
International	  Journal	  of	  Stroke.	  2012.	  
322.	   Gottesman	  RF,	  Kleinman	  JT,	  Davis	  C,	  Heidler-­‐Gary	  J,	  Newhart	  M,	  Hillis	  AE.	  The	  NIHSS-­‐
plus:	   improving	   cognitive	   assessment	   with	   the	   NIHSS.	   Behavioural	   neurology.	   2010;22(1-­‐
2):11-­‐5.	  
323.	   Noel-­‐Storr	   AH,	   McCleery	   JM,	   Richard	   E,	   Ritchie	   CW,	   Flicker	   L,	   Cullum	   SJ,	   et	   al.	  
Reporting	   standards	   for	   studies	   of	   diagnostic	   test	   accuracy	   in	   dementia:	   The	   STARDdem	  
Initiative.	  Neurology.	  2014.	  
324.	   Curran	  CA,	  Ponsford	  JL,	  Crowe	  S.	  Coping	  strategies	  and	  emotional	  outcome	  following	  
traumatic	   brain	   injury:	   a	   comparison	   with	   orthopedic	   patients.	   Journal	   of	   Head	   Trauma	  
Rehabilitation.	  2000;15(6):1256-­‐74.	  
325.	   Elliott	  R.	  Executive	  functions	  and	  their	  disorders.	  Brit	  Med	  Bull.	  2003;65:49-­‐59.	  
326.	   Damian	   AM,	   Jacobson	   SA,	   Hentz	   JG,	   Belden	   CM,	   Shill	   HA,	   Sabbagh	  MN,	   et	   al.	   The	  
Montreal	   Cognitive	   Assessment	   and	   the	   mini-­‐mental	   state	   examination	   as	   screening	  
instruments	   for	   cognitive	   impairment:	   item	   analyses	   and	   threshold	   scores.	   Dementia	   and	  
geriatric	  cognitive	  disorders.	  2011;31(2):126-­‐31.	  
327.	   Ankolekar	  S,	  Renton	  C,	  Sprigg	  N,	  Bath	  P.	  The	  Cog-­‐4	  subset	  of	  the	  national	  Institutes	  of	  
health	   Stroke	   Scale	   as	   a	   Measure	   of	   Cognition:	   relationship	   with	   Baseline	   Factors	   and	  
Functional	   Outcome	   after	   Stroke	   Using	   Data	   from	   the	   Virtual	   International	   Stroke	   Trials	  
Archive.	  Stroke	  Research	  and	  Treatment.	  2013;2013:6.	  
328.	   Riepe	  MW,	  Riss	  S,	  Bittner	  D,	  Huber	  R.	  Screening	  for	  cognitive	  impairment	  in	  patients	  
with	  acute	  stroke.	  Dementia	  and	  geriatric	  cognitive	  disorders.	  2004;17(1-­‐2):49-­‐53.	  
329.	   Schmidt	   R,	   Mechtler	   L,	   Kinkel	   PR,	   Fazekas	   F,	   Kinkel	   WR,	   Freidl	   W.	   Cognitive	  
impairment	   after	   acute	   supratentorial	   stroke:	   a	   6-­‐month	   follow-­‐up	   clinical	   and	   computed	  
tomographic	   study.	   European	   archives	   of	   psychiatry	   and	   clinical	   neuroscience.	  
1993;243(1):11-­‐5.	  
330.	   Tombaugh	   TN,	   McIntyre	   NJ.	   The	   mini-­‐mental	   state	   examination:	   a	   comprehensive	  
review.	  Journal	  of	  the	  American	  Geriatrics	  Society.	  1992;40(9):922-­‐35.	  
331.	   Hoops	  S,	  Nazem	  S,	  Siderowf	  AD,	  Duda	  JE,	  Xie	  SX,	  Stern	  MB,	  et	  al.	  Validity	  of	  the	  MoCA	  
and	   MMSE	   in	   the	   detection	   of	   MCI	   and	   dementia	   in	   Parkinson	   disease.	   Neurology.	  
2009;73(21):1738-­‐45.	  
332.	   Crawford	  S,	  Whitnall	  L,	  Robertson	  J,	  Evans	  JJ.	  A	  systematic	  review	  of	  the	  accuracy	  and	  
clinical	  utility	  of	  the	  Addenbrooke's	  Cognitive	  Examination	  and	  the	  Addenbrooke's	  Cognitive	  
	  259	  
Examination-­‐Revised	   in	   the	  diagnosis	  of	  dementia.	   Int	   J	  Geriatr	  Psychiatry.	  2012;27(7):659-­‐
69.	  
333.	   Larner	  AJ.	  Addenbrooke's	  Cognitive	  Examination-­‐Revised	  (ACE-­‐R)	  in	  day-­‐to-­‐day	  clinical	  
practice.	  Age	  and	  ageing.	  2007;36(6):685-­‐6.	  
334.	   Spitzer	   RL,	   Kroenke	   K,	  Williams	   JB.	   Validation	   and	   utility	   of	   a	   self-­‐report	   version	   of	  
PRIME-­‐MD:	   the	   PHQ	   primary	   care	   study.	   Primary	   Care	   Evaluation	   of	   Mental	   Disorders.	  
Patient	  Health	  Questionnaire.	  JAMA.	  1999;282(18):1737-­‐44.	  
335.	   Mahoney	   J,	   Drinka	   TJ,	   Abler	   R,	   Gunter-­‐Hunt	   G,	   Matthews	   C,	   Gravenstein	   S,	   et	   al.	  
Screening	   for	   depression:	   single	   question	   versus	   GDS.	   Journal	   of	   the	   American	   Geriatrics	  
Society.	  1994;42(9):1006-­‐8.	  
336.	   Goodman	  WK,	  Price	  LH,	  Rasmussen	  SA,	  Mazure	  C,	  Fleischmann	  RL,	  Hill	  CL,	  et	  al.	  The	  
Yale-­‐Brown	   Obsessive	   Compulsive	   Scale.	   I.	   Development,	   use,	   and	   reliability.	   Arch	   Gen	  
Psychiat.	  1989;46(11):1006-­‐11.	  
337.	   Watkins	   C,	   Daniels	   L,	   Jack	   C,	   Dickinson	   H,	   van	   Den	   Broek	   M.	   Accuracy	   of	   a	   single	  
question	  in	  screening	  for	  depression	  in	  a	  cohort	  of	  patients	  after	  stroke:	  comparative	  study.	  
Bmj.	  2001;323(7322):1159.	  
338.	   Department	  of	  Health.	  Using	  the	  Commissioning	  for	  Quality	  and	  Innovation	  (CQUIN)	  
payment	   framework:	   Guidance	   on	   new	   national	   goals	   for	   2012-­‐13	   In:	   Dementia	   SCP-­‐OP,	  
editor.	  Leeds	  (UK)2012.	  p.	  1-­‐33.	  
 
